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Abstract 
 
The mammalian innate immune system defines the first line of defense against pathogens. 
Immune cells expressing receptors that are specialized to recognize structures typical for 
pathogens play a central role in the detection of hostile organisms. One of these receptor-
mediated mechanisms involves the formyl peptide receptors (FPRs). Their members, which 
are predominantly expressed on mammalian leukocytes of the innate immune system, are 
named after their affinity towards N-terminally formylated peptides, a pattern typical for 
bacterial metabolism. Besides formyl peptides, they recognize many exogenous and host 
endogenous substances that are involved in inflammatory processes. Interestingly, the 
vomeronasal organ of mouse, an accessory olfactory organ, expresses five structurally-related 
members of the formyl peptide receptor family. The current dissertation is based on the 
hypothesis that vomeronasal formyl peptide receptors of mice mediate the olfactory detection 
of pathogens. To test this hypothesis in the long run, profound pharmacological understanding 
of the vomeronasal formyl peptide receptors (mFpr-rs1, mFpr-rs3, mFpr-rs4, mFpr-rs6 and 
mFpr-rs7) is a prerequisite. Therefore, I cloned all five known vomeronasal formyl peptide 
receptors for high-throughput in-vitro pharmacological analysis in HEK293T cells. My initial 
observations with calcium imaging showed that the FPR family segregates into two functional 
groups: the promiscuous immune FPRs and the more stringent vomeronasal FPRs. In fact, 
only one of the vomeronasal receptors, mFpr-rs1, was able to induce calcium signals in 
response to certain peptides that exhibit chemical modifications characteristic for bacteria. 
Some of these peptides were also capable of activating vomeronasal sensory neurons, a cell 
type that naturally expresses mFpr-rs1. Interestingly, the corresponding peptide motifs are 
found in distinct pathogenic microorganisms, which is consistent with the idea that 
vomeronasal FPRs mediate the recognition of pathogens. Structure-function analysis of these 
peptides revealed a molecular signature important for activation of mFpr-rs1. Employing this 
knowledge, our group discovered that bacterially-derived signal peptides represent a large 
class of novel ligands for the FPR family, including mFpr-rs1 and human and mouse immune 
FPRs when expressed in HEK293T cells. With biochemical techniques as well as 
pharmacological and genetic manipulation, I show that these peptides specifically activate 
FPRs in primary innate human and mouse immune cells. Furthermore, my data provide clear 
evidence that signal peptides activate host anti-bacterial actions of human innate immune cells. 
With this, my work reveals conceptual insight into a possible novel detection mechanism by 
Abstract  
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which the mammalian immune system can sense the presence of bacteria at the molecular 
level. 
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Zusammenfassung 
 
Bei Säugetieren bildet das angeborene Immunsystem die erste Verteidigungslinie gegen 
Infektionen durch Pathogene. Bei der Detektion feindseliger Organismen spielen 
Immunzellen die spezialisierte Rezeptoren zur Erkennung pathogener Strukturen exprimieren 
eine zentrale Rolle. Einer dieser Rezeptor-vermittelten Mechanismen wird unter anderem von 
den Formylpeptid-Rezeptoren (FPRs) übernommen. Ihre Mitglieder, welche hauptsächlich 
auf Leukozyten von Säugetieren exprimiert werden, wurden nach Ihrer Affinität zu N-
terminal formylierten Peptiden, ein Muster welches man dem bakteriellen Metabolismus 
zuschreibt, benannt. Neben den Formylpeptiden, erkennen sie auch viele exogene sowie 
wirtseigene Substanzen die bei entzündlichen Prozessen eine Rolle spielen. Interessanterweise 
exprimiert das Vomeronasalorgan der Maus, ein akkzessorisches olfaktorisches Organ, fünf 
Struktur-verwandte Mitglieder der Formylpeptid-Rezeptor-Familie. Die vorliegende Arbeit 
basiert auf der Hypothese, dass die vomeronasalen Formylpeptid-Rezeptoren von Mäusen die 
olfaktorische Detektion von Pathogenen ermöglichen. Um diese Hypothese auf lange Sicht zu 
prüfen sind profunde pharmakologische Kenntnisse der vomeronasalen Formylpeptid-
Rezeptoren (mFpr-rs1, mFpr-rs3, mFpr-rs4, mFpr-rs6 und mFpr-rs7) erforderlich. Daher habe 
ich alle fünf bekannten vomeronasalen Formylpeptid-Rezeptoren kloniert um sie mittels 
Hochdurchsatz-Kalzium-Imaging in HEK293T-Zellen pharmakologisch zu untersuchen. 
Meine ersten Beobachtungen zeigten, dass sich die FPR Familie in zwei funktionelle Gruppen 
aufteilt: die promiskuitiven Immun-FPRs und die stringenteren vomeronasalen FPRs. Genau 
genommen konnte nur ein vomeronasaler Rezeptor, mFpr-rs1, aktiviert werden. Dieser 
antwortete auf bestimmte Peptide, welche für Bakterien charakteristische chemische 
Modifikation trugen, mit Kalzium-Signalen. Einige dieser Peptide waren dazu in der Lage 
vomeronasale Neurone zu aktivieren. Die entsprechenden Peptid-Motive sind in bestimmten 
pathogenen Mikroorganismen zu finden, was mit der Idee, dass FPRs die Erkennung von 
Pathogenen vermitteln, einher geht. Struktur-Funktionsanalysen dieser Peptide offenbarten 
eine molekulare Signatur die wichtig zur Aktivierun des mFpr-rs1 ist. Durch Nutzung dieses 
Wissens entdeckte unsere Arbeitsgruppe, dass von Bakterien stammende Signal-Peptide eine 
riesige Gruppe neuer Liganden für heterolog exprimierte FPRs, inklusive der Immun- und der 
vomeronasalen FPRs, darstellen. Mit biochemischen Techniken sowie durch 
pharmakologische und genetische Manipulation, zeige ich, dass die FPRs in primären Zellen 
des angeborenen Immunsystems von Maus und Mensch, spezifisch durch diese Peptide 
Zusammenfassung 
 
XIII 
 
aktiviert werden. Darüber hinaus liefern meine Daten klare Beweise dafür, dass diese Signal-
peptide wirtseigene anti-bakterielle Reaktionen in Zellen des angeborenen menschlichen 
Immunsystems auslösen. Damit liefert meine Arbeit konzeptionelle Einsichten in einen 
möglichen neuen Mechanismus, mit dem das Immunsystem von Säugetieren die Anwesenheit 
von Bakterien auf molekularer Ebene erkennen kann. 
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Chapter 1 
 
Introduction 
 
 
 
1.1. The Vomeronasal Organ 
Communication with the environment is of uttermost importance for every living organism. 
The detection of food and water, and the cognition of danger are mainly facilitated by systems 
of chemosensory perception. One of the most important chemosensory systems in mammals is 
the olfactory system, which is organized into distinct subsystems. The vomeronasal organ 
(VNO) of rodents has received special attention as it emerged to be important in pheromone-
dependent conspecific communication and detection of predator associated kairomones 
(Chamero et al., 2012). Recognition of these molecular cues is mediated by specific receptors 
that are expressed in the corresponding sensory system. The rodent VNO, encased in a bony 
capsule located at the ventral base of the nasal septum, (Døving and Trotier, 1998) comprises 
a large receptor repertoire, organized in a complex molecular architecture (Figure 1-1). Cell 
bodies of vomeronasal sensory neurons (VSNs) organize into distinct layers of the sensory 
epithelium (Ryba and Tirindelli, 1997). The apical layer comprises cell bodies predominantly 
expressing the G protein-coupled vomeronasal type 1 receptors (V1Rs) together with the G 
protein Gαi2 (Berghard and Buck, 1996; Jia and Halpern, 1996). V1R expressing cells are 
involved in the detection of small organic molecules which provide information on the 
physiological status and hormone level of other animals (Leinders-Zufall et al., 2000; Nodari 
et al., 2008). Vomeronasal type 2 GPCRs (V2Rs) on the contrary, are predominantly 
expressed by neurons residing in the basal layer, co-localizing with the expression of Gαo 
(Berghard and Buck, 1996; Jia and Halpern, 1996). V2R-expressing neurons are activated by 
peptide cues, including exocrine gland-secreting peptides (Kimoto et al., 2005), major urinary 
proteins (Chamero et al., 2007), fragments of mitochondrial peptides (Chamero et al., 2011), 
and MHC class I peptides (Leinders-Zufall et al., 2004). More and more intriguing novel 
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findings are emerging, nourishing the hypothesis that the VNO represents an interface 
between the immune and the nervous system (Chamero et al., 2012). Subsets of VSNs express 
molecules usually involved in immune surveillance. These include β2-microglobulins (Ishii et 
al., 2003; Loconto et al., 2003) and members of the non-classical class 1b family of the major 
histocompatibility complex (MHC) (Ishii et al., 2003; Loconto et al., 2003). VSNs positive 
for non-classical MHC receptors recognize with high sensitivity formylated peptides that are 
presented by MHC molecules in the immune system (Leinders-Zufall et al., 2014). Recent 
publications show that sensory neurons of the vomeronasal organ have extended their receptor 
repertoire by five members of the formyl peptide receptor family (Ibarra-Soria et al., 2014; 
Liberles et al., 2009; Rivière et al., 2009).  
 
Figure 1-1 | Schematic overview of the olfactory subsystems in mice with a coronal section of the VNO 
[A] Schematic overview of the anatomical organization of the distinct known olfactory subsystems in mice. 
Shown in green are the Main Olfactory Epithelium (MOE), the Septal Organ of Masera (SO) and the Grüneberg 
Ganglion (GG). The Vomeronasal Organ (VNO), embedded in the vomer bone, is shown in blue and yellow. [B] 
Coronal section of the VNO illustrating a simplified scheme its complex molecular architecture. The colors 
indicate the expression pattern of the receptors shown in C. [C] Three families of G protein-coupled receptors 
have been identified so far: vomeronasal receptors type 1 (V1R, yellow), vomeronasal receptors type 2 (V2R, 
blue) and formyl peptide receptors (FPR, red). The number of known receptor genes of a given family is 
indicated in parentheses.  
Formyl peptide receptors (FPRs) which are constitutively expressed in cells of the innate 
immune system, contribute to host defence through recognition of pathogenic cues such as 
bacterial N-terminally formylated peptides or endogenous immunomodulatory molecules (Ye 
et al., 2009). Four of its members (mFpr-rs3, mFpr-rs4, mFpr-rs6, and mFpr-rs7) are 
expressed in neurons of the VNO apical region while one receptor, mFpr-rs1, was found in 
VSNs residing in the basal layer (Figure 1-1). It has recently been confirmed that in mice the 
VNO mediates the avoidance of sick conspecifics (Boillat et al., 2015). This avoidance is 
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presumably mediated through recognition of disease-related odours (Kavaliers et al., 2005; 
Boillat et al., 2015, Shirasu and Touhara, 2011). However, so far, there is no molecular 
mechanism known that mediates olfactory detection of pathogens. Intriguingly, it has been 
shown that bacterially-derived f-MLF, the prototypical FPR activator, can activate sensory 
neurons in the vomeronasal organ (Rivière et al., 2009). Hence, formyl peptide receptors in 
the vomeronasal organ are excellent candidates for the olfactory detection of pathogen-
derived molecules. 
 
1.2. Expression of formyl peptide receptors 
Formyl peptide receptors (FPRs) belong to the superfamily of seven transmembrane domain 
G protein-coupled receptors. First functional evidence for a formyl peptide receptor was 
described in 1975 when Schiffmann et al. (Schiffmann et al., 1975) challenged human 
neutrophil granulocytes with N-terminally formylated peptides. These bacterially-derived 
peptides proved to be highly potent in attracting human granulocytes. Schiffmann’s 
experiments suggested the presence of a surface receptor tuned for recognition of the 
eponymous formyl peptides. Fifteen years later this surface receptor turned out to be a germ 
line-encoded G protein-coupled receptor (Boulay et al., 1990). Today the existence of three 
human formyl peptide receptors (hFPR1, hFPR2, and hFPR3) has been shown innumerable 
times. The prototypical hFPR1 and the homolog hFPR21 are both abundantly expressed in 
cells of the innate immune system, with neutrophil granulocytes being the most prominent 
ones found in peripheral blood (Durstin et al., 1994). hFPR1 and hFPR2 have also been 
shown to be expressed in tissue-residing macrophages, microglia, dendritic cells, and their 
predecessors, monocytes (Lacy et al., 1995; Durstin et al., 1994; Migeotte et al., 2005). 
Interestingly, hFPR3 was not found in human granulocytes and macrophages. Instead, it 
seems that its expression is restricted to monocytes and dendritic cells (Migeotte et al., 2005). 
Besides cells of the myeloid lineage, FPR expression has been reported for many tissues and 
cell types (Migeotte et al., 2006). Expression of FPRs is not restricted to humans. On the 
contrary: genes and active orthologs of FPRs are found not only in diverse mammalian 
species (Liberles et al., 2009), but also in other phylogenetic classes like birds (Panaro et al., 
2007). In mice, like in other rodents, the FPR gene cluster has undergone species-specific 
expansion (Gao et al., 1998; Wang and Ye, 2002). In addition to orthologs of hFPR1 and 
                                                     
1 In this work hFPR2/ALX will simply be referred to as hFPR2. The name of the corresponding gene is fprl1. 
Many publications, especially the former ones, therefore use the name FPRL1.  
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hFPR2 (mFpr1 and mFpr2, respectively), mice express five related-sequence FPRs (mFpr-rs1, 
mFpr-rs3, mFpr-rs4, mFpr-rs6, and mFpr-rs7). In contrast to mFpr1 and mFpr22 (also called 
mFpr-rs2), which show tissue distribution resembling those of human FPRs, members of the 
FPR-rs subfamily (mFpr-rs1, mFpr-rs3, mFpr-rs4, mFpr-rs6 and mFpr-rs7) are predominantly 
found in sensory neurons of the vomeronasal organ. With exception of mFpr-rs1 all these 
receptor are localized in the apical zone of the vomeronasal sensory epithelium, where they 
are co-expressed with the G protein Gαi2 (Liberles et al., 2009). mFpr-rs1, which has also been 
reported to be expressed in murine granulocytes (Takano et al., 1997), is localized exclusively 
in the basal zone of the VNO, in cells expressing Gαo (Liberles et al., 2009).  
 
1.3. Physiological functions mediated by FPRs  
FPRs were originally identified as receptors for chemotactic peptides. The chemotactic 
capability of hFPR1 expressed in neutrophils was remarkable, as the calculated EC50 values 
were in the lower picomolar range (Schiffmann et al., 1975). Nowadays, FPRs are thought to 
act as end-target chemotaxis receptors, meaning that in the signaling hierarchy they are above 
other chemotactic receptors, like for example chemokine receptors (Ye et al., 2009). This 
means: when chemotaxis of human neutrophils is mediated via activation of FPRs, the cells 
do not migrate in the direction of chemokines. This underlines the biological significance of 
FPRs. It was later shown that FPR-induced activation of human neutrophils leads to a plethora 
of additional immunogenic responses like degranulation or superoxide production (Ye et al., 
2009). Activation of hFPR1 by the prototypical FPR agonist f-MLF quickly leads to secretion 
of several hydrolase-containing vesicles, a process called degranulation (Showell et al., 1976). 
These vesicles are important for several reasons. First, they enable migration of the cells 
through extracellular matrices to approach their final target, the pathogen. Second, it is widely 
assumed that these hydrolases are involved in pathogen elimination (Kolaczkowska and 
Kubes, 2013). Neutrophils and monocytes respond to FPR activation with the extracellular 
formation of reactive oxygen species, a process that is directly involved in pathogen killing 
(Klebanoff, 2005). 
Mouse neutrophils exhibit immune responses very similar to their human counterparts when 
activated via FPR-dependent pathways. Experiments with Fpr1 and Fpr1/Fpr2 knockout mice 
have shown that in contrast to wildtype animals, the mice were highly susceptible to Listeria 
                                                     
2 mFpr2 is also called mFpr-rs2. It is to note that mFpr1 and mFpr-rs1 are different receptors. 
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monocytogenes infection (Gao et al., 1999; Liu et al., 2012). FPRs have been put in context 
with many infectious and autoimmune diseases (Li and Ye, 2013). Uncontrolled activation of 
FPRs expressed in brain microglial cells may be a major determinant of neurogenic 
inflammation. However, in contrast to the immune FPRs, the function of the vomeronasal 
FPRs remains unknown. First clues indicating their potential function were obtained when 
Rivière et al. (2009) reported the activation of vomeronasal sensory neurons by classical 
formyl peptide receptor agonists. 
 
1.4. Ligands of the FPR family 
The human FPR family has been described to be highly promiscuous with respect to ligand 
recognition. Their ligand repertoire encompasses bacterial (Schiffmann et al., 1975) and viral 
peptides (Shen et al., 2000; Moore et al., 1995), host endogenous immune-modulatory 
peptides (Takenouchi and Munekata, 1995; Balbach et al., 2000) and mitochondrial peptides 
(Rabiet et al., 2005), neuro-protective and anti-microbial peptides (Ying et al., 2004; 
Kurosaka et al., 2005) and even anti-inflammatory fatty acid derivatives (Takano et al., 1997). 
Human FPR1 is the most prominent receptor for bacterially-derived formyl peptides. It 
recognizes the eponymous N-terminally formylated peptides with high affinity (Schiffmann et 
al., 1975). N-terminally formylated peptides are an evolutionary hallmark attributed to 
bacteria (Capecchi, 1966). Translation of bacterial proteins predominantly starts with a 
formylated methionine, underlining the immune defensive assignment of the FPRs. The 
prototypical formylated tripeptide f-MLF activates hFPR1 at concentrations in the upper 
picomolar range (Showell et al., 1976). This was also shown for for formylated mitochondrial 
peptides (Rabiet et al., 2005; Carp, 1982). Release of mitochondrial peptides is usually a side 
effect of necrosis, which is why they define a damage-associated molecular pattern (DAMP) 
or danger signal (Pittman and Kubes, 2013). Although hFPR2 also recognizes formyl peptides, 
this generally occurs with significantly decreased affinity (Migeotte et al., 2006). However, 
the complex pharmacological landscape of hFPR2 includes the recognition of many host-
specific ligands. They include the human acute phase protein SAA (Su et al., 1999a), the 
Alzheimer-related Aβ1-42 (Le, 2001), soluble uPAR (Resnati et al., 2002), which is part of the 
plasminogen activating system and antimicrobial peptides like human LL37, a cleavage 
product of cathelicidin (De Yang et al., 2000). In addition, hFPR2 binds several highly 
lipophilic organic compounds like Lipoxin A4 and some of its derivatives (Ye et al., 2009) as 
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well as Resolvin D1 (Krishnamoorthy et al., 2010) giving it the name of the lipoxin receptor 
or hFPR2/ALX (Ye et al., 2009). hFPR3 (or FPRL2) the most-recently identified member of 
the human FPR family, is not well understood till now. Its small ligand repertoire includes the 
human neuro-protective humanin (Ying et al., 2004) and parts of the heme-binding-protein 
F2L (Migeotte et al., 2005). Although it can detect some formyl peptides, this happens at very 
high concentrations > 10 µM (Migeotte et al., 2006).  
Although the murine FPR family has not been as intensively studied as the human family, it is 
clear that they share common features with the human FPRs. mFpr1 and mFpr2, like their 
human orthologs, are able to recognize f-MLF and its formylated analogues. While mFpr1 
seems to prefer formylated peptides as agonists, mFpr2 is also activated by many host-
endogenous peptides, resembling the behavior of hFPR2. Two of the most potent naturally 
occurring agonists described so far are F2L and the antimicrobial peptide CRAMP, the 
murine ortholog of human LL37 (Kurosaka et al., 2005). Interestingly, an allele of mFpr-rs1 
(not mFpr2) was first described as the murine ortholog of the lipoxin receptor, named mLxa4r 
(Takano et al., 1997). Unlike the murine immune FPRs, the recently discovered vomeronasal 
FPRs have not been investigated well. So far, only few agonists have been described for the 
vomeronasal FPRs. Rivière et al. (2009) reported the activation of heterologously expressed 
mFpr-rs3, mFpr-rs4, mFpr-rs6 and mFpr-rs7 by 9 µM of the bacterial f-MLF in calcium 
imaging experiments. They also showed activation of these receptors, including mFpr-rs1, by 
5 µM antimicrobial CRAMP. Furthermore, they reported activation of mFpr-rs4 and mFpr-rs6 
transfected cells with the immune-modulatory compounds Lipoxin A4 and uPAR, 
respectively (Rivière et al., 2009). Intriguingly, application of these four classical FPR ligands 
was able to induce calcium signals in dendritic knobs of vomeronasal sensory neurons. 
A number of inhibitors, selective for single members of the human FPR family, have been 
described during the last 40 years. Among the most prominent inhibitors for hFPR1 are 
N-tert-butoxy-MLF (tBoc1), N-tert-butoxy-FlFlF (tBoc2) and Cyclosporin H (CsH). In tBoc1 
the formyl group of f-MLF is replaced by a urethane-linked tert-butyloxycarbonyl group. 
tBoc2 carries the same tert-butyloxycarbonyl moiety, probably competing for the same 
binding site on hFPR1 as f-MLF (Wenzel-Seifert, 1993). When used in higher micromolar 
concentrations, tBoc2 also partly antagonizes hFPR2 (Stenfeldt et al., 2007; Wenzel-Seifert 
and Seifert 1993). The cyclic undecapeptide CsH (Wenzel-Seifert et al., 1991) was 
determined to be highly selective for hFPR1 and is one of the most-potent hFPR1 antagonists 
so far (Ye et al. 2009; Wenzel-Seifert and Seifert, 1993). Besides tBoc2, which is a partial 
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inhibitor for hFPR2, there are two well-described blockers for this receptor. WRW4 is a 
hexapeptide that was identified as a selective antagonist of hFPR2 (Bae et al., 2004). Another 
well-accepted inhibitor is the Gelsolin-derived peptide PBP10 (Forsman et al., 2012). This 
cell-permeable RhodaminB-coupled decapeptide acts as an allosteric inhibitor on hFPR2 but 
not hFPR1.  For hFPR3 no selective blockers are known at the moment.   
In contrast to the human FPRs, inhibitors for mouse FPRs are only poorly investigated. tBoc2, 
mentioned above, is the only established antagonist for mFpr1 and mFpr2.  
 
1.5. Structure and signaling of formyl peptide receptors 
All above-mentioned FPRs are G protein-coupled receptors (GPCRs) that span the plasma 
membrane seven times. With their intracellular C-terminal tail immune FPRs interact with 
various heterotrimeric G proteins (Migeotte et al., 2006). Although many alternative 
pathways are in discussion (Selvatici et al., 2006), the most prominent one concludes direct 
interaction with G protein alpha subunit Gαi2 (Lad et al., 1985, Wenzel-Seifert et al., 1999). 
Upon agonist binding, the receptor activates the G protein alpha subunit, which catalyzes the 
exchange of GDP for GTP. This results in the dissociation of the alpha subunit and its 
corresponding beta and gamma subunits. The latter activate phospholipase Cβ2 (Figure 1-2). 
The phospholipase catalyzes the cleavage of the membrane phospholipid phosphatidylinositol 
bisphosphate (PIP2) to inositol trisphosphate (IP3) and diacylglycerol (DAG). DAG then 
activates protein kinase C while IP3 activates the endoplasmic reticulum-membrane-bound IP3 
receptor, leading to mobilization of endoplasmic calcium. Mouse immune FPRs have been 
described to employ similar pathways, including Gαi and/or Gαq-mediated signaling (Shi et al., 
2007). Because FPRs with related sequences (Fpr-rs) are expressed in sensory neurons that 
co-express either Gαi2 or the closely related Gαo, it is possible that these receptors utilize the 
same signal transduction pathways.  
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Figure 1-2 | Schematics of FPR-mediated signal 
transduction  
Upon ligand binding, receptor conformational 
changes induce separation of heterotrimeric Gi2 
protein subunits (αi2, β, γ). β and γ subunits then 
activate phospholipase Cβ2 (PLCβ2) which 
hydrolyzes phosphatidylinositol 4,5-bisphosphate 
(PIP2) to inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG). IP3 activates the IP3-
receptor (IP3R) which is a cooperative calcium 
channel situated in the membrane of the 
endoplasmic reticulum. Modified from 
Schumann, 2010. 
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1.6. Hypothesis and aims of this work 
Formyl peptide receptors represent a key component in the attraction of phagocytes to sites of 
infection where they contribute to elimination of pathogens. During an evolutionary process, 
the FPR family of some rodents has extended into the olfactory system, thereby adding the 
FPR subfamily of FPR-rs to the receptor repertoire of the vomeronasal organ. In mice, five 
members of this subfamily are expressed in sensory neurons of the vomeronasal organ. 
However, although their function is not understood, it is assumed that they serve as detectors 
of pathogens or sick conspecifics. The current thesis is based on the idea that vomeronasal 
FPRs mediate the olfactory detection of pathogens.  
To get first insights into the actual function of these receptors, profound knowledge of their 
pharmacology is a prerequisite. The aim is to understand, which classes of agonists can 
activate the vomeronasal FPRs and whether there are specific preferences of receptor for a 
given ligand. In order to see which agonists are able to activate vomeronasal FPRs, I tested an 
array of selected substances that are involved in inflammatory processes and screened them 
on heterologously expressed vomeronasal FPRs. To verify possible common ligands and 
common pharmacological properties, the resulting response profile was compared to that of 
FPRs expressed in the immune system. In order to investigate their pharmacology in a more 
physiological environment, newly identified ligands were tested on primary cells that 
naturally express the corresponding FPRs. For analyses of vomeronasal FPRs I employed 
single cell calcium imaging of isolated vomeronasal sensory neurons. For investigation of the 
immune FPRs I chose to observe innate immune cells of human and mouse. To get first 
insights into the biological significance of these newly identified ligands, I investigated their 
potential of inducing immune-defensive responses in human neutrophils and monocytes.  
With this approach I am confident to contribute to a better understanding of the FPR family, 
including the immune FPRs and the vomeronasal FPRs, and their role in pathogen sensing. 
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Chapter 2 
 
Materials & Methods 
  
 
 
2.1. Molecular cloning of the formyl peptide receptors 
2.1.1. Amplification of the FPR genes 
The human receptor genes hFPR1, hFPR2 and hFPR3 were amplified from human genomic 
DNA, isolated from HEK293 cells. Mouse receptor genes mFpr1, mFpr2 and mFpr-rs3 were 
amplified from C57BL/6N genomic DNA during my diploma thesis (Schumann, 2010). 
mFpr-rs1, mFpr-rs4, mFpr-rs6 and mFpr-rs7 were amplified from cDNA of C57BL/6N mice. 
cDNA and genomic DNA were kindly provided by Dr. Bernd Bufe (Saarland University, 
Medical School Homburg, Department of Physiology). The necessary primers were chosen to 
amplify the complete open reading frame (consisting of one exon) between the exon’s start 
codon (forward primer) and its stop codon (reverse primer). All forward primers contained an 
additional 5' sequence (5’-AAAGAATTCAAGCTTCCTGCAGGCGCCACC-3’) upstream of 
the start codon (ATG), including a restriction site for SbfI (CCTGCAGG) and a consensus 
Kozak sequence (GCCACC) for enhanced ribosome binding. The reverse primers were fused 
with an additional sequence (5’-TTTCCTCAATTGGATATCGCGGCCGCAAGAGCTCA-
3’), adding a stop codon (TCA) and a NotI restriction site (GCGGCCGC) for directed vector 
insertion to the 3’ end of the amplified product. All primers were purchased from Sigma-
Aldrich. PCRs were carried out using Phusion HF Master Mix (Thermo Scientific) according 
to manufacturer’s protocol with the following agents: 
 10 µl 2x Phusion Master Mix  
 0.5 µl cDNA or 1 ng genomic DNA  
 0.5 µl forward primer (à 10 µM) 
 0.5 µl reverse primer (à 10 µM) 
 ad 20 µl water (deionized)  
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All reagents were mixed on ice. PCR was run immediately on a My Cycler (Bio Rad) using 
the following program: 
Hot-Start    at 98°C 
pre-denaturation:     98°C, 15 s 
denaturation:            98°C, 15 s 
annealing:   see Table 2.1, 15 s 
extension:                72°C, 35 s 
final extension:        72°, 1 min 
hold    at 4°C  
 
The amplified genes, their online reference numbers, and the used primer sequences are listed 
in Table 2-1. 
Table 2-1 | Cloned genes, PCR primers and accession numbers of nucleotide sequences* 
Receptor  
gene 
Accession 
number 
Specific sequences of primers # 
(forward) 
(reverse) 
Annealing  
temperature 
[°C] 
mFpr1 NM_013521.2 ATGGACACCAACATGTCTCTCCTCA 
TT TCCTCAATTG GATATC GCGGCCGC AA GAGC 
59°C 
mFpr2 NM_008039.2 ATGGAATCCAACTACTCCATCCATCT 
TGGGGCCTTTAACTCAATGTCTG 
64°C 
mFpr-rs1 NM_008042.2 ATGGAATCCAACTACTCCATCCATCT 
TATTGCCTTTATTTCAATGTCTTCAGGAAG 
64°C 
mFpr-rs3 NM_008040.2 ATGGAAGCCAACTCCTCCATC 
TAGTTCAGAGTCGGCAGGACATGA 
64°C 
mFpr-rs4 NM_008041.2 ATGGAAGTCAACATTTCAATGCCTCT 
GTCTTCCCTCAGGGCCCTCTC 
64°C 
mFpr-rs6 NM_177316.2 ATGGAAGCCAACTTCTCCATACCTC 
GAGTCTTTGTGAAGACAAGTTTCTG 
64°C 
mFpr-rs7 AF437513.1 ATGGAAGCCAACTTCTCCATACCTC 
GAGTCTTAAGTTTGTGAAGACAAGTTTCTGATTT 
64°C 
hFPR1 NM_001193306.1 ATGGAGACAAATTCCTCTCTCCC 
CTTTGCCTGTAACTCCACCTCTGC 
65°C 
hFPR2 NM_001462.3 ATGGAAACCAACTTCTCCACTCCTCGCTTTACCTCCT 
CATTGCCTGTAACTCAGTCTCTGCA 
65°C 
hFPR3 NM_002030.3 ATGGAAACCAACTTCTCCATTCCT 
CATTGCTTGTAACTCCGTCTCCTC 
65°C 
*Forward primers and reverse primers are listed in 5’ to 3’ direction. Shown are the specific primer sequences (= 
sequences complementary to target DNA). The reverse primers are given without the stop codon. #An extended 
nucleotide sequence was added to the 5’-end of all primers. All forward primers were fused to the sequence  
5’-AAAGAATTCAAGCTTCCTGCAGGCGCCACC–3’, which includes a restriction site for SbfI 
(CCTGCAGG) and a Kozak-sequence (GCCACC). All reverse primers have been fused with the sequence  
5’-TTTCCTCAATTGGATATCGCGGCCGCAAGAGCTCA-3’ carrying diverse restriction sites, including that 
for NotI (GCGGCCGC) and the stop codon (TCA). Online accession numbers are valid for BLAST 
(www.ncbi.nlm.nih.gov/blast/). 
PCR products were purified subsequently. 
 
34x 
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2.1.2. DNA-purification via DNA Clean & ConcentratorTM -5 -Kit 
The PCR products were purified with the DNA Clean & ConcentratorTM -5 kit (Zymo 
Research, D4003) according to manufacturer’s protocol. In brief: PCR product was diluted 
1:5 with the binding buffer.  Mixture was transferred to a Zymo-SpinTM Column and then 
centrifuged at 14.000 rpm for 30 s. The columns were rinsed with the wash buffer and 
subsequently centrifuged. Elution of the DNA in deionized, sterilized, nuclease free water was 
done in a final centrifugation step. Following this, the purified PCR products were analyzed 
by separation with agarose gel electrophoresis. 
 
2.1.3. Gel electrophoresis 
To investigate the size and purity of the purified PCR products, they were separated on 1% 
[w/v] agarose gels (dissolved in TBE). The separation chamber was filled with 100 ml TBE 
that contained one drop of 1%  [v/v] ethidium bromide (Roth, >98%). 10 µl of the DNA was 
mixed with 2 µl of 6x Fast Digest Loading Buffer (Fermentas) and then loaded on the agarose 
gel. Electrophoresis was performed in electrophoresis buffer containing 100 ml of 0.5% [v/v] 
TBE containing one drop of ethidium bromide. Electrophoresis was performed at 80 mV for 
30 min, with a start current of 400 mA. Acquisition of the gels was performed with a 
Gel/ChemiDocTM system (BioRad). Pure products of the correct size were used as inserts for 
cloning into target expression vectors. 
 
2.1.4. Expression vectors 
The amplified complete coding sequence of each gene was ligated into two distinct 
mammalian expression vectors (complete coding sequences are given in appendix 5). Both 
vectors are modified versions of commercially available plasmids, provided by Dr. Bernd 
Bufe (Saarland University, Medical School Homburg, department of Physiology). One 
plasmid is based on the pcDNA3.1(+) vector (Invitrogen) and was modified by inserting a 
SbfI restriction site between the HindIII and NotI restriction sites (Figure 2-1 A). It was used 
generally for functional studies3. All receptor genes cloned into pcDNA3.1 are referred to as 
unmodified or native receptors. The second plasmid is based on the pcDNA5/FRT/TO vector 
(Invitrogen) and was used for immunocytochemical detection (Figure 2-1 B).  
                                                     
3 For functional analysis of  mFpr-rs1 the pcDNA5/FRT/TO construct was used 
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pcDNA5/FRT/TO contains an additional SbfI restriction site between the restriction sites for 
HindIII and NotI. In addition, the plasmid contains a sequence that encodes a peptide 
comprising the first a 39 amino acids of bovine rhodopsin, fusing this Rho-tag to the 
N-terminus of the receptor. This Rho-tag sequence serves as an N-terminal epitope for anti-
Rho antibodies and therefore allows immunefluorescence analysis of receptor expression. The 
nucleotide sequence of the Rho encoding element is given in appendix 4. Both plasmids 
provide ampicillin resistance for selective growth in E. coli.  
 
Figure 2-1 | Schematics of expression vectors  
Shown is the insertion site for the PCR products. [A] Unmodified receptors cloned into pcDNA3.1(+) using SbfI 
and NotI restriction sites. [B] Receptors cloned into pcDNA5/FRT/TO carrying a 5’ fusion sequence that codes 
the first 39 amino acids of bovine rhodopsin (Rho-tag). Start (ATG) and Stop (TGA) codons are indicated below 
gene cassettes. The first start codon of pcDNA5/FRT/TO belongs to the rhodopsin sequence. Restriction sites are 
indicated as black bars. Corresponding restriction enzymes are shown above the gene cassettes. Abbreviations: 
BGH = Bovine Growth Hormone poly-adenylation site, CMV = cytomegalovirus promotor sequence, Rho = 
rhodopsin-derived fusion sequence, TO = tetracycline operator (image and text adapted from Schumann, 2010). 
All PCR products were cloned into the vectors by using SbfI and NotI as restriction enzymes.  
 
2.1.5. DNA digestion 
For a directed ligation into the plasmid, purified PCR products as well as target vectors were 
digested with two different octamer-cutting restriction endonucleases (SbfI and NotI). 
Digestion was performed according to the Fast Digest digestion enzyme protocol (Fermentas): 
 1 µl 10x Fast Digest Buffer (Fermentas) 
 0.5 µl NotI (= 10 Units) 
 0.5 µl SbfI (= 10 Units) 
 PCR product (150-200 ng) or vector plasmid (1 µg), respectively 
 The reaction was adjusted to a final volume of 10 µl with deionized H2O  
 To prevent re-circularization all plasmids were dephosphorylated adding 0.5 µl  
(1 MBU) of thermosensitive alkaline phosphatase (Promega) to the reaction 
 After incubation at 37°C for 45 minutes, the reaction was ready for ligation. 
Materials & Methods 
Page | 14  
 
2.1.6. DNA ligation 
The sticky ends of the digested DNA (plasmid and PCR products, respectively) were ligated 
according to the fast-link-ligation protocol (Fermentas). The reaction contained the following 
components: 
 0.5 µl 10x ligation buffer (Fermentas) 
 0.5 µl ATP (Fermentas) 
 0.5 µl T4-DNA-ligase (Fermentas) 
 Insert ( = PCR products), 10-20 ng 
 Target-plasmid, 5-10 ng 
 Adjust volume to 5 µl with H2O (de-ionized) 
The whole reaction was mixed on ice and then incubated at RT for 60 min. After this, the 
resulting receptor constructs were ready for transformation. 
 
2.1.7. Transformation 
Heat shock transformation was performed with chemically highly competent E. coli cells 
(NEB 10-β, >109, New England Biolabs). Bacterial stocks were stored at –80°C and thawed 
on ice. 15 µl of the thawed stocks were incubated with 1 µl of the ligation reaction on ice for 
10 min. Water bath heat shock was performed for 30 s at 42°C and the reaction was 
subsequently cooled on ice for 60 s. For regeneration, bacteria were suspended in 150 µl 
SOC-medium (RT) and then incubated for 1 h at 37°C, shaking. Bacteria were grown over 
night at 37°C on agar plates containing 50 µg/ml ampicillin. 
 
2.1.8. DNA isolation 
For each genetic construct, at least three ampicillin-resistant clones were picked for restriction 
analysis. In addition, all picked clones were plated on a replica plate for back-up.  The clones 
that were picked for restriction analysis were suspended in 5 ml of 2YT-medium in 15 ml 
reaction tubes and kept shaking overnight at 37°C. Grown bacteria were harvested by 
centrifugation (3200 x g, RT, 10 min) and plasmids were purified using the Promega 
PureYieldTM Plasmid Miniprep kit according to the manufacturer’s protocol.  
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2.1.9. Restriction analysis 
To identify bacterial clones carrying the desired insert, restriction analyses were conducted 
with the purified plasmids. Digestion was usually performed with EcoRI and SacI following 
the Fast Digest protocol (see 2.1.5.). Prediction of the restriction sites was performed with the 
Vector NTI® software (life technologies). Specific restriction patterns were analyzed via 
separation by agarose gel electrophoresis.  
 
2.1.10. Gel electrophoresis for restriction analysis 
Digested DNA was separated on 1% [w/v] agarose gels as described in 2.1.3. Clones 
exhibiting the correct restriction pattern were chosen for large-scale DNA purification in 
order to precipitate high amounts of the desired plasmid. 
 
2.1.11. DNA purification and precipitation 
Clones carrying the desired constructs were picked from the replica plate and suspended in 
250 ml of 2YT-medium, supplemented with ampicillin (1 µg/ml) and incubated overnight at 
37°C. Bacteria were then harvested and the plasmids were isolated according to the 
PureYieldTM Plasmid Midiprep system (Promega). The purified DNA was precipitated (see 
below) and dispensed in deionized water to a concentration of 1 µg/µl. 
Precipitation protocol: 
 10% (v/v) of 3 M sodium-acetate pH 5.2 were added to the purified plasmid DNA 
 absolute ethanol (> 99,8% [v/v]) was added at 250% [v/v], with a final 
concentration of 70% enabling overnight precipitation at -20°C  
 precipitated reaction was then centrifuged at 12,000 rpm at 4°C for 15 min and 
then washed with 1 ml 80% [v/v] ethanol 
 after centrifugation (5 min, 12,000 rpm, 4°C) the precipitate was dried at RT and 
resuspended in deionized water. 
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2.1.12. DNA sequencing 
The insert sequences of the resuspended plasmids were sequenced by MWG-Biotech AG 
using Sanger technology. The sequencing Probes were dispatched as premixes containing the 
forward or reverse primers, respectively, and the DNA templates. The primers were 
synthesized by Sigma-Aldrich. Forward primer: 5’-cgcaaatgggcggtaggcgtg-3’, anneals to the 
CMV promoter sequence (Tm = 76.8°C). Reverse primer: 5’-tagaaggcacagtcgagg-3’, anneals 
to the BGH poly adenylation site (Tm = 59°C). Plasmids carrying the desired genes were 
stored at -20°C and used for transfection in HEK cells. 
 
2.2. HEK cell culture 
2.2.1. Cell line and cultivation 
Authenticated, mycoplasma-free HEK293T PEAKrapid cells were obtained from ATCC® 
(CRL2828™). This immortalized cell line is retrieved from fetal human embryonic kidney 
cells that were transformed with adenovirus 5 DNA. The cells were grown in 75 cm2 cell 
culture flasks in 20 ml cell culture medium (DMEM with [4.5 g/l] glucose (Invitrogen) + 5% 
[v/v] heat-inactivated bovine calf serum (Biochrom), 10,000 U/ml penicillin G (Sigma), 
10 mg/ml streptomycin and 2 mM L-glutamine (Sigma) and kept until 80 - 90% confluence. 
Culture propagation was performed by rinsing cells in Dulbecco’s Phosphate Buffer (Sigma-
Aldrich) until the cells were detached from the flask bottom. For regeneration, cell culture 
medium was added to the phosphate buffer (9/1). After centrifugation (900 rpm, 3 min) cells 
were resuspended in 10 ml fresh culture medium. One ml of the suspension was used to 
inoculate a new flask. For experimental analysis, cells were seeded at 20 - 30% confluence on 
poly-D-lysine (Sigma) coated optic 96-well µ-clear plates (greiner bio-one). The coating 
procedure was performed with 50 µl of 10 µg/ml poly-D-lysine (dissolved in PBS) per well 
and incubated for 30 min at RT. The cell line was generally propagated until 35 passages were 
reached. Then a new aliquot was thawed.  
 
2.2.2. Transient transfection 
Cells were seeded in 96-well plates as described above (chapter 2.2.1) and transfected after 
48 h at a confluence of 50-70%. Transient transfection was accomplished with the poly-
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cationic DNA transfection-reagent jetPEITM (PeqLab), according to manufacturer’s 
instruction: For one well, 0.25 μg of plasmid-DNA was diluted in 150 mM NaCl to a final 
volume of 10 μl, gently mixed and spun down. At the same time, 0.5 μl of jetPEI™ were 
diluted in 150 mM NaCl to a final volume of 10 μl, and mixed thoroughly. The 10 μl jetPEI™ 
solution and the 10 μl DNA solution were combined, mixed and spun down. The mixed 
solution was then incubated for 30 minutes at RT. Before transfection, the cell culture 
medium in each well (100 µl) was replaced once to remove dead cells and debris. For the 
actual transfection, 20 μl of the jetPEI™/DNA mix were added to each well. The plates were 
carefully swirled and then incubated for 48 h (37°C, 5% [v/v] CO2). For calcium imaging 
experiments, cells were generally co-transfected with the G protein alpha subunit Gα16 (if not 
stated otherwise, see chapter 2.6.1). Both plasmids were mixed in equal amounts while the 
total amount of transfected DNA was kept constant. Cells were imaged 48 h after transfection, 
with a cell density of approximately 50,000 cells / well.  
 
2.2.3. Handling of frozen cell stocks 
HEK293T cell aliquots were kept in cell culture medium (chapter 2.2.1.) supplemented with 
10% [v/v] DMSO and an additional 10% [v/v] FCS according to the instructions of the ATCC 
and then frozen to -80°C at a rate of 1°C/min using a Nalgene cryo container. Cells were then 
transferred to liquid nitrogen at -196°C and stored until use. For inoculation of new cell 
passages, stock cells were thawed at 37°C and then transferred to cell culture medium in a 
10 cm diameter culture dish. The medium was replaced after 4 h to wash out remaining 
DMSO and cell debris. 
 
2.3. Isolation and cultivation of primary cells  
2.3.1. Human blood collection 
All donors were apparently healthy adults of both genders that volunteered for the blood 
donation. Use of human blood for the investigation of monocytes and granulocytes has been 
approved by the local ethics committee. 
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2.3.1.1. Blood collection for isolation of human monocytes 
Blood for monocyte purifications was kindly provided by the Institute of Clinical 
Haemostaseology and Transfusion Medicine, University of Saarland School of Medicine, 
under direction of Prof. Dr. Hermann Eichler. All donors donated whole blood for 
thrombocyte collection. Therefore, thrombocytes were filtered out of the blood. The 
thrombocyte-depleted blood was kept in leukocyte-reducing-system chambers at RT for 2 h 
before it was used for the monocyte isolation. All donations were anonymous to me. 
2.3.1.2. Blood collection for isolation of human granulocytes 
Whole blood was taken from adult volunteers in accordance with Ethics commission 
application HA249/11 (11-21-2011, Ärztekammer des Saarlandes). Blood was collected into 
blood collection tubes containing 16 international units (I.U.) heparin (S-Monovette Li-
Heparin®, SARSTEDT) and was subsequently used for granulocyte isolation. All donors were 
familiar to me. 
2.3.1.3. Collection of autologous serum 
Autologous (= donor self) serum was collected by draining the donor’s blood into serum 
collection tubes with silicate as clot activator (S-Monovette Serum-Gel®, SARSTEDT). For 
clotting, the tube was inverted several times and the blood was incubated for 30 min at RT.  
After centrifugation, (2500 x g, 10 min at 20°C) supernatant autologous serum was ready for 
use. For each experiment, only freshly prepared serum was used. 
 
2.3.2. Isolation of human monocytes 
Peripheral blood leukocytes (PBLs) were purified from thrombocyte-filtered blood by Ficoll 
density gradient centrifugation using LeucosepTM filter columns (greiner bio-one) according 
to the manufacturer’s instructions: Blood was transferred to LeucosepTM columns filled with 
Ficoll (LSM1077, PAA) and centrifugalized (1000 x g, 10 min, RT). Centrifugation of human 
blood in a separation medium like Ficoll results in four phases or bands (Figure 2-2). The 
uppermost phase contains serum or plasma, respectively. The second band is the cell-enriched 
interphase (or buffy coat) comprising peripheral blood mononuclear cells (PBMCs, = 
lymphocytes, macrophages and monocytes). The third phase contains the separation medium 
and the last phase encompasses granulocytes and erythrocytes. The cell-enriched fraction, 
which contained PBMCs was harvested and washed three times with HBSS (Sigma-Aldrich) 
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Figure 2-2 | Schematics of 
blood separation by Ficoll 
density gradient 
centrifugation 
Shown is the dispersion of the 
blood into different phases after 
centrifugation. PBMC = 
Peripheral blood mononucleated 
cells. PMN = Polymorph 
nucleated cells. RBC = Red 
blood cells. 
by centrifugation (250 x g, 10 min, RT). The resulting pellet 
was resuspended in 5 ml HBSS. Remaining erythrocytes and 
thrombocytes were abolished by lysis for 2 min (lysis buffer in 
mM: 155 NH4Cl, 10 KHCO3 and 0.13 EDTA in H2O, pH 7.3). 
Lysis was stopped by washing with HBSS and leukocytes were 
resuspended in PBS supplemented with 0.5% BSA [w/v]. 
PBMCs were enriched in a cell incubator through adhesion in 
standard culture flasks containing monocyte cell culture 
medium (RPMI1640 + 10% FCS [v/v] + 1% [v/v] 
penicillin/streptomycin). During this procedure, monocytes will 
adhere to the flask bottom, while lymphocytes will remain in 
suspension and can hence be washed out. After two hours, the 
medium was exchanged and the supernatant (including non-
adherent lymphocytes) discarded. After overnight incubation at 
37°C and 5% [v/v] CO2, the cells were washed with PBS plus 
0.5% [w/v] BSA, scratched from the flask surface and resuspended in fresh medium. For 
regeneration, cells were then seeded in 24-well Ultra-Low attachment plates (Corning, 3473) 
at a density of 1 - 4 x 106 cells/ml, and incubated overnight at 37°C and 5% [v/v] CO2. Cells 
were then ready for experiments. 
 
2.3.3. Isolation of human granulocytes 
2.3.3.1. Isolation of human granulocytes by Ficoll/dextran separation 
10 ml of heparinized whole blood were supplemented with 17 ml of cool Ca2+/Mg2+ - free 
Dulbecco’s Phosphate Buffered Saline (DPBS). Then, 13 ml of the separation medium 
(FicoLIte-H, Linaris) was layered above the cell suspension and subsequently centrifuged 
(560 x g, 25 min, RT and with brakes turned off). The PBMC interphase and the Ficoll 
supernatant were withdrawn and discarded. The remaining phase, containing granulocytes and 
red blood cells was then transferred to a new 50 ml reaction tube and DPBS was added to a 
maximal volume of 25 ml.  3% Dextran solution (T500, Pharmacosmos A/S) was added 1/1 
and mixed well. Cells were incubated for 15-30 min at RT. Dextran promotes erythrocyte 
rouleaux formation, resulting in differential sedimentation of the erythrocytes and leukocytes, 
the latter of which will remain in the supernatant. The supernatant, including the cells was 
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then transferred to a new tube and filled with DPBS to a volume of 50 ml and then 
centrifuged (339 x g, 6 min and 4°C). For hypotonic lysis of remaining erythrocytes, the 
resulting supernatant was removed and the cell pellet was gently suspended in 5 ml of sterile 
water (Aqua ad iniectabilia, Braun). To stop the lysis, 45 ml of DPBS were added after 30 
seconds. The complete lysis was repeated once. The resulting granulocyte pellet was gently 
resuspended in autologous medium (RPMI 1640 + L-Glutamine + 1% [v/v] Na-Pyruvate  
+ 1% [v/v] Pen-Strep and + 1% [v/v] autologous Serum) and kept on ice until use. 
Granulocytes were now ready for use in chemotaxis assays, ROS detection, calcium imaging, 
and immunocytochemistry.  
2.3.3.2. Isolation of human granulocytes using CD16+ pluriBeads 
Isolation of human granulocytes by the pluriBead kit (CD16 S-pluriBeads® anti-hu, 
19-01600-10, pluriSelect) enables direct purification of granulocytes from whole blood 
without the use of separation media. This method relies on specific antibodies targeted against 
the surface marker CD16, which is expressed in high amounts on human granulocytes. The 
antibodies are chemically conjugated to polystyrene beads, which are 30 µm in diameter and 
cannot be phagocytized. Cells bound by these antibodies are retained by a 27 µm cell strainer 
(size exclusion) while non-bound cells will run through. Granulocytes were prepared from 
heparinized whole blood according to the manufacturer’s protocol. After harvesting, the cells 
were suspended in the corresponding calcium imaging loading solution. 
 
2.3.4. Isolation of mouse leukocytes 
2.3.4.1. Isolation of murine neutrophils from peripheral blood with Ly6G pluriBeads  
Mice were euthanized by introduction of CO2 and subsequently decapitated. Blood (~ 500 µl / 
mouse) was squeezed out of the body and collected into a polystyrene tube. The blood was 
directly supplemented with 4 mM EDTA to suppress coagulation. Isolation of murine 
granulocytes using the pluriBead kit (S-pluriBeads® anti-mouse-Ly6G, 21-Ly6G0-11, 
pluriSelect) was carried out according to the manufacturer’s instructions. This method works 
equivalent to the CD16+ pluriBeads kit described above, but relies on specific antibodies 
targeted against Ly6G, which is located in the plasma membrane of murine neutrophils. After 
harvesting, the cells were suspended in the corresponding calcium imaging loading solution 
(chapter 2.12.2.). 
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2.3.4.2. Isolation of murine leukocytes from bone marrow 
Bones represent an excellent source for large numbers of white blood cells, as they are 
developed and stored within the bone marrow. Isolation of fresh mouse bone marrow 
leukocytes was performed according to Boxio (Boxio et al., 2003). Adult mice (male and 
female) were euthanized by CO2 introduction and subsequently decapitated. Abdomen and 
legs were rinsed with 70% [v/v] ethanol prior to organ collection. Tibia from both hind legs 
was freed of soft tissue and stored in cooled Ca2+/Mg2+ - free HBSS buffer for 10 minutes. 
Epiphysis was cut off both sides and 3 ml buffer was forced through the diaphysis (bone shaft) 
with a syringe (needle: 20G) to flush out the bone marrow. The resulting solution was strained 
with a 100 µm cell strainer (BD) and then centrifuged (300 x g, brake on lowest level) for 8 
min at 4°C. Supernatant was discarded, cells were counted with a MOXITM Z cell counter and 
softly resuspended in HBSS (Ca/Mg) + 1/1000 Fluo-4 AM. 150,000 cells were seeded per 
well (100 µl) in uncoated µ-clear plates (greiner) and incubated for 45 min at RT. Wells were 
rinsed two times with HBSS prior to experiment. Calcium responses of bone marrow 
neutrophils to several ligands were compared to responses of neutrophils isolated via Ly6G 
beads from peripheral blood. I could not detect a significant functional difference and decided 
to use the direct isolation from bone marrow as it yielded ~ 10 times more healthy cells. 
 
2.3.5. Dissociation of mouse vomeronasal sensory neurons 
Adult OMP/GFP mice (Potter et al., 2001) were anesthetized and killed by introduction of 
CO2 and subsequent decapitation. The VNO sensory epithelium was isolated as described 
before (Chamero et al., 2011). In brief: the vomeronasal sensory epithelia of adult mice 
(usually three per experiment) were detached from the cartilage of the vomer bone and 
transferred to PBS at 4°C. With a scalpel, the epithelia were minced in freshly prepared 
dissociation solution, which contained 2.2 units/ml Papain (Worthington), 1.1 mM EDTA 
(Fermentas), 5.5 mM cysteine-HCl (Sigma), and 50 units DNAseI (Fermentas) in PBS. The 
minced tissue was slightly triturated with a 1 ml pipette tip prior to incubation in the incubator 
(37°C, 24% [v/v] O2, 5% [v/v] CO2) for 18 minutes. Afterwards cells were triturated using a 
200 µl pipette tip and incubated for 2 min at RT. The reaction was stopped by adding stopping 
solution containing high-glucose DMEM (Invitrogen), 10% [v/v] FBS (Biochrom), and 1% 
[v/v] P/S (Sigma). Cells were then collected by centrifugation (0.2 rcf, 5 min, pre-cooled to 
8°C). After suspension in loading solution the cells were ready for calcium imaging. 
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2.4. Mice  
2.4.1. Mouse strains 
2.4.1.1. Wild type mice 
Adult C57Bl/6NCrl were purchased from Charles River and classified as specific pathogen-
free (SPF). These animals served as wild type controls for the knockout experiments and are 
denoted as +/+ mice. 
2.4.1.2. Fpr1-deficient mice 
Mice with a global deficiency in Fpr1 (C57BL/6NTac-Fpr1tm1GaoN6, denoted as –/– mice) 
were obtained from Taconic and reported as SPF. The Fpr1 ablation was created by targeted 
disruption of the Fpr1 open reading frame by a neomycin resistance cassette (Gao et al., 1999) 
(Figure 2-3).  
 
Figure 2-3 | Schematics showing the construct used for targeted disruption of Fpr1 in mice 
Shown are schematics of the targeting construct and the wild type locus of Fpr1. In the targeting construct a 
neomycin resistance gene (neor), shown in gray, is replaced 150 bp of the FPR open reading frame (red). The 
single headed arrows indicate open reading frames. The construct was targeted to a 7.8 kilo bases-encompassing 
allele in the wild type mouse. Modified from Gao et al., 1999. 
2.4.1.3. Mice heterozygous for Fpr1 
Heterozygous control animals (+/-) were bred by pairing C57BL/6NTac-Fpr1tm1GaoN6 with 
C57Bl/6NCrl mice. 
2.4.1.4. Heterozygous dOMP-GFP mice 
In dOMP-GFP mice, B6;129P2-OMPtm3Mom-MomJ, the coding region of the OMP (= 
olfactory marker protein) gene and part of the 3’ untranslated region was replaced by GFP 
(Potter et al., 2001). This process results in GFP expression in olfactory sensory neurons 
(Potter et al., 2001). Mice are available from the Jackson Laboratory (Stock number: 006667). 
To create heterozygous mice, dOMP-GFP mice were paired with C57Bl/6NCrl mice. 
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2.4.2. Mouse keeping and breeding 
Breeding pairs were kept in SPF areas. Offspring was kept in SPF areas until weaning (~ 3-4 
weeks). A 12-hour light-dark cycle was set, starting at 7.15 MET. Sterile water and food 
(Teklad 18% Protein Rodent Diet, Harlan) were fed ad libitum by the personnel of the animal 
facility. Mice used for experiments were between 5 and 12 weeks old. The German Animal 
Protection Act has been complied during husbandry and experiments.  
 
2.5. Immunocytochemistry 
2.5.1. Antibodies 
2.5.1.1. Primary antibodies 
All primary antibodies used in this study are summarized in Table 2-2.  
Table 2-2 | Primary antibodies used in this study* 
Antibody Target Clonality Isotype Provider Order number 
Used 
concentration 
hFPR1 human FPR1 monoclonal mouse IgG2A R&D Systems MAB3744 1 µg/ml 
hFPR2 human FPR2 monoclonal mouse IgG1,κ SANTA CRUZ 
BIOTECHNOLOGY, INC. 
sc-57141 0.2 µg/ml 
hFPR3 human FPR3 monoclonal mouse IgG2B R&D Systems MAB3896 1 µg/ml 
Rho 
4D2 of bovine 
rhodopsin 
polyclonal 
not 
determined 
Centre for Macular 
Research, University of 
British Columbia, Canada 
Dr. R. 
Molday,  
1/500 
CD14 human CD14 monoclonal mouse IgG1,κ Biolegend 325601 0.5 µg/ml 
CD66 
human 
CD66abce 
monoclonal mouse IgG2B Miltenyi Biotech 
130-093-155 
(APC)  
33 ng/ml 
Ly-6G mouse Ly6G monoclonal Rat IgG2a, κ Biolegend 127601 5 µg/ml 
KLH 
Keyhole 
Limpet 
Hemocyanin 
monoclonal mouse IgG2A R&D Systems MAB0031 1 µg/ml 
MOPC-21 unknown monoclonal mouse IgG1,κ Biolegend 400101 
 
0.2 µg/ml 
(hFPR2) 
0.5 µg/ml 
(CD14) 
*The table lists all primary antibodies used in this study. Shown are their specific targets, clonality, isotype of 
their constant region, provider, order number and the final concentrations at which they were used. The hFPR2 
antibody of Santa Cruz is the same as GM-0601 of aldevron, which has been used in many studies. 
All shown antibodies are directed against extracellular epitopes. Besides the CD66 antibody, 
which was conjugated with allophycocyanin, all other antibodies were unconjugated for 
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staining with a secondary antibody. Antibodies were stored and handled according to the 
provider’s instructions. 
2.5.1.2. Secondary antibodies 
The secondary antibodies used in this study were polyclonal goat anti-mouse antibodies, 
conjugated with either Alexa Fluor 488 or Alexa Fluor 555 (Invitrogen). They were used in 
final concentrations of 2 µg/ml. Alexa 488 was used in conjunction with the Rho-antibody 
while the Alexa 555 antibody was used for stainings with the remaining primary antibodies. 
Antibodies were stored and handled according to the provider’s instructions. 
2.5.2. Immunostaining 
HEK293T cells were fixated for 4 min at RT in 4% [v/v] methanol-free paraformaldehyde 
(Polyscience Inc.). Human monocytes and granulocytes as well as mouse leukocytes were 
fixated with 3% [v/v] methanol-free paraformaldehyde. All wells were washed three times by 
complete exchange of solutions by PBS. This procedure was used to fixate the cells without 
permeabilization of the plasma membrane, enabling analysis of cell surface expression. To 
permeabilize the cells (for visualization of total cellular expression), 0.3% [v/v] Triton-X was 
added for 30 min at RT after the fixation step. After blocking with 5% [v/v] FCS in PBS for 
30 min, the cells were incubated overnight at 4°C with the corresponding antibody in 
blocking solution. After washing three times, cells were incubated with the secondary 
antibody (dissolved in blocking solution) for 45 min at RT. The total number of nucleated 
cells was obtained by a counterstaining of the cell nuclei with 1 µg/ml Hoechst 33342 
(Hoechst) diluted with the secondary antibody. All wells were washed three times and 
subsequently analyzed. In general, only non-stimulated cells were used for 
immunocytochemical analysis. 
White blood cells naturally express receptors for binding of the constant regions of antibodies 
(Fc receptors), which can result in strong background signals during immunostainings. 
Therefore, so-called isotype controls are commonly used as background controls for 
immunefluorescence. These controls are of the same isotype as the desired antibody but 
targeted against antigens that are not present in the target cells. Isotype controls used were 
KLH for hFPR1 and MOPC-21 for hFPR2 and CD14. 
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2.5.3. Analysis and evaluation of immunefluorescence 
Pictures were taken with the imaging system BD Pathway Bioimager 855 (BD Bioscience) 
and quantified with the delivered software BD-image Explorer. Layer thickness (z-axis) of 
confocal images was 2.7 µm.  
 
2.6. Calcium Imaging 
2.6.1. G protein coupling of HEK293T cells  
Formyl peptide receptors are described as Gαi2-coupled GPCRs that employ signal 
transduction pathways utilizing phospholipase beta 2 (PLCβ2) to increase intracellular calcium 
levels (see chapter 1.5). However, the used cell line does not express all components of the 
signal transduction cascade required for intracellular calcium mobilization. To enable FPR-
dependent mobilization of internally stored calcium, a plasmid encoding the G alpha subunit 
Gα16 was co-transfected for calcium imaging experiments. G16 is a human G protein of the Gq 
type, naturally expressed in cells of the myeloid lineage (Tenailleau et al., 1997), which is 
known to couple a variety of GPCRs to the PLCβ1/IP3 signaling pathway (Offermanns and 
Simon, 1995). Once activated, the catalytic domain of Gα16 activates the PLCβ1/IP3 signaling 
cascade, resulting in an increase of intracellular calcium. It was tested, whether FPRs interact 
with distinct G proteins. To couple the GPCR interacting C-terminus of distinct G protein 
alpha subunits to the Gα16-induced PLCβ1/IP3 signaling pathway, G protein chimeras were 
used. These chimeras were created by substituting the last 44 to 47 C-terminal amino acids of 
human Gα16 or mouse G α15 by amino acids of other G protein alpha subunits (Table 2-3).  
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Table 2-3 | Plasmids used for co-transfection encoding distinct G protein chimeras* 
Name of co-transfected plasmid 
as listed in the lab 
Encoded protein or chimera C-terminal sequence derived from 
G protein type 
PHB102 G16-Gi2-44 human Gi2, Gi type 
PHB21 G16-Gz-44 human Gz, Gz type 
PHB185 G16-Go1A-44 human Go1A, Go type 
PHB9 G16-Ggust-44 human gustducin, Gi type 
PHB4 G16 (unmodified) human G16, Gq type 
PHB3 G15 (unmodified) murine G15, Gq type 
PHB226 G15-Golf-47 human Golf, Gs type 
*All vectors coding for chimeras and G proteins were provided by Dr. Bernd Bufe Bufe (Saarland University, 
Medical School Homburg, Department of Physiology). For creating the chimeras, the alpha subunit of human 
G16 was modified by replacing the last 44 amino acids with that of the indicated G proteins. The G15-Golf-47 
chimera was created by replacing the last 47 amino acids of G15 with that of Golf (table and text adapted from 
Schumann, 2010). 
 
2.6.2. Ratiometric single cell calcium imaging  
2.6.2.1. The BD Pathway 855 
Automated high-throughput Ca2+ imaging with single-cell resolution was performed with the 
BD Pathway 855 (BD Bioscience) bioimaging system. This fully automated confocal 
microscope allows high content kinetic live-cell imaging with an optional confocal setup. An 
automated liquid handling unit enables programmed application of liquids (e.g. ligands) in 
96-well plates with simultaneous live-cell imaging of individual cells. Coordinates of the 
imaged cells are saved and can be monitored after the experiment, enabling post-hoc analysis 
(e.g. with immunocytochemistry). Light is generated by 103 W mercury short arc lamps, 
which provide a broad excitation spectrum of 330 to 900 nm. A variety of excitation/emission 
spectra are made possible by a set of dichroic mirrors, excitation- and emission filters. Signals 
are detected by a Hamamatsu ORCA ER CCD camera. 
2.6.2.2. Ratiometric dye Fura-2 AM 
For ratiometric calcium imaging cells were loaded with the calcium sensitive dye Fura-2 AM 
(Molecular Probes). The acetoxymethyl ester of Fura-2 (Fura-2 AM) can pass the plasma 
membranes of cells. The ester moiety is then cleaved by intracellular esterases, yielding free 
Fura-2. This has its excitation maximum at 365 nm in calcium-free state. However, when 
bound to calcium, the excitation maximum of Fura-2 shifts to 340 nm and the emitted 
fluorescence increases with rising calcium concentrations. At the same time, the fluorescence 
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decreases when excited at 380 nm (Grynkiewicz et al., 1985). Calculation of the 340/380 nm 
ratio enables measuring of intracellular calcium concentrations independent from the 
intracellular dye concentration. Fura-2 was excited at 340 nm and 380 nm, respectively. 
Emission was measured at 435 nm due to preset filter sets. Hence, the calcium-induced Fura-2 
fluorescence intensity is given as the ratio of 340/380 nm. 
2.6.2.3. Loading procedure for conventional single cell imaging 
Fura-2 AM was dissolved 2 mM in DMSO. Cells in 96-well plates were loaded by exchange 
of culture medium with the corresponding loading solution (see chapter 2.13.) plus 2 µM 
Fura-2 AM. HEK cells, monocytes and granulocytes were then incubated at RT for three and 
one hour respectively. The HEK cells were loaded 48 h after transfection; granulocytes 30 
minutes and monocytes 48 h post isolation. Dissociated vomeronasal sensory neurons were 
suspended in loading solution (chapter 2.3.5 and 2.12.2), plated on Concanavalin A Type V –
coated (1 mg/ml, Sigma) 384-well plates (greiner, 655090) and incubated for 45 minutes on 
ice. All plates were then rinsed three times using the ELx50 ELISA cell-washer (BioTek).  
Loading solutions (buffer formulation is given in Table 2-5) 
 HEK293T cells: C1 + 2 µM Fura-2 AM 
 Human monocytes: Ringer + 2 µM Fura-2 AM 
 Human granulocytes: Ringer + 2 µM Fura-2 AM 
 Mouse leukocytes: HBSS (Ca/Mg) + 2 µM Fura-2 AM 
 Mouse vomeronasal sensory neurons: C1 + 3 µM Fura-2 AM + 1/20 BD Signal 
enhancer (BD Biosciences, 644243) 
2.6.2.4. Loading procedure for single cell imaging under perfusion conditions 
48 h post-transfection, cells were resuspended in imaging solution (chapter 2.12.2) + 2.2 µM 
Fura-2 AM (Invitrogen) by vigorous pipetting. Cells were then seeded into Poly-D-Lysine-
coated (10 µg/ml in PBS, Sigma) µ-slides (ibiTreat 6-channel µ-slides VI0.4, ibidi) to a 
confluency of 80-90% according to manufacturer’s protocol and incubated for 2 h at ambient 
temperature to load and adhere to the slide. Prior to imaging, each channel was rinsed with 
three volumes of C1 buffer solution to remove dye precipitates and other debris. Stimulation 
was done by application of 1.5 volumes of the diluted ligands and incubation for 30 seconds. 
Cells were rinsed for three minutes with a total of 256 volumes of bath solution after each 
stimulation. Calcium-dependent fluorescence signals of eGFP-positive cells were recorded at 
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0.5 Hz. Images were taken with the Bioimager 855 system and quantified using Attovision 
software (BD Bioscience). 
2.6.2.5. Recording and evaluation  
Fluorescence images were recorded at 0.5 Hz and analyzed with the attovision software. 
Ratiometric fluorescence maxima recorded from HEK293T cells were quantified by using the 
BD-image Explorer software (BD Bioscience) and plotted with Excel2007.  
 
2.6.3. High-throughput calcium imaging of cell populations with the FLIPR 
2.6.3.1. The FLIPR system (Fluorescence Imaging Plate Reader) 
The FLIPR system (Molecular Probes) is predominantly used in industry for pharmacological 
screenings. The system can detect fluorescence signals in all 96 wells of a given micro plate 
simultaneously. It is equipped with an automated pipetting robot that applies fluids to all 96 
wells at the same time. Excitation light is provided by an argon laser, exciting probes with 
488 nm. The fluorescence detection technology of the FLIPR is based on a cooled charge-
coupled device set-up (CCD camera). The detection optics is optimized to detect signals of a 
cell monolayer at the bottom of each well. 
2.6.3.2. The calcium sensitive dye Fluo-4 AM 
Similar to the Fura-2 AM described in chapter 2.6.2.2, Fluo-4 AM is an acetoxymethyl-
esterified product of Fluo-4 (Molecular Probes) which passes the plasma membrane and is 
then hydrolyzed intracellularly. Increase of intracellular Ca2+ levels leads to enhanced 
formation of calcium complexes with the dye, resulting in an increased fluorescence signal. 
Fluo-4, in contrast to Fura-2, is not ratiometric. Thus, the observed signals are not only 
dependent on calcium, but also on the intracellular dye concentration. It is to note that in 
several cell types anionic forms of the dye are actively extruded into the extracellular medium 
by ABC transporters (Di Virgilio et al., 1990). For experiments with HEK293T cells, the 
anionic-exchange-protein inhibitor probenecid (Sigma-Aldrich) was used to block the anion 
transport systems.  
2.6.3.3. Loading procedure 
Fluo-4 AM was dissolved 2 mM in DMSO. Cells in 96-well plates were loaded by exchange 
of culture medium with 50 µl of the corresponding loading solution (Table 2-5). Cells were 
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then incubated at RT in the dark for 4 h (HEK293T cells), 2 h (human monocytes), 1 h 
(human granulocytes) or 45 min (mouse leukocytes) respectively. HEK293T cells were 
loaded 48 h after transfection and monocytes 48 h post isolation. Granulocytes and mouse 
leukocytes were loaded directly after isolation. The 96-well plates were then rinsed 3 times 
using the ELx50 ELISA cell-washer (BioTek) and measured subsequently. For hFPR2 
blocking experiments in granulocytes, 5 µM PBP10 was added to the loading solution. 
Loading solutions (buffer formulation is given in Table 2-5) 
 HEK293T cells: C1 + 2 µM Fluo-4 AM, + 50 µM probenecid 
 Human monocytes: Ringer + 2 µM Fluo-4 AM 
 Human granulocytes: Ringer + 2 µM Fluo-4 AM 
 Mouse leukocytes: HBSS (Ca/Mg) + 2 µM Fluo-4 AM 
For calcium imaging with human granulocytes, two loading procedures were compared. One 
loading solution was in the above listed Ringer. The other one was in culture medium. Both 
worked similarly well. 
2.6.3.4. Recording and evaluation 
Fluorescence was measured in relative fluorescence units (RFU) and signal analysis was 
performed with the FLIPR software. The fluorescence baseline was recorded before ligand 
application (ten images, in intervals of two seconds). The recorded baseline signal inherits 
information about the loading condition of the cells since it is measured in absence of physical 
and chemical stimuli. This baseline signal (F0) was used for normalization of the recorded 
fluorescence amplitudes after stimulation (dF). Signal amplitudes (dF) were determined as the 
maximal signal minus the minimal signal after application of the ligand. Normalization of 
calcium responses was calculated by dividing the maximal change in fluorescence after 
stimulation by baseline fluorescence (dF/F0). Evaluation was performed with Excel2010 
(Microsoft). Dose-response curves were calculated using GraphPad Prism 5.0 (see below). 
Experiments were routinely performed in duplicates. Experiments on HEK293T cells, human 
monocytes and granulocytes were generally performed as duplicates. Experiments on mouse 
leukocytes were generally done in triplicates. 
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2.7. Detection of reactive oxygen species (ROS) 
2.7.1. Radical detection with Amplex®UltraRed 
2.7.1.1. The Amplex®UltraRed dye 
Monocyte/granulocyte-dependent radical production was measured using the hydrogen 
peroxide (H2O2) reactive Amplex®UltraRed (Molecular Probes). Amplex®UltraRed is not 
cell permeable and thus, enables exclusive measurement of extracellular reactive oxygen 
species (ROS). This assay does not discriminate between the distinct ROS as the substrate 
does only react with H2O2. Upon stimulation, phagocytes respond primarily by producing 
superoxide radicals, which in turn can also react to form H2O2. Therefore, this assay was used 
for detection of ROS in general. Amplex®UltraRed is a fluorogenic substrate for horseradish 
peroxidase (HRP) which catalyzes the H2O2-dependent reduction of the reagent to the 
fluorescent dye Resorufin (global excitation/emission maxima: 568 nm / 581 nm). To 
accelerate the formation of hydrogen peroxide, superoxide dismutase (SOD) that catalyzes the 
dismutation of superoxide into oxygen and hydrogen peroxide was added. 
2.7.1.2. Loading procedure of monocytes and granulocytes for ROS detection 
Amplex®UltraRed was dissolved in DMSO to a concentration of 5 mM. After isolation, the 
cells were transferred into Ringer solution containing 50 µM Amplex®UltraRed, 0.1 Units/ml 
HRP (Sigma-Aldrich) and 10 Units/ml SOD (Sigma). The cells were then carefully seeded in 
black 96-well µ-clear plates (greiner bio-one) to the following densities: monocytes ~ 30,000; 
granulocytes ~ 100,000 per well in 180 µl). The subsequent application of stimuli was done 
manually directly before measurement. 
2.7.1.3. Recording and evaluation of ROS detection experiments 
The plates were placed in a pre-heated (37°C) fluorescence plate reader (Tecan GENios Pro) 
and rocked for 30 s. The fluorescence dye was excited at 535 nm excitation and emission was 
recorded at 590 nm with bottom reading settings. H2O2 concentrations were calculated from 
relative fluorescence units (RFU) 10 min after application by employing H2O2 calibration 
curves. Experiments were routinely performed as duplicates. 
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2.8. Chemotaxis 
2.8.1. Chemotaxis assay principle 
For chemotaxis experiments HTS Transwell® chambers (pore size: 3 µm; Corning) were used. 
This assay uses an upper Transwell® insert that is placed on a clear 96-well cell-culture plate 
(lower compartment). The cells are seeded into chambers of the Transwells while the stimuli 
are present in the lower compartment. The bottom of the Transwells® is made up by a 
polycarbonate membrane with pores of 3 µm in diameter (pore density: 2 x 106 pores per cm²). 
Human neutrophils, which are between 12 to 15 µm in diameter, can only pass the membrane 
by morphological changes during active processes like diapedesis. Therefore, only adequately 
activated cells will migrate through the membrane. Since the stimuli are dissolved in the 
lower compartments and not in the Transwell® inserts, a concentration gradient is established 
by diffusive exchange of the media components through the pores. After 2 hours, the cells that 
adhered to the bottom of the lower compartment were counted in the BD pathway 855. To 
facilitate automatic focusing, the cells were stained with the live cell plasma membrane stain 
CellMaskTM Deep Red. 
 
2.8.2. Granulocyte stimulation for chemotaxis 
Migration assays were performed according to the manufacturer’s protocol. Briefly: chambers 
of the lower compartment were filled with 235 µl of medium supplemented with the desired 
stimulus or control, respectively. The Transwell insert was then placed on the plate. For each 
chamber, 100,000 granulocytes were suspended in 75 µl medium (supplemented with 
1/10,000 CellMaskTM Deep Red) and then seeded into a chamber of the Transwell insert. The 
cells were incubated for 2 h in a cell culture incubator (37°C, 5% [v/v] CO2) and then counted 
with the BD pathway855 at RT. For the counting, the Transwell insert was discarded.  
 
2.8.3. Evaluation 
The number of transmigrated cells was determined by automated counting with the BD 
Pathway 855 system. Measurements were always done in duplicates. 
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2.9. Image processing software 
2.9.1. Drawing of the ligand structures 
Natta projections of chemical structures of amino acids and modifications were drawn with 
Accelrys Draw, 4.1 (accelrys). 
 
2.9.2. Figures and images 
Fluorescence images were processed with Adobe Photoshop Elements 10 (Adobe systems 
Incorporated). All figures were composed and processed in Adobe Illustrator CS6 (32-bit) on 
a computer using Micrsosoft Windows 7. The schematic organization of the olfactory system 
was composed and processed with Corel DRAW®X5 version 15.0.0.486 (Corel Corporation). 
 
2.10. Statistics and mathematics 
2.10.1. Significance tests 
Statistical significance was generally calculated with Excel2010 (Microsoft), using the 
formula for unpaired, two-tailed t-tests with unequal variance (heteroscedastic t-test). Each 
t-test was performed by including all population sample values (i.e. each single data point). 
2.10.2. Average and standard deviation 
Experiments were generally performed in duplicates or triplicates. Calculation of the 
experiment’s sample average was done with the basic calculation for arithmetic mean for each 
experiment (= experimental mean). Subsequently, all experimental mean values (obtained 
from independent experiments, e.g. transfection, donors) were averaged with the basic 
calculation for the arithmetic mean. Empirical/population standard deviation was calculated 
using the formulaටஊሺ௫ି௫̅ሻమ௡ 	 , with ̅ݔ  being the sample’s arithmetic mean and n being the 
sample size. Error bars show the empirical standard deviation of the average, if not stated 
otherwise. 
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2.10.3. Concentration-response curves 
Maximal amplitudes of normalized curves were set to 100% and curves were calculated with 
Graph Pad Prism 5.0 (GraphPad Software) using the equation for sigmoidal dose response 
with variable slope (“log(agonist) vs. normalized response -- Variable slope”). Normalization 
was used for comparison of ligand affinities. Usually, the difference of EC50 values obtained 
with normalized and non-normalized curves was not higher than a factor of 2. Curves with 
non-normalized peaks were calculated using the following equation: “log (agonist) vs. 
response -- Variable slope”. For statistical analysis, only curves with calculated R2-
values > 0.95 were used in general. The absolute sum of squares for normalized curves was 
generally < 900. Usually, 10 µM was the highest ligand concentration used to create 
concentration-response curves. Empirical standard deviation and average were calculated 
from independently obtained EC50 values. 
 
2.11. Online tools and databases 
2.11.1. Internet addresses 
Signal peptide database (update 2010-06-11)      http://www.signalpeptide.de/ 
Virulence Factor database (update 2014-22-01)    http://www.mgc.ac.cn/VFs/main.htm 
Sequence blast (latest access 2014/08)      http://blast.st-va.ncbi.nlm.nih.gov/Blast.cgi 
TMHMM Server v. 2.0 (latest access 2015/01)  http://www.cbs.dtu.dk/services/TMHMM/ 
 
2.11.2. Prediction of transmembrane helices of cloned FPR constructs 
Prediction of transmembrane helices of cloned FPR constructs was performed with the online tool 
for “Prediction of transmembrane helices in proteins” (TMHMM) of the Center for Biological 
sequence Analysis, Technical University of Denmark. 
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2.12. Solutions, media and ligands 
2.12.1. Ligands  
Substances were routinely dissolved in watery solutions (C1, Ringer) to concentrations 
between 0.1 and 1 mM. Strongly hydrophobic substances were generally dissolved as 10 mM 
stocks in DMSO (99.7%, Sigma). All stocks were stored in small aliquots at -20°C until use. 
All ligands are listed in Table 2-4. 
Table 2-4 | Ligands used in this study*  
Ligand Primary structure Provider and purity Solvent 
Organic compounds 
LXA4 (LipoxinA4) C20H32O5 Biozol, Cayman Chemical, ≥95% Ethanol 
ATL (15-R-Epi-Lipoxin) C20H32O5 Biozol, Cayman Chemical, ≥95% Ethanol 
DMSO C2H6OS Sigma, 99,73%  / 
n-pentyl acetate CH3CO2(CH2)4CH3 abcr , ≥ 99% / 
2-heptanone CH3(CH2)4COCH3 Sigma, ≥ 99% / 
LPS Lipopolysaccharide extract of Salmonella typhimurium Sigma (L2262) Water 
Naturally-derived peptides 
CRAMP33 GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ Innovagen, >95%  C1 
CRAMP39 ISRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ Innovagen, >95%  C1 
rCRAMP33 GLLRKGGEKFGEKLRKIGQKIKDFFQKLAPEIEQ Innovagen, >95%  C1 
Temporin A, amide  FLPLIGRVLSGIL-NH2  Anaspec/MoBiTec ≥95% C1 
CO1 f-MFINRWLFS GenScript Corporation, >96,9% DMSO 
ND1-6I f-MFFINILTL Gen Script Corporation, >95,3% DMSO 
ND1-6T f-MFFINTLTL Gen Script Corporation, >98,2% DMSO 
f-MLF f-MLF Sigma, ≥97%  C1 
T20  (DP178, Enfuvirtide) Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-
NH2 
Anaspec/MoBiTec ≥95% C1 
V3 [ADP715] RKRIHIGPGRAFYTTKN Anaspec/MoBiTec, ≥95% C1 
V3 gp120 HIV (JR-FL) SIHIGPGRAFYTT Anaspec/MoBiTec, ≥95% C1 
V3 gp120 HIV (BK-130) RIHIGPGRALYTT Anaspec/MoBiTec, ≥95% C1 
µPAR (84 – 95)  Ac-AVTYSRSRYLEC-NH2  Anaspec/MoBiTec, ≥95% C1 
Beta – Amyloid (16 – 22)  KLVFFAE Anaspec/MoBiTec, ≥95% C1 
Beta – Amyloid (35 – 42)  MVGGVVIA Anaspec/MoBiTec, ≥95% C1 
Ac2-26 Ac-AMVSEFLKQAWFIENEEQEYVQTVK Tocris, 95% C1 
Substance P RPKPQQFFGLM-NH2 Biotrend, 98,1% C1 
RANTES (11 – 22)  CFAYIARPLPRA Anaspec/MoBiTec, ≥95% Ringer 
C5a (37 – 53) RAARISLGPRCIKAFT Anaspec/MoBiTec, ≥95% C1 
ESP-1 ADQKTNHEADLKNPDPQEVQRALARILCALGELDKLVK
DQANAGQQEFKLPKDFTGRSKCRSLG 
Gift of Dr. Pablo Chamero# C1 
W-peptide library 
W-Peptide WKYMVm-NH2 Innovagen, >95%,  C1 
(L)-W-Peptide WKYMVM- NH2 Tocris, 99.2%  C1 
M-peptide MMHWAm- NH2 GenScript Corporation, >99.6% C1 
(L)-M-peptuide MMHWAM- NH2 GenScript Corporation, >96.8% C1 
W-Library Peptide 9 WKYMVVm- NH2 GenScript Corporation, >95% C1 
W-Library Peptide 10 WKYMVmm- NH2 GenScript Corporation, >97% C1 
W-Library Peptide 20 AAAWKYMVm- NH2 GenScript Corporation, >98.8% C1 
W-Library Peptide 19 AAWKYMVm- NH2 GenScript Corporation, >96.3% C1 
W-Library Peptide 12 AWKYMVm- NH2 GenScript Corporation, >98% C1 
W-Library Peptide 1 WKYMVm- NH2 GenScript Corporation, >97% C1 
W-Library Peptide 2 KYMVm- NH2 GenScript Corporation, >99% C1 
W-Library Peptide 3 YMVm- NH2 GenScript Corporation, >99% C1 
W-Library Peptide 4 MVm- NH2 GenScript Corporation, >95% C1 
W-Library Peptide 5 Vm- NH2 GenScript Corporation, >95% C1 
W-Library Peptide 11 WKYMVm GenScript Corporation, >97% C1 
W-Library Peptide 32 WKYMVm-CHO American peptide Company, 86.9% C1 
W-Library Peptide 47 f-MVMYKW GenScript Corporation, >97.8% C1 
Table is continued on the next page. 
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Ligand Primary structure Provider and purity Solvent 
Bacterial signal peptides 
Streptococcus-SP1 f-MGFFIS VCPBIO, >95.43% C1 
Bacillus-SP2 f-MKNFKG VCPBIO, >96.42% C1 
Staphylococcus-SP3 f-MFIYYCK VCPBIO, >97.24% C1 
Salmonella-SP4 f-MAMKKL VCPBIO, >96.14% C1 
Borrellia-SP9 f-MLKKVY VCPBIO, >95.24% C1 
Haemophilus-SP5 f-MVMKFK VCPBIO, >95.74% C1 
Staphylococcus-SP22 f-MKKFNI VCPBIO, >95.30% C1 
Salmonella-SP23 f-MKKFYS VCPBIO, >97.18% C1 
Salmonella-SP24 f-MKKFRW VCPBIO, >98.34% C1 
Psychromonas-SP6 f-MLFYFS VCPBIO, >95.59% DMSO 
Desulofotomaculum-SP8 f-MLFYLA VCPBIO, >97.04% C1 
Shewanella-SP7 f-MLFKYS VCPBIO, >95.18% C1 
Vibrio-SP10 f-MPKLNR United biosystems, >95.32% Ringer 
Vibrio-SP11 f-MVKIIF United biosystems, >96.63% Ringer 
Staphylococcus-SP12 f-MNKKLL United biosystems, >95.21% Ringer 
Clostridium-SP13 f-MKKNLV United biosystems, >95.67% Ringer 
Corynebacterium-SP14 f-MEQQNK United biosystems, >95.72% Ringer 
Streptomyces-SP15 f-MVPISI United biosystems, >95.85% Ringer 
Hydrogenobacter-SP16 f-MKKFLL United biosystems, >95.78% Ringer 
Bacillus-SP17 f-MMKMEG United biosystems, >96.38% Ringer 
Listeria-SP18 f-MKKIML United biosystems, >95.27% Ringer 
Desulfovibrio-SP19 f-MKFCTA United biosystems, >95.44% Ringer 
Zymomonas-SP20 f-MTNKIS United biosystems, >95.91% Ringer 
Neisseria-SP11 f-MKTSIR United biosystems, >96.04% Ringer 
SP8 FuLe f-MLFYLALPCTLVIFFASKALYAI VCPBIO, >95.59% Ringer 
SP1 FuLe f-MGFFISQSKQHYGIRKYKVGVCSALIALSILGTRVAA VCPBIO, >95.18% Ringer 
SP22 FuLe1 f-MKKFNILIALLFFTSLVISPLNVKA VCPBIO, >96.83% C1 
Cytokines 
MIP1-a APYGADTPTA CCFSYSRKIP RQFIVDYFET SSLCSQPGVI 
FLTKRNRQIC ADSKETWVQE YITDLELNA 
Peprotech, >98% Ringer 
RANTES (CCL5) SPYSSDTTPC CFAYIARPLP RAHIKEYFYT 
SGKCSNPAVV FVTRKNRQVC ANPEKKWVRE 
YINSLEMS  
Peprotech, >98% Ringer 
MCP-1 (CCL2) QPDAINAPVT CCYNFTNRKI SVQRLASYRR 
ITSSKCPKEA VIFKTIVAKE ICADPKQKWV 
QDSMDHLDKQ TQTPKT  
Peprotech, >98% Ringer 
FPR antagonists 
Boc1 N-tertbutoxy-MLF  Bachem, 98% DMSO 
Boc2 N-tertbutoxy-FlFlF Bachem, 98% DMSO 
WRW4 WRWWWW-NH2 Tocris, 98% C1 
Cyclosporin H C62H111N11O12 santa cruz biotechnology, inc.(≥95%) DMSO 
PBP10 RhodaminB-QRLFQVKGRR Calbiochem, ≥95% DMSO 
*The table lists all ligands used in this study. All peptide/protein sequences are given in one letter code. Small 
case letters denote D-amino acids. Ac- = N-terminal acetylation, -CHO = C-terminal form aldehyde, f- = 
N-terminal formylation, -NH2 = C-terminal amidation. # Dr. P. Chamero, Saarland University, Medical School 
Homburg, Department of Physiology 
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2.12.2. Imaging buffers  
All buffers listed in Table 2-5 were freshly prepared from sterile stock solutions directly 
before use.  
Table 2-5 | Buffers used for functional imaging* 
 C1 Ringer HBSS (Ca/Mg) 
NaCl 130 155 138 
KCl 5 4.5 5.3 
CaCl2 2 1 1.3 
MgCl2 / 1 0.5 
MgSO4 / / 0.4 
D-Glucose 5 10 5.5 
HEPES (pH7.3,NaOH) 10 5 10 
Na2HPO4 / / 0.3 
KH2PO4 / / 0.4 
Used for imaging of HEK293T, mouse neurons Human monocytes/neutrophils Mouse leukocytes 
*Shown is the composition of the used imaging buffers. Concentrations are given in mM.  
 
2.12.3. Cell culture media  
All media listed in Table 2-6 were stored at 4°C and kept for no longer than 6 weeks after 
opening. 
Table 2-6 | Cell culture media# 
Supplemented with Basic medium 
 Dulbecco’s Modified Eagle 
Medium (Sigma, D6429) 
RPMI-1640 
(Gibco, 21875) 
RPMI-1640 
(Gibco, 21875) 
Penicillin/streptomycin (Sigma) 1%* 1%* 1%* 
L-Glutamine (Sigma) 2 mM* 2 mM 2 mM 
Serum 5% FCS (heat inactivated)* 10% FCS (heat inactivated)* 1% autologous serum* 
Sodium-pyruvate (Sigma) / / 1%* 
Used for culture of HEK293T Human Monocytes Human neutrophils 
#Shown is the composition of the used cell culture media. Heat inactivated, tetracyclin/LPS free FCS was 
purchased from Biochrom; 1% [v/v] penicillin/streptomycin (= 10,000 U/ml penicillin, 10 mg/ml streptomycin).  
* = added manually after purchase. All media were stored at 4°C and kept for no longer than 1 month after 
opening. 
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2.12.4. Bacterial growth media  
Bacterial growth media listed in Table 2-7 were freshly prepared and autoclaved subsequently. 
Table 2-7 | Bacterial growth media# 
 LB-medium  2x YT-medium  SOC-medium 
Casein hydrolyzate 1% (w/v) 1.6% (w/v) 2% (w/v) 
Yeast extract 0.5% (w/v) 1% (w/v) 5% (w/v) 
NaCl 1% (w/v), pH 7 0.5% (w/v), pH 7 0.05% (w/v) 
KCl / / 2.5 mM 
MgCl2 / / 10 mM 
D-Glucose / / 20 mM 
Ampicillin 100 µg/ml (agar plates) * 100 μg/ml, before culture start / 
pH 7 7 7.4 
#Shown is the composition of the used bacterial growth media. All components were purchased from Carl Roth 
GmBH or VWR International. * = For LB-agarplates 100 μg/ml ampicillin and 1.5% (w/v) agar were added 
 
2.12.5. Other solutions 
PBS (general buffer) 
140 mM NaCl 
10 mM Na2HPO4 
2.7 mM KCl 
1.76 mM KH2PO4 
pH: 7.4 (NaOH) 
 
TBE (Electrophoresis buffer) 
89 mM tris base 
89 mM boric acid 
2 mM EDTA-Na2 
 
HBSS (buffer for mouse leukocyte isolation) 
138 mM NaCl 
5.3 mM KCl 
0.4 mM KH2PO4 
0.3 mM Na2HPO4 
5.5 mM D-Glucose  
10 mM HEPES (pH7.3/NaOH)
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Chapter 3 
 
Results 
 
 
 
3.1. Pharmacological analysis of formyl peptide receptors of the immune 
and the vomeronasal system 
3.1.1. Functional analysis of formyl peptide receptors in HEK293T cells 
3.1.1.1. FPRs from the immune and vomeronasal system can be expressed in HEK293T cells 
In order to investigate the pharmacological properties of formyl peptide receptors, the full 
coding sequences of all three human FPRs (hFPR1, hFPR2 and hFPR3) and seven murine 
FPRs (mFpr1, mFpr2, mFpr-rs1, mFpr-rs3, mFpr-rs4, mFpr-rs6, and mFpr-rs7) were cloned 
into expression vectors used for heterologous expression in HEK293T cells (chapter 2.1). The 
coding regions of all cloned receptors were sequenced for at least two times. The sequences of 
mFpr1, mFpr2, mFpr-rs1, mFpr-rs3, mFpr-rs4, mFpr-rs6, hFPR2 and hFPR3 did not contain 
nucleotide exchanges leading to altered amino acid sequences of the receptors compared to 
the reference sequences (Table 3-1). Two receptors, mFpr-rs7 and hFPR1 exhibited variations 
in their nucleotide sequence that resulted in amino acid exchanges. For mFpr-rs7, the leucine 
at position 147, at the N-terminal edge of the 4th transmembrane domain, was replaced by 
phenylalanine in the cloned construct. This single nucleotide polymorphism is also found in 
several BAC clones (AC154490, AC121539.7). The construct of hFPR1 showed three 
variations leading to exchanges in the amino acid sequence. There was a conservative 
substitution of valine at position 101 (3rd transmembrane helix) by leucine, which has already 
been described by several groups (Boulay et al., 1990b; Sahagun-Ruiz et al., 2001). Arginine 
at position 163 (4th transmembrane helix) was replaced by histidine and asparagine at position 
192 (2nd extracellular loop) was replaced by lysine. The substitution N192K has already been 
observed by Sahagun-Ruiz and been allocated to one haplotype with V101L (Sahagun-Ruiz et 
al., 2001).  
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Table 3-1 | Overview of cloned receptors, online accession, and detected amino acid exchanges* 
Receptor Amino acid exchanges to 
reference sequence 
Accession 
(online reference) 
mFpr1 / NM_013521.2 
mFpr2 / NM_008039.2 
mFpr-rs1 / NM_008042.2 
mFpr-rs3 / NM_008040.2 
mFpr-rs4 / NM_008041.2 
mFpr-rs6 / NM_177316.2 
mFpr-rs7  F147L AF437513.1 
hFPR1 V101L, R163H, N192K NM_001193306.1 
hFPR2/ALX / NM_001462.3 
hFPR3 / NM_002030.3 
*The table lists all cloned formyl peptide receptors investigated in this study. Observed differences in the amino 
acid sequence of the cloned receptors compared to the reference sequence are shown in the middle column. The 
first letter marks the amino acid of the reference sequence that is substituted in the cloned receptor (second 
letter). The number between the letters indicates the amino acid position of this substitution. The right column 
contains the online accession numbers of the reference sequences. Complete coding sequences are given in 
appendix 5. Online references are valid for BLAST (www.ncbi.nlm.nih.gov/blast/).  
In order to investigate whether these receptor constructs can be used for heterologous 
expression, immunocytochemistry, employing antibodies targeted against specific epitopes of 
the receptors were used to monitor receptor expression. Thus far, most murine FPRs lack 
specific antibodies. To circumvent this problem, an epitope containing the 39 most N-terminal 
amino acids of bovine rhodopsin was fused to the N-terminus of each receptor (Rho-tag). This 
enabled comparative examination of the expression levels with an antibody directed against 
this Rho-epitope. Figure 3-1 A depicts a representative immunocytochemistry staining of 
permeabilized cells transfected with mFpr1 and the empty vector control. The staining 
showed prominent expression of mFpr1 in the HEK293T cells (Figure 3-1 A). Detailed 
quantification of total cellular expression levels for all human and mouse FPRs is given in 
Figure 3-1 B. The overall expression levels ranged from 47% to 87% of the cells in the visual 
field. Expression rates of the human FPRs were 61 ± 18% for hFPR1, 87 ± 6% for hFPR2 and 
61 ± 13% for hFPR3. The expression rates of the murine FPRs were as follows: 73 ± 6% 
(mFpr1), 48 ± 6% (mFpr2), 49 ± 13% (mFpr-rs1), 50 ± 8% (mFpr-rs3), 58 ± 11% (mFpr-rs4), 
58 ± 7% (mFpr-rs6) and 50 ± 7% (mFpr-rs7). The negative control (empty vector transfected 
cells) did not show any staining. Note that the expression levels of all human FPRs were 
comparable to those of the mouse Fprs. Pharmacological analysis of G protein-coupled 
receptors (GPCRs) requires sufficient expression and correct insertion of the receptors into 
the cell’s plasma membrane. Therefore, the immunocytochemical staining was also performed 
on non-permeabilized cells. As the Rho-tag was fused to the N-terminus of the receptors, only 
receptors whose N-terminus was correctly located on the extracellular side could be stained 
(Figure 3-1 C). Figure 3-1 C shows a representative cell surface staining of unpermeabilized 
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cells transfected with mFpr1. In line with the expectations, the surface staining of 
unpermeabilized cells showed a clearly prominent signal located at the plasma membrane. 
Quantification of cell surface expression rates for all receptors is given in Figure 3-1 D. 
 
Figure 3-1 | Expression of human and murine formyl peptide receptors in HEK293T cells 
[A] Representative immunostaining of permeabilized HEK293T cells transfected with either mFpr1 or empty 
vector (mock), showing cytoplasmic localization of mFpr1. The cells were stained with an antibody directed 
against the Rho-tag fused to the receptor’s N-terminus. [B] Quantification of cytoplasmic expression of all 
human and mouse receptors. Data were recorded in octuplicates. [C] Representative cell surface staining using 
the same antibody as in A. The cells were not permeabilized to visualize receptors exclusively expressed in the 
cell membrane. [D] Quantification of cell surface expression of all receptors. Data are representative for one 
experiment measured in octuplets. Scale bar: 40 µm; Numbers in parentheses above each bar denote the number 
of measured cells; error bars = standard deviation.  
Surface expression rates ranged from 21% to 46%, with a mean of 37% ± 6%, while the 
background was below 0.1%. Expression rates for hFPR1 and hFPR2 were 44% and 47% 
respectively, while for hFPR3 it was 21%. The percentage of cells expressing vomeronasal 
FPRs (mFpr-rs1, mFpr-rs3, mFpr-rs4, mFpr-rs6, and mFpr-rs7) was comparable to that of 
cells expressing human and mouse FPR1 and FPR2. While mFpr1 and mFpr2 expression was 
detected in 25% and 37% of the cells respectively, the detected surface expression rates were 
28% for mFpr-rs1, and over 40% for mFpr-rs3 (40%), mFpr-rs4 (50%), mFpr-rs6 (43%), and 
mFpr-rs7 (40%). Expression rates of 5% are already sufficient for functional studies of 
GPCRs, as former publications have shown (Bufe et al., 2002).  
This shows that the receptor constructs can be heterologously expressed in HEK293T cells 
and should be suited for pharmacological analysis. For this, a high-throughput calcium 
imaging assay was established that enables investigation of agonist-induced calcium 
responses of the heterologously expressed formyl peptide receptors.  
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3.1.1.2. Heterologously expressed immune FPRs can be measured in calcium imaging  
To verify if receptor activation can be detected, single-cell Ca2+ imaging was used. To ensure 
efficient G protein coupling the cells were co-transfected with a plasmid encoding the human 
Gq - type G protein subunit Gα16. This promiscuous G protein subunit has been shown to 
efficiently couple hFPR1 to the IP3/Ca2+ pathway (Offermanns and Simon, 1995). For 
activation of the cells they were challenged with the well-known FPR agonist f-MLF. f-MLF 
is the prototypical high affinity agonist (EC50 in the upper picomolar range) for human and 
mouse FPR1 (Schiffmann et al., 1975; Quehenberger et al., 1993). It is also an agonist for 
human and mouse FPR2, however, with reduced affinity (Quehenberger et al., 1993). In line 
with my expectations, 258 of 364 cells (~71%) transfected with hFPR14 did respond with 
calcium elevations when treated with 9 µM of f-MLF (Figure 3-2 A). Notably, the cells did 
not respond to application of buffer. This excludes mechanical stimulation of the transfected 
cells. Moreover, none of the 337 control cells (empty vector transfection) responded to f-MLF. 
However, the cells responded to 30 µM of ATP, an activator of endogenous purinergic 
receptors that served as an excitability control (Figure 3-2 A).  
Figure 3-2 | Single cell calcium imaging of human and murine FPRs in HEK293T cells 
[A] Representative calcium imaging experiment with single cell resolution: shown are calcium transients of cells 
transfected with hFPR1 or empty vector upon stimulation with 9 µM of the prototypical agonist f-MLF. Each 
trace represents a single cell. Upper panel: 258 of 364 hFPR1-transfected cells responded to f-MLF (red traces = 
responding cells, gray traces = non-responder). Lower panel: 337 cells transfected with empty vector served as 
control. Bath solution was served as a control for application artifacts; 30 µM ATP, an activator of endogenous 
purinergic was used to monitor cell excitability. Scale: y-axis (A334/380 ratio = 1); x-axis (time = 0.5 min). [B] 
Quantification of single cell experiments averaged over eight wells. Numbers in parentheses above each bar 
denote the number of measured cells. Error bars = standard deviations. 
This demonstrates that heterologously expressed hFPR1 can readily be monitored in calcium 
imaging. Detailed quantification for all receptors showed responses for 34 ± 7% of cells 
transfected with hFPR2,  49 ± 4% of cells transfected with mFpr1 and  20 ± 3% of cells 
transfected with mFpr2 (Figure 3-2 B). Note that the number of responders detected for 
                                                     
4 The cells were transfected with the plasmid coding for the receptor hFPR1. For easier understanding, only the 
name of the genetic construct will be used (hFPR1). 
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mFpr2 transfected cells is about 50% reduced compared to mFpr1 transfected ones. Under 
these conditions, no responses were observed for hFPR3 or any of the mouse vomeronasal 
FPRs. Since no signals have been observed for the vomeronasal FPRs, I next tested other 
well-described FPR ligands to verify the functionality of the heterologous expression assay. 
The single cell calcium imaging assay grants high spatial resolution but it takes much time to 
test larger array of substances on several receptors. Therefore, a high-throughput calcium 
imaging system, which simultaneously monitors cell populations of approximately 50,000 
cells/well rather than single cells in 96 well plates, was established to test several well-known 
FPR agonists on human and mouse receptors. First, to verify that the assay is suited for 
calcium imaging of heterologously expressed FPRs, f-MLF was tested in concentration-
response experiments on HEK293T cells expressing hFPR1 (Figure 3-3 A). f-MLF has been 
described to be highly affine in calcium imaging assays, with EC50 values in the upper 
picomolar range (Quehenberger et al., 1993). As expected the ligand proved to be highly 
affine for hFPR1, exhibiting a threshold activation of ≤ 100 pM with an EC50 of 544 pM. 
Following this, a number of well-known FPR agonists were tested on hFPR1, hFPR2, mFpr1 
and mFpr2 (Figure 3-3 B). These agonists comprised the formylated mitochondrial peptides 
CO1 and ND1-6I (Rabiet et al., 2005) and the synthetic hexapeptides W-peptide and L-W-
peptide (Bae et al., 2001; Baek et al., 1996). All substances were able to activate human and 
mouse FPR1 and FPR2 (Figure 3-3 B).  
Figure 3-3 | Mass population calcium imaging of human and murine FPRs in HEK293T cells  
[A] Representative concentration-response experiment as measured in the FLIPR: shown are calcium transients 
of cells transfected with hFPR1 upon stimulation with decreasing concentrations of f-MLF. RFU = relative 
fluorescence units. [B] Quantification of calcium responses of cells transfected with hFPR1, hFPR2, mFpr1, 
mFpr2 or empty vector (mock) towards various known FPR agonists (representative for at least two independent 
transfections). 
Interestingly, the signal amplitude observed for mFpr2 was 50% reduced compared to mFpr1 
when challenged with 10 µM f-MLF. This reduction corresponds nicely to the 50% reduced 
number of responders observed in the single cell calcium imaging assay (Figure 3-2 B), 
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demonstrating the fidelity of the FLIPR assay. However, when f-MLF, CO1 and ND1 where 
applied on vomeronasal FPRs, no responses could be observed (not shown). To verify that the 
lack of response is not due to a failure in interaction with Gα16, the cells were co-transfected 
with distinct G proteins or G protein-chimeras. The enzymatic body of these chimeras 
consisted of Gα16 but the last 44 amino acids of the C-terminal tail were substituted by those 
of other G protein α-subunits like Gi2 and Go1A (chapter 2.6.1). Since the C-terminus of the G 
protein is a determinant in interaction with GPCRs, this modification enables coupling of 
receptors that usually interact with Gi2 or Go1A (or other respective subunits) to the IP3/Ca2+ 
pathway (Mody et al., 2000). Tests with G protein-chimeras, including those of Gi2 and Go1A, 
showed that immune FPRs can interact with a variety of G protein chimeras carrying 
C-termini from Gi,  Gz, Go, Ggust, and Golf  (Fig. 3-4). Both, mFpr1 and mFpr2 showed 
responses towards f-MLF when co-transfected with plasmids coding for G protein-chimeras 
with C-termini from Gi, Gz, Go, and Ggust. These signals were comparable to the signals 
observed by co-transfection of Gα16. However, no signals were detected for the vomeronasal 
FPRs. Gα16 is a human G protein subunit and it is not imperative that murine FPRs can 
employ this G protein to its full extent. Hence, it was tested whether the mouse receptors 
prefer Gα15, the murine ortholog of Gα16 (Fig. 3-4). Both, mFpr1 and mFpr2 exhibited calcium 
responses following stimulation with f-MLF. These responses however, were about 50% 
lower than those observed for Gα16. Again: no signals for the VNO FPRs. To test whether the 
vomeronasal FPRs prefer interaction with olfactory G proteins, a chimera consisting of Gα15 
in which the 47 C-terminal amino acids were replaced by that of the Gαolf subunit was co-
transfected. Although mFpr1 and mFpr2 were able to couple to this G-protein, no signals 
were observed for the VNO FPRs. Very similar results have been observed with the 
mitochondrial peptide CO1.   
These data verify the general functionality of the assay and suggest that there is no deficiency 
in G protein coupling.  
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Figure 3-4 | Influence of G protein chimeras on calcium imaging of human and murine FPRs in HEK293T 
cells 
Influence of G protein co-transfection on receptor-dependent calcium signal as measured in the FLIPR cell 
population assay (representative for two experiments). Cells were co-transfected with plasmids coding for mouse 
FPRs and different G proteins alpha subunits or chimeras and were stimulated with 33.3 µM f-MLF. Each 
combination was averaged over three wells. The chimeras were Gα16, carrying a C-terminal substitution of the 
44 most C-terminal amino acids by those of the corresponding G protein alpha subunits (Gαi2, Gαo1A, Gαz, 
Gαgust). The Golf-chimera consisted of the enzymatic body of Gα15, carrying a C-terminal substitution of the 47 
most C-terminal amino acids by that of Golf. All receptors carried Rho-tags. no receptor/no G protein = empty 
vector. Error bars = standard deviations. Adapted from Schumann, 2010. 
The next step involved the testing of a set of eleven substances on all three human and all 
eight mouse receptors to see whether the vomeronasal FPRs can be activated in general. First 
experiments revealed surprising results: for initial experiments hydrophobic ligands were 
diluted in the organic solvent DMSO. Unexpectedly, DMSO alone activated cells expressing 
hFPR2, mFpr1 or mFpr2 at a concentration of 2% [v/v] (= 282 mM) (Fig. 3-5 A). Cells 
transfected with hFPR1, hFPR3, mFpr-rs1, mFpr-rs3, mFpr-rs4, mFpr-rs6, or mFpr-rs7 
showed no specific response toward 2% DMSO. The threshold of concentrations capable of 
inducing calcium signals in receptor transfected cells were 0.3% for mFpr1 and mFpr2 (Fig. 
3-5 B) and 1% for hFPR2. Concentrations > 2% always led to unspecific signals in the control 
group transfected with the empty vector. The threshold concentration for these unspecific 
signals was 2%. However, those signals had different kinetics as those of cells transfected 
with mFpr1 or mFpr2 (Fig. 3-5 B). In contrast to the control group, calcium signals of mFpr1 
and mFpr2 transfected cells showed a fast onset with a steep slope (Fig. 3-5 B), enabling 
discrimination of specific and unspecific signals. Nevertheless, to verify if these responses 
were indeed receptor-dependent, control experiments were performed. First, it was 
investigated whether the signals were mediated by the co-expressed G protein Gα16. Indeed, 
DMSO-evoked signals were only seen in cells co-expressing the receptor and the G protein 
(Fig. 3-1-5 C). Second, it was tested whether the DMSO evoked signals seen in mFpr1 or 
mFpr2 transfected cells could be abolished if the receptors were desensitized by pre-
application of the agonist f-MLF. The results show that cells, pre-treated with 30 µM f-MLF, 
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did not respond to subsequent application of 2% DMSO (Fig. 3-5 D). Third, dose-response 
experiments on mouse mFpr1 and mFpr2 showed that the activation was dose-dependent, 
with an EC50 of 97 mM for mFpr1 and an EC50 of 55 mM for mFpr2 (Fig. 3-5 E). Together 
these data indicate that the calcium signals evoked by 2% DMSO are mediated by mFpr1, 
mFpr2 and hFPR2, respectively, as only the combination of receptor and G protein led to 
DMSO-dependent calcium mobilization. These results show that the use of DMSO as an 
organic solvent or cosolvent is critical. Therefore, concentrations > 0.1% [v/v] were avoided 
in this study.  
 
Figure 3-5 | Specific activation of hFPR2, mFpr1 and mFpr2 by DMSO 
Mouse FPRs were heterologously expressed in HEK293T cells and responses of the receptors to DMSO were 
measured using calcium imaging (FLIPR). [A] 2% [v/v] DMSO (= 282 mM) activates the immune FPRs hFPR2, 
mFpr1 and mFpr2 (gray and blue) but none of the vomeronasal FPRs (red). Data averaged over three 
independent transfections. [B] Original calcium transients as measured in the FLIPR. Threshold activation for 
unspecific signals (empty vector) was observed at concentrations ≥ 2% [v/v]. RFU = relative fluorescence units. 
[C] Signals evoked by 2% [v/v] DMSO depended on the presence of co-transfected Gα16. (Data averaged over 
two independent transfections). [D] DMSO evoked signals (2% [v/v]) could be cross-desensitized by 30 µM 
f-MLF. (Data averaged over three independent transfections). [E] mFpr activation is dose-dependent (EC50 
mFpr1 = 97 mM, EC50 mFpr2 = 55 mM). To generate a dose-response profile the background signal (empty 
vector) was subtracted from signals obtained for FPR expressing cells. Curves are representative for five 
independent transfections. Black dotted line = amplitude of empty vector signal (background). Statistical 
significance of homoscedastic t-test: * = p ≤ 0.05, ** = p ≤ 0.001; n.s. = not significant (compared to empty 
vector control).  
To perform the compound screening on the murine FPRs, at first eleven substances were 
tested in calcium imaging. In order to create high pharmacological variance, the chosen 
peptides were of different origins, thereby exhibiting highly disparate primary structures. The 
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well-known f-MLF was used as a control. Although the immune FPRs mFpr1 and mFpr2 
were activated in nanomolar concentrations, no signals have been observed for the 
vomeronasal FPRs in concentrations up to 30 µM5. Similar results have been observed for the 
N-terminally formylated peptide ND1-6I (Fig. 3-6 A and B). This peptide is derived from the 
mouse mitochondrial NADH-dehydrogenase subunit I and belongs to some of the most potent 
FPR ligands (Rabiet et al., 2005). While it activated mFpr1 and mFpr2, no responses were 
monitored for the vomeronasal FPRs when applied to concentrations up to 5 µM. FPRs are 
also described to respond to several peptides derived from viral hull proteins. V3 gp120 HIV 
(BK-130), a peptide derived from the V3 loop of HIV-1 (Shen et al., 2000), was able to 
activate mFpr1 while another HIV-1-derived peptide, T20 (Su et al., 1999b), induced calcium 
signals in cells expressing mFpr1 (Fig. 3-6 B). Neither of the two substances was capable of 
evoking responses by activating one of the vomeronasal FPRs.  The human annexin A1 
mimetic peptide Ac2-26 is an N-terminally acetylated peptide containing 25 amino acids 
(Walther et al., 2000). It is known to activate hFPR1, hFPR2, hFPR3 as well as mFpr1, and 
mFpr2 (Ernst et al., 2004). In my experiments it could clearly activate mFpr1 and mFpr2 but 
no vomeronasal FPR (Fig. 3-6 B). The rana temporaria-derived Temporin A amide (Chen et 
al, 2004), which belongs to the class of anti-microbial peptides selectively activated mFpr2 
but no other mouse FPR at concentrations up to 3 µM (Figure 3-6 C). Similar results haven 
been observed for CRAMP39, another anti-microbial peptide known to activate mFpr2 
(Kurosaka et al., 2005). When mFpr2 transfected HEK293T cells were challenged with 3 µM 
CRAMP39, they responded with calcium signals (not shown). At first, it seemed that 
CRAMP39 was also a powerful activator of all vomeronasal FPRs. This ligand however, 
elicited unspecific signals in cells transfected with the empty vector when applied at 10 µM 
(Appendix 1 A). mFpr2, which is a described receptor for CRAMP (Kurosaka et al., 2005), 
showed significantly increased signals towards CRAMP.  In rare occasions, such unspecific 
signals have been detected at concentrations of 1 µM (Appendix 1 B). This was also observed 
for the isoforms CRAMP33 and rCRAMP33 (Appendix 1 B). Those three CRAMP 
substances were therefore excluded from further experimentation and evaluation.  
So far, no responses have been observed for the vomeronasal FPRs, questioning the functional 
expression of this receptor subfamily. In further experiments, however, two compounds were 
investigated that were capable of activating at least one of the VNO-FPRs: mFpr-rs1 showed 
                                                     
5 Concentrations of 100 µM induced calcium currents in cells transfected with the mFpr-rs1 construct. The 
observed signals were at the detection limit (not shown). 
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calcium responses towards the synthetic hexapeptides W-peptide and M-peptide (Figure 3-6 
D). Both substances did also activate all human FPRs as well as the mouse immune FPRs 
mFpr1 and mFpr2. For mFpr1, peaks of responses induced by W-peptide and M-peptide were 
similar to those seen for the formylated peptides f-MLF and ND1-6I (Figure 3-6).  
 
Figure 3-6 | Cell population-based calcium imaging of heterologously expressed FPRs 
Mouse FPRs were heterologously expressed in HEK293T cells and stimulated with various FPR agonists. 
Calcium responses were measured with the FLIPR. mFprs naturally expressed in the immune system are shown 
in blue while vomeronasally expressed FPRs are shown in red. [A] N-terminally formylated peptides like the 
bacterial f-MLF or the mitochondrial ND1-6I activated mFpr1 and mFpr2 but no other tested mouse FPR. [B] 
Calcium responses towards HIV-1-derived peptides. [C] Calcium responses towards the human endogenous 
immune modulator Ac2-26 and the frog anti-microbial Temporin A amide. [D] mFpr-rs1 (red arrow) is activated 
by the synthetic immune FPR agonists W-peptide and M-peptide. Black dotted line = amplitude of background 
signal (empty vector). Statistical significance (compared to empty vector): ** p ≤ 0.01. Each bar was averaged 
over three (two for M-peptide) independent transfections.  
The results shown in Figure 3-6 demonstrate that the vomeronasal receptor mFpr-rs1 responds 
to W-peptide and M-peptide. The calcium transients observed for mFpr-rs1 were smaller in 
amplitude with a less steep slope compared to mFpr1 and mFpr2 (Figure 3-7 A), indicating a 
lower grade of sensitivity. In order to get deeper insights into the pharmacological profiles of 
W-peptide and M-peptide, the responses of mFpr1, mFpr2 and mFpr-rs1 were compared in 
concentration-response analyses (Figure 3-7 B). Comparison of W-peptide concentration-
response curves demonstrated a remarkable functional conservation between immune system-
derived mouse FPRs. The EC50 values for mFpr1 and mFpr2 were 1.1 ± 0.17 nM and 
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0.39 ± 0.25 nM, respectively (Figure 3-7). Similar results were observed for the M-peptide. 
The computed EC50 values were 18.7 ± 6.7 nM for mFpr1 and 87.5 ± 20.7 nM for mFpr2. 
Interestingly, both receptors showed a higher affinity towards W-peptide than M-peptide. This 
however, does not apply for mFpr-rs1: the calculated EC50 values were 505 ± 209 nM for W-
peptide and 738 ± 174 nM for M-peptide. 
 
Figure 3-7 | W-peptide and M-peptide are activators of mFpr-rs1 
Concentration-response curves of W-peptide and M-peptide on heterologously expressed mFpr-rs1 obtained by 
calcium imaging. [A] Typical calcium traces of cells expressing mFpr1, mFpr2 or mFpr-rs1 compared to the 
empty vector as monitored by the FLIPR. RFU = relative fluorescence units. Data are representative for three 
independent transfections [B] Dose-response-relationship of cells transfected with mFpr-rs1 towards W-peptide 
and M-peptide. Number of independent experiments is given in parentheses. EC50 values are given in nM.  
These experiments confirm that at least one vomeronasal FPR can be activated and measured 
in calcium imaging. It does suggest that vomeronasal FPRs can respond but that the lack of 
responses for mFpr-rs3, mFpr-rs4, mFpr-rs6, and mFpr-rs7 is due to the fact that they were 
not challenged with the appropriate stimulus. Hence, the compound screening was extended 
to more substances, adding up to 23 in total.  
 
3.1.2. FPR agonist screening reveals divergent pharmacological profiles of immune 
FPRs and vomeronasal FPRs 
In order to get further insights into the pharmacology of the vomeronasal FPRs, in summary a 
set of 23 ligands was selected for screening (chapters 3.1.1. and 3.1.2). The ligand selection 
was based on several parameters: First, the selected compounds should comprise well-known 
FPR ligands, including powerful FPR agonists. Second, the selected agonists should originate 
from different biological areas with distinct functions. Third, the selected ligands should 
comprise substances of distinct chemical classes. Fourth, since many FPR ligands are peptides, 
the selected peptides should exhibit diversity in amino acid sequence, peptide chain length 
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and chemical modifications. Fifth, to increase the structural variability, some substances were 
chosen as structural derivatives of known FPR ligands. 14 substances, W-peptide, M-peptide, 
Ac2-26, f-MLF, ND1-6I, CO1, T20, Temporin A amide, uPar 84-95, LipoxinA4, 15-(R)-
Lipoxin, CRAMP39, Substance P, and WRW4 were chosen because they are described 
human, mouse or rabbit FPR ligands (Migeotte et al., 2006). Five peptides are structural 
variants of already known FPR agonists: V3 gp120 HIV (JR-FL), V3 gp120 HIV (BK-130), 
and ADP715 HIV-I are orthologs of the V3 peptide, isolated from the HIV-1 envelope loop 
V3 of distinct HIV-I strains (Shen et al., 2000; Moore et al., 1995). CRAMP39 is an extended 
isomer of CRAMP33 and rCRAMP33 is its corresponding rat ortholog (Kurosaka et al., 2005; 
Chromek et al., 2006). beta amyloid 16-22 is a breakdown product of the well-known FPR2 
agonist beta amyloid 1-42 (Balbach et al., 2000; Le et al., 2001). Two compounds, C5a 37-53 
and RANTES 11-22, are derived from cytokines (Nardese et al., 2001; Fujita et al., 2004), 
molecules with proven effects on chemotactic GPCRs. One compound, Substance P, was 
chosen because it is assumed to activate innate immune cells via FPRs (Marasco et al., 1981; 
Takenouchi and Munekata, 1995). The organic solvent DMSO was first used as an internal 
control for solubilized hydrophobic peptides (chapter 3.1.1). The structural properties of the 
substances and their origin are listed in Table 3-1-2.  
3.1.2.1. Activation pattern of human FPRs 
Testing each ligand on each receptor led to an interesting picture: 15 of the chosen substances 
elicited receptor-dependent signals in cells transfected with human FPRs (Table 3-2). Of the 
15 ligands that activated at least one human FPR, ten activated at least two receptors and only 
five were selective for a given hFPR. As described in the literature, M-peptide, W-peptide, 
and Ac2-26 activated all three human FPRs (Migeotte et al., 2006). hFPR1 responded to all 
three tested formylated peptides, the two synthetic hexapeptides W-peptide and M-peptide, 
the immunomodulatory Ac2-26 and the viral peptide V3 gp120 HIV (BK-130). Interestingly, 
the receptor did not respond to the strain orthologs V3 gp120 HIV (JR-FL), which varies from 
BK-130 by substitution of two amino acids (Table 3-2). While there was no ligand that acted 
solely on hFPR1, two compounds, Substance P and DMSO, selectively activated hFPR2. 
Interestingly, hFPR2 was able to recognize each substance that activated hFPR1 in the applied 
concentrations. On top of that, hFPR2 was activated by the anti-microbial Temporin A amide, 
the cytokine fragment RANTES 11-22 and the viral T20. All these substances were also able 
to activate hFPR3.  Besides T20, hFPR3 was also activated by two of the other three viral 
peptides V3 gp120 HIV (BK-130) and V3 gp120 HIV (JR-FL). Signals induced by the latter 
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were at the detection limit within the range of the used concentrations. V3 gp120 HIV (JR-FL) 
was one of the three substances that acted selectively on hFPR3. It was furthermore 
selectively activated by the cytokine isomer C5a and the hexapeptidic hFPR2 inhibitor 
WRW4.  
In summary, hFPR1 was activated by seven out of 23 substances. Although the receptor was 
highly sensitive for all these substances, exhibiting EC50 values in lower nanomolar 
concentrations (not shown), the responses were not restricted to hFPR1. All hFPR1 activators 
also proved to be activators for hFPR2 and/or hFPR3. hFPR2 in contrast, responded to twelve 
of the 15 activators of human FPRs. Among these agonists were the organic substance DMSO 
and 14 peptides with variant structure, chain length and modifications like acetylation, 
formylation or amidation, suggesting a quite promiscuous behavior of hFPR2. This 
assumption is further strengthened by the fact that hFPR2 was activated by three substances 
that activated hFPR3. Interestingly, hFPR3 was not activated by any of the three formylated 
peptides which could activate hFPR1 and hFPR2 but was selective for three substances. 
hFPR3 was the only receptor that recognized both cytokine-derived peptides as well as three 
out of four viral peptides,. Together these data argue for distinct ligand binding properties of 
hFPR3. 
3.1.2.2. Activation pattern of mouse immune FPRs 
The murine receptors mFpr1 and mFpr2 showed a remarkable similarity to human FPRs with 
respect to ligand recognition. Of the twelve substances that activated mFpr1 or mFpr2, eleven 
were also recognized by the human FPRs. In contrast to the human FPRs, mFpr1 shared most 
of the ligands with mFpr2; out of ten ligands that activated mFpr2, nine did also induce 
calcium responses via mFpr1. Like hFPR1 and hFPR2, both mouse receptors responded to 
M-peptide, W-peptide, Ac2-26, V3 gp120 HIV (BK-130), and all three formylated peptides 
(Table 3-2).  In addition, both murine receptors responded to Substance P and DMSO. mFpr1 
proved to be selective for T20 and the murine prion fragment beta-amyloid 16-22, the latter of 
which did not activate any human FPR within the range of the tested concentrations. mFpr2 
did selectively respond to the anti-microbial Temporin A amide . 
3.1.2.3. Activation pattern of mouse vomeronasal FPRs 
Unlike the human and mouse immune FPRs, the responses of the vomeronasal FPRs confined 
to three peptides: f-MLF (even in concentrations of 100 µM at the detection limit), W-peptide 
and M-peptide were able to activate mFpr-rs1 but no other vomeronasal FPR. In order to 
Results 
Page | 51  
 
increase the chance of identifying possible activators for vomeronasal FPRs, the tested ligand 
array included a selection of structurally highly heterogeneous peptides (Table 3-2). All tested 
peptides that belong to the group of the eponymous N-terminally formylated peptides 
activated mFpr1 and mFpr2 but none of the vomeronasal FPRs in concentrations below 
100 µM (Figure 3-6). It has been shown that besides formyl peptides, N-terminally acetylated 
peptides are very potent FPR agonists too (Gao et al., 1994). The prominent pan-immune FPR 
agonist Ac2-26, an acetylated mimetic of Annexin A1, was able to induce calcium responses 
in cells expressing mFpr1 or mFpr2. However, none of the vomeronasal FPRs showed 
calcium responses (Figure 3-6). V3 gp120 HIV (BK-130) was able to activate the immune 
receptor mFpr1 (Figure 3-6). But again, from the vomeronasal FPRs no responses were 
observed. Some powerful human FPR agonists are modified by an amidation at their carboxy 
terminus. The amidated anti-microbial Temporin A amide was able to activate mFpr2 while 
the viral T20 could activate cells expressing mFpr1 (Figure 3-6). Both substances were 
incapable of activating vomeronasal FPRs.  
The complete response profile of the distinct receptors is summarized in Table 3-2. Compared 
to the remarkable functional similarity and the broadly tuned agonist profiles of mouse 
immune FPRs, a relatively narrow tuning was observed for the vomeronasal receptors (Table 
3-2 and Figure 3-6), segregating the mouse FPRs into two functionally distinct groups: the 
promiscuous immune FPRs (including mFpr1 and mFpr2, shown in blue) and the more 
restrictive vomeronasal FPRs (comprising mFpr-rs1, mFpr-rs3, mFpr-rs4, mFpr-rs6, and 
mFpr-rs7, shown in red). This activation however is so far restricted to mFpr-rs1. mFpr-rs3, 
mFpr-rs4, mFpr-rs6 and mFpr-rs7 did not show specific calcium responses to any of the 23 
tested ligands. 
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Table 3-2 | Agonist profiling of FPRs in HEK293T cells* 
Ligand Primary structure Ligand class Tested concentration
hFPR
1
hFPR
2
hFPR
3
m
Fpr1
m
Fpr2
m
Fpr-rs1
m
Fpr-rs3
m
Fpr-rs4
m
Fpr-rs6
m
Fpr-rs7
W-peptide WKYMVm-NH2 synthetic peptide 30 µM ● ● (●) ● ● ● ○ ○ ○ ○
M-peptide MMHWAm-NH2 synthetic peptide 30 µM ● ● ● ● ● ● ○ ○ ○ ○
Ac2-26 Ac-AMVSEFLKQAWFIENEEQEYVQTVK immunomodulatory peptide 5 µM ● ● ● ● ● ○ ○ ○ ○ ○
V3 gp120  HIV (BK-130) RIHIGPGRALYTT viral peptide 30  µM ● (●) (●) ● (●) ○ ○ ○ ○ ○
f-MLF f-MLF bacterial peptide 100 µM ● ● ○ ● ● (●) ○ ○ ○ ○
CO1 f-MFINRWLFS mitochondrial peptide 1 µM ● ● ○ ● ● ○ ○ ○ ○ ○
ND1-6I f-MFFINILTL mitochondrial peptide 1 µM ● ● ○ ● ● ○ ○ ○ ○ ○
T20 Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2 viral peptide 10 µM ○ ● ● ● ○ ○ ○ ○ ○ ○
Temporin A  amide FLPLIGRVLSGIL-NH2  anti-microbial peptide 3 µM ○ ● ● ○ ● ○ ○ ○ ○ ○
RANTES 11-22 CFAYIARPLPRA cytokine fragment 10 µM ○ ● ● n.d. n.d. ○ ○ ○ ○ ○
Substance P RPKPQQFFGLM-NH2 neuro peptide 10 µM ○ ● ○ ● ● ○ ○ ○ ○ ○
DMSO C2H6OS organic solvent 5.6 x105 µM ○ ● ○ ● ● ○ ○ ○ ○ ○
beta-amyloid  16-22 KLVFFAE immunomodulatory peptide 10 µM ○ ○ ○ ● ○ ○ ○ ○ ○ ○
WRW4 WRWWWW-NH2 FPR2 antagonistic peptide 30 µM ○ ○ ● ○ ○ ○ ○ ○ ○ ○
C5a 37-53 RAARISLGPRCIKAFTE synthetic antisense cytokine 10 µM ○ ○ (●) ○ ○ ○ ○ ○ ○ ○
V3 gp120  HIV (JR-FL) SIHIGPGRAFYTT viral peptide 30 µM ○ ○ (●) ○ ○ ○ ○ ○ ○ ○
ADP715,  HIV-I RKRIHIGPGRAFYTTKN viral peptide 30 µM ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
uPAR 84-95  Ac-AVTYSRSRYLEC-NH2 immunomodulatory peptide 10 µM ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
Lipoxin A4 C20H32O5  immunomodulatory eicosanoid 1 µM ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
15-(R)-Epi- Lipoxin C20H32O5  immunomodulatory eicosanoid 1 µM ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
CRAMP33 GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ anti microbial peptide 10 µM u.s. u.s. u.s. u.s u.s u.s u.s u.s u.s u.s
CRAMP39 ISRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ anti microbial peptide 10 µM u.s. u.s. u.s. u.s u.s u.s u.s u.s u.s u.s
rCRAMP33 GLLRKGGEKFGEKLRKIGQKIKDFFQKLAPEIEQ anti microbial peptide 10 µM u.s. u.s. u.s. u.s u.s u.s u.s u.s u.s u.s
*The table summarizes the response profiles of all tested human (h) and murine (m) receptors. The highest 
ligand concentrations tested are indicated. Each box represents the results from at least two independent 
transfections. ● = receptor-dependent calcium signal, (●) = signal at detection limit, ○ = no response, u.s. = 
unspecific response observed in untransfected cells, n.d. = not determined. Peptide sequences are given in one 
letter code. Chemical modifications: Ac = acetylation, f = formylation, m = D-methionine, NH2 = amidation.  
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3.2. Structural requirements for activation of mFpr-rs1 by W-peptide 
3.2.1. mFpr-rs1 shows stereo-selective tuning for related peptides containing D-amino 
acids 
The dose-response analysis seen in Figure 3-7 shows that W-peptide and M-peptide exhibit 
remarkably similar affinities towards mFpr-rs1 (505 ± 209 nM for W-peptide and 
738 ± 174 nM for M-peptide). Both, W-peptide (WKYMVm-NH2) and M-peptide 
(MMHWAm-NH2) are quite different in their primary structure, i.e. the amino acid sequence. 
However, they share obvious structural features distinguishing them from other peptides 
tested in this study: first, they are rather short hexapeptides, second, they carry a C-terminal 
D-methionine and third, this methionine is amidated at its carboxy-terminus (Figure 3-8 A). 
With reference to the functional similarity, this suggests a hidden structural consensus that is 
necessary for the activation of mFpr-rs1.  
In order to address the assumption that mFpr-rs1 exhibits structural preferences for such 
peptides, the pharmacology of mFpr-rs1 expressing cells was investigated on single cell 
resolution level. For this, a novel automated high-content single cell calcium imaging assay 
was established (see also chapter 2.6.2.4). To enable active removal of applied stimuli, the 
single cell bio-imaging system was equipped with an automated cell rinsing mechanism. Each 
ligand application was followed by a three minute perfusion sequence that rinsed the cells by 
a 256 volume buffer exchange. This assay allowed the consecutive stimulation of cells 
enabling investigation and comparison of calcium responses of single cells to several ligands 
(Figure 3-8 B). To identify cells that express mFpr-rs1, a vector coding for the green 
fluorescent protein eGFP was co-transfected with mFpr-rs1 in a 1/5 ratio. Since statistically 
only 1/5th of the plasmids were coding for eGFP it is likely that those cells expressing eGFP 
also express mFpr-rs1. Hence, only eGFP positive cells were investigated. 30 µM ATP was 
used to verify viability/excitability of the cells at the end of the experiment.  
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Figure 3-8 | Selective activation of mFpr-rs1 by disparate structures suggests a specific ligand recognition 
mechanism 
Single cell calcium responses of HEK293T cells transfected with plasmids encoding mFpr-rs1 and eGFP (ratio: 
5/1) upon stimulation with distinct peptides. Following each application, the cells were rinsed for 3 minutes with 
256 volumes of buffer to remove the peptide ligand. [A] Linear amino acid sequence of W-peptide and 
M-peptide. Although their amino acid sequences are very dissimilar, both peptides share a C-terminal amidated 
methionine in D-configuration (blue frame). [B] Representative (three similar experiments) single cell calcium 
imaging traces demonstrating relative changes in cytosolic Ca2+ concentrations of mFpr-rs1 expressing 
HEK293T cells. The graph shows the traces of 353 GFP positive cells in the visual field. Of those, 135 
responded to M-peptide, 236 to W-peptide and 266 to ATP. Red traces: cells responding to M-peptide and 
W-peptide. Gray traces = cells not responding to M-peptide. Black curve = mean response. x-scale = 1 min, y-
scale = 10% increase in 340/380 fluorescence ratio. The lower panel shows peak calcium responses of 
representative sections from the visual field in pseudo-color images after stimulation with a given substance. 
Purple indicates low, white indicates high calcium levels. The numbers indicate the corresponding time points 
shown in the graph of the upper panel. RFU = relative fluorescence units. [C] Percentage of M-peptide 
responding cells responding to additional stimuli summarized over three experiments. Absolute cell numbers are 
shown parentheses. In total 1482 cells have been observed. Of those 450 were positive for GFP. Of those, 151 
responded to M-peptide, 258 to W-peptide and 316 to ATP. 
To get a closer look at the agonist properties of mFpr-rs1, single HEK293T cells were 
challenged with peptides displaying different chemical modifications. Of 450 investigated 
cells, 258 responded to W-peptide and 151 to the amidated D-methionine carrying M-peptide 
(Figure 3-8 C). Of the 151 M-peptide responding cells, 147 were activated by W-peptide. Of 
the cells responding to M-peptide two did also respond to formylated CO1 and zero to 
ND1-6I, which is close to the background of buffer application (one cell). Four of the M-
peptide responders were stimulated by the amidated uPAR 84-95 and four could be activated 
by the acetylated Ac2-26. This further supports the idea that mFpr-rs1 is activated by short 
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peptides carrying an amidated C-terminal D-amino acid. To exclude that the absence of 
signals following the first stimulation is not due to receptor desensitization, it was checked 
whether the cells can be repetitively stimulated by a given stimulus (Figure 3-9). Therefore, 
mFpr-rs1 expressing cells were consecutively stimulated with 1 µM W-peptide six times in 
five minute intervals. Of 106 viable eGFP positive cells monitored in three independent 
transfections, 82 ± 5 % were excitable by 1 µM W-peptide (not shown). Of 87 W-peptide 
excitable cells, 51 (= 58%) responded to all six consecutive applications of W-peptide. 9 ± 5% 
responded to five consecutive applications of W-peptide, 1% responded to four, 6% 
responded to three, 6% responded to two and 21% responded only to the first application of 
W-peptide. 
 
Figure 3-9 | Single cell calcium imaging assay with buffer perfusion for repetitive stimulation  
Single cell calcium responses of HEK293T cells transfected with plasmids encoding mFpr-rs1 and GFP (ratio: 
5/1) upon repeated application of W-peptide. Following each application, the cells were rinsed with 256 volumes 
of buffer to remove the ligand. Typical calcium imaging experiment showing that mFpr-rs1 transfected 
HEK293T cells can be repetitively activated by the same stimulus. Only cells expressing the green fluorescent 
protein eGFP were investigated. Since mFpr-rs1 was transfected in 5-fold higher amounts, it is likely that all 
GFP positive cells do also express mFpr-rs1. In total 32 of 39 GFP-positive cells in the visual field responded to 
the first stimulus. Red traces denote cells responding to the first W-peptide application. Gray = cells that did not 
respond to the first W-peptide stimulus. The black trace shows the averaged response. 30 µM ATP served as 
excitability control. Scale bars: y-axis: Ratio 340/380 = 0.4; x-axis: 2 min. RFU = relative fluorescence units. 
Data are representative for three independent transfections.  
Since all cells in Figure 3-9 responded to the first stimulus but not each subsequent 
stimulation, the averaged signal of the first calcium response is higher than the following 
signals. However, the average signal strength of all subsequent calcium responses is identical. 
This shows that mFpr-rs1 transfected cells can be stimulated by six consecutive ligand 
applications and that this assay is suited to monitor single cell calcium responses towards 
various stimulations in a row.  
In order to further specify the pharmacological preferences of mFpr-rs1, additional 
experiments were performed in which the concentration-response behavior of W-peptide and 
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M-peptide was compared to their epimers, carrying the corresponding amidated L-amino acid 
at the C-terminus (Figure 3-10).  
 
Figure 3-10 | Heterologously expressed mFpr-rs1 prefers C-terminal D-amino acids 
Concentration-response curves of mFpr-rs1 expressed in HEK293T cells towards W-peptide and M-peptide 
compared to their epimers obtained by calcium imaging in the FLIPR. [A] W-peptide shows a higher affinity 
towards mFpr-rs1 than its epimer with a C-terminal L-amino acid. [B] M-peptide shows a higher affinity towards 
mFpr-rs1 than its epimer with a C-terminal L-amino acid. Amino acid sequences are given in one letter code. 
Lower case letters denote amino acids in D-configuration. Curves and EC50 values for each substance are 
averaged over at least two independent experiments (see numbers in parentheses). 
W-peptide exhibited an EC50 value of 505 ± 209 nM on mFpr-rs1. Its epimer, L-W-peptide, 
showed a 16-fold increase in EC50 value (Figure 3-10 A). Very similar results have been 
observed for M-peptide. The EC50 value of L-M-peptide (3210 ± 4460 nM) was shifted to 
~ 6 fold higher concentrations than that calculated for M-peptide (738 ± 174 nM) (Figure 3-10 
B). In both cases the maximal signal amplitude observed after stimulation with the L-epimer 
was reduced around 40% compared to the amplitude caused by the D-epimer. Together, these 
data show that mFpr-rs1 prefers short peptides with D-amino acids rather than L-amino acids. 
Biogenic D-amino acids are a rather unusual feature in biosynthesized proteins. Most natural 
proteins and peptides consist of biogenic L-amino acids. However, certain microorganisms 
provide a natural source for D-amino acids (Cava et al., 2011). This supports the hypothesis 
that mFpr-rs1 functions as a sensor for microorganisms. 
 
3.2.2. Activation of mFpr-rs1 requires the four C-terminal amino acids of W-peptide 
The C-terminal methionine and its stereochemistry have been shown to be important for 
activation of mFpr-rs1 (chapter 3.2.1). In order to identify additional key structures in 
W-peptide, which are necessary for activation of mFpr-rs1, a number of W-peptide 
derivatives with N-terminal truncations were tested on mFpr-rs1 (Figure 3-11).  
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Figure 3-11 | Amino acid residues of W-peptide critical for mFpr-rs1 activation 
Concentration-response analysis of W-peptide-derived isomers on mFpr-rs1 heterologously expressed in 
HEK293T cells. N-terminal truncations of W-peptide show positions that are crucial for mFpr-rs1 activation 
while N-terminal elongation of W-peptide did not affect affinity of the ligand towards mFpr-rs1. Blue letters 
indicate amino acid insertions referred to W-peptide. Blue underlines indicate elimination of amino acids 
referred to W-peptide. Peptide sequence is shown in one letter amino acid code. Small case letters (m) denote 
amino acids in D configuration. All peptides were C-terminally amidated. Experiments were in general averaged 
over at least two independent transfections (see numbers in parentheses). One experiment of the MVm-NH2 was 
conducted by Bernd Bufe. 
To determine the influence of the peptide length on mFpr-rs1 activation, several elongated 
and truncated peptide derivatives were tested (Figure 3-11). Elongation of W-peptide by one 
N-terminal alanine resulted in an EC50 value of 399 ± 240 nM, which is close to the EC50 
value gained for W-peptide (505 ± 209 nM) (Figure 3-11). This suggests that elongations at 
the N-terminus display minor influence on the affinity towards mFpr-rs1.  However, deletion 
of the first N-terminal amino acid position (W1) led to a ~ 10-fold right shift of the 
concentration-response curve with an EC50 value of 4037 ± 1478 nM (Figure 3-11). Removal 
of the first two N-terminal amino acids (W1, K2) showed an EC50 value of 1673 ± 458 nM. 
Deletion of the first three N-terminal amino acids including the tyrosine in the third position 
(W1, K2 and Y3) resulted in a complete loss of capability to activate the receptor. It seems that 
tyrosine at amino acid position three is a key feature for interaction between W-peptide and 
mFpr-rs1. These data show that the last four C-terminal amino acids are critical for receptor-
ligand interaction, and that the N-terminal influence is less important. Furthermore, the 
tyrosine, i.e. the 4th residue, counted from the C-terminus, seems to play a key role in the 
interaction between mFpr-rs1 and W-peptide 
 
3.2.3. Influence of C-terminal amidation of W-peptide on affinity6 to mFpr-rs1  
In addition to peptide length and the stereo-selective preference, the chemical modification of 
W-peptide and M-peptide might be important for activation of mFpr-rs1. Thus, it was tested 
whether this amidation could influence the peptide’s affinity towards the receptor. 
                                                     
6 The term affinity is usually used in ligand binding assays. I will refer to this term to describe the sensitivity of 
receptor activation by a given ligand in terms of intracellular calcium mobilization.  
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Comparison of concentration-response curves between the amidated W-peptide 
(WKYMVm-CONH2) and a non-amidated isoform (WKYMVm-COO-) showed that the 
presence of the amidation does indeed increase the affinity towards mFpr-rs1 (Figure 3-12). 
When the C-terminal amidation was removed, exhibiting the negatively charged carboxyl-tail 
with a delocalized electron, there was a ~ 16-fold decrease in affinity, with EC50 values of 
505 ± 209 nM for the amidated W-peptide and 8307 ± 3370 nM for the isomer with the free 
carboxyl moiety. Moreover, the peak signal observed for the carboxylated isomer was about 
60% reduced compared to the amidated W-peptide. In order to determine whether the 
nitrogen of the amide moiety is important, the C-terminal amide group was replaced by a 
C-terminal formaldehyde (-CHO). This group contains the same carbonyl group (-C=O) as 
the amidated residue (Figure 3-12), is uncharged under physiological conditions and does not 
contain a nitrogen atom. Interestingly, this modification was able to rescue the loss of affinity 
towards mFpr-rs1. Its EC50 value (1016 ± 18 nM) was only about two times higher than that 
of the amidated W-peptide but approximately eight times lower than that of the unmodified 
W-peptide. Interestingly, the maximal signal amplitudes observed for the aldehyde isomer 
were comparable to that of the amidated W-peptide (Figure 3-12). Together, these data 
demonstrate the importance of the C-terminal amidation for the W-peptide consensus motif. 
Moreover, they indicate that the carbonyl moiety (-C=O) rather than the amine is the 
determinant for W-peptide sensitivity towards mFpr-rs1.  
 
Figure 3-12 | Heterologously expressed mFpr-rs1 is selective towards C-terminally amidated W-peptide  
Concentration-response curves of mFpr-rs1 expressed in HEK293T cells towards W-peptide, a non-amidated 
derivative and a derivative carrying a C-terminal aldehyde obtained by calcium imaging. Amino acid sequences 
are given in one letter code. Lower case letters denote amino acids in D-configuration. Curves and EC50 values 
are averaged over at least two independent experiments (see numbers in parentheses). The chemical structures 
show the D-methionine of the tested peptide (m) with the corresponding C-terminal modification/moiety. Blue 
letters indicate the modification of the C-terminal D-methionine: (CONH2) = C-terminal amidation, (COO-) = 
free carboxyl group with a negative net charge (-1), (CHO) = C-terminal aldehyde. 
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3.2.4. Activation of mFpr-rs1 by N-terminally formylated peptides 
The experiments described in 3.2.1 show that W-peptide, carrying a C-terminal D-methionine 
that has C-terminal formaldehyde is an activator of mFpr-rs1. Notably, N-terminal 
formylation describes the addition of formaldehyde to the N-terminus of a peptide. The only 
difference between an N-terminal formylation and C-terminal formaldehyde is that the 
N-terminal aldehyde group is added to the nitrogen of the peptide’s amino moiety (Figure 
3-13). 
 
Figure 3-13 | Stereo-chemical resemblance of D-methionine carrying a C-terminal formaldehyde function 
and L-methionine with N-terminal formylation 
[A] Structural comparison of C-terminal D-methionine (m) with a formaldehyde group at its carboxy-tail and a 
N-terminal L-methionine (M) that is formylated at its amino-terminus. The structures of the corresponding 
methionines are shown in natta projections (black). They are part of a peptide chain which is shown in gray 
capitals. The corresponding modifications are shown in blue. The D-methionine is part of a W-peptide derivative 
carrying a C-terminal aldehyde (left) and the L-methionine is part of the retro-inverted W-peptide (right) as 
measured with calcium imaging in the FLIPR.  
Since both formaldehyde groups contain the essential carbonyl moiety (chapter 3.2.3), it is 
tempting to hypothesize that if amidated peptides activate FPRs including the vomeronasal 
mFpr-rs1, formylated peptides will do so as well. To address this hypothesis, an N-terminally 
formylated, retro-inverse 7 isomer of the W-peptide was synthesized. To understand the 
biochemistry and the structural requirements of a retro-inversion the following has to be 
considered: W-peptide probably binds to the receptor’s binding pocket by exposing its 
C-terminal tail carrying an amidated methionine (or the formaldehyde, respectively). If the 
amino acid sequence of W-peptide (WKYMVm) was reversed i.e. turned around to 
mVMYKW (= retro-peptide), it would be logical that this retro-peptide would use the same 
receptor binding pocket as W-peptide, only with its N-terminus exposed. Formylation would 
                                                     
7 I refer to this peptide as a retro-inverse peptide: the peptide’s amino acids are assembled in reverse order but 
only the terminal D-methionine has been replaced by its (L-) stereoisomer. A reversed peptide in which all 
amino acids have been replaced by the corresponding stereoisomer is termed retro-inverso peptide. 
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introduce the formaldehyde group to the N-terminus of methionine. According to the rules of 
Cahn, Ingold and Prelog (Cahn, Ingold and Prelog, 1966), reversal of a peptide sequence 
results in a change of the relative chemical configuration of the amino acids because the 
positions of the carboxyl and amine groups in the amide bonds are exchanged. To compensate 
for this, the D-conformation of methionine (mVMYKW) must be inverted to the 
L-conformation (MVMYKW), which equals the exchange of the side chain’s positions. Both 
changes at the same time (a retro-inversion) command a double change of absolute 
configuration of the methionine’s chirality center. By inducing this double change of the 
absolute configuration, the original relative configuration is retained (Cahn, Ingold and Prelog, 
1966; Brady and Dodson, 1994).  
To test this hypothesis, a formylated retro-inverted peptide (f-MVMYKW) was chemically 
synthesized and tested on mFpr-rs1 (Figure 3-14). Interestingly, the retro-inverted peptide 
displayed an EC50 value of 3017 ± 1150 nM, which is approximately three times higher than 
that observed for the W-peptide with the C-terminal aldehyde (WKYMVm-CHO; 
EC50 = 1016 ± 18 nM) (Figure 3-14). Although the curve of the retro-inverted W-peptide had 
a shallower slope than that of WKYMVm-CHO (Figure 3-14), the peak responses were 
comparable in height. These data suggest that there is a clear structural link between 
N-terminally formylated and C-terminally amidated peptides in respect to FPR activation. 
Furthermore, they demonstrate that heterologously expressed mFpr-rs1 can be activated by 
formylated peptides.  
 
Figure 3-14 | Heterologously expressed mFpr-rs1 can be activated by formyl peptides  
Concentration-response curves of mFpr-rs1 expressed in HEK293T cells towards a W-peptide derivative 
carrying a C-terminal aldehyde (left) and the retro-inverted W-peptide (right) as measured with calcium imaging 
in the FLIPR. The corresponding modifications of the terminal methionines are shown in blue. Data were 
averaged over two independent transfections. Error bars = SD. 
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The experiments illustrated so far have shown that heterologously expressed mFpr-rs1 is 
activated by W-peptide. Furthermore, it has been demonstrated, that the receptor is activated 
by this peptide if certain key requirements are met. First, the peptide needs a minimal length 
of four amino acids, second, the peptide must carry a C-terminal methionine in 
D-configuration and third, this methionine must be amidated or carry a formaldehyde moiety 
at its carboxyl-tail. Interestingly, the amino acid sequences of W-peptide and its truncated 
isoforms that were able to activate mFpr-rs1 are found in proteins and peptides of microbes 
(Table 3-3). For example, sequence blast for the sequence KYMVM yielded 367 hits In the 
UniProtKB database of which the majority (> 86%) refers to microorganisms like bacteria, 
fungi and viruses (Table 3-3 A). Interestingly, a number of these hits were identified for 
various pathogenic microorganisms. The sequence KYMVM for example has been identified 
for the Iron-regulated surface determinant protein B (A7X146) of Staphylococcus aureus or a 
DNA methylase of Leptospira biflexa (Table 3-3 B). 
Considering that mFpr-rs1 is also activated by N-terminally formylated peptides, these data 
provide evidence that supports the idea that mFpr-rs1 is able to recognize pathogenic 
organisms or molecules. 
 
Table 3-3 | mFpr-rs1 agonist motifs are frequently found in proteins of various pathogenic 
microorganisms* 
A 
Motif Total hits bacteria fungi virus mouse human 
WKYMVM 1 100% 0 0 0 0 
KYMVM 367 76 % 10% 0.3% 0 0 
YMVM 8160 58% 8% 0.5% 0.6% 1.3% 
B 
Motif Pathogen Protein Accession 
WKYMVM Kribbella flavida Cyanobacterial globin D2PTJ8 
KYMVM Staphylococcus aureus Iron-regulated surface determinant protein B A7X146 
KYMVM Leptospira biflexa DNA methylase B0SG88 
KYMVM Fluoribacter gormanii FEZ-1 protein Q9K578 
YMVM Candida albicans Pheromone-regulated membrane protein 10 Q5AH11 
YMVM Clostridium novyi UDP-N-acetylglucosamine 2-epimerase A0PZ05 
YMVM  Burkholderia mallei Putative serine/threonine protein kinase A5TNL9 
YMVM Haemophilus influenzae Lon protease A5UA27 
YMVM Yersinia pestis Putative ABC transport integral membrane subunit A6BSU6 
YMVM  Listeria monocytogenes Glycerol uptake operon antiterminator regulatory protein Q4ETR1 
YMVM Suid herpesvirus 1 Major capsid protein Q00705 
YMVM Lymphocytic choriomeningitis 
virus 
RNA-directed RNA polymerase L E2D673 
* [A] The table lists the number of database hits for the indicated peptide motifs and their distribution in distinct 
phylogenetic branches. [B] The table shows some examples of natural pathogens that exhibit the peptide motif in 
proteins. The sequences were identified via assessing UniProtKB/SwissProt, UniProtKB/ TrEMBL (July 2012) 
employing the ScanProsite software (release 20.83) and the taxa analysis tool.  
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3.3. Vomeronasal sensory neurons of mice respond to the mFpr-rs1 ligand 
W-peptide 
The results in chapter 3.2 have shown that the vomeronasal receptor mFpr-rs1 is activated by 
W-peptide when expressed in HEK293T cells. It would be interesting to see whether this 
substance can be recognized by neurons of the vomeronasal sensory epithelium where 
mFpr-rs1 is naturally expressed. Therefore, ligand-dependent responses of dissociated 
vomeronasal sensory neurons (VSNs) were investigated in single cell calcium imaging.  
In order to investigate the pharmacology of vomeronasal sensory neurons, the VNO was 
extracted from mice and dissociated enzymatically (chapter 2.3.5). To visualize olfactory 
neurons the mice expressed the green fluorescent protein GFP under control of the OMP 
promoter. The olfactory marker protein (OMP) is expressed in sensory neurons of olfactory 
organs, i.e. all OMP positive sensory neurons express GFP and therefore, VSNs can be easily 
identified by green fluorescence. Fluorescence analysis showed that of 4204 cells in the visual 
field, isolated from 27 animals, 1574 cells (~ 37%) had intense green fluorescence (Figure 
3-15). In order to investigate whether these cells are excitable, they were challenged with 
80 mM KCl in single cell calcium imaging. In vomeronasal sensory neurons application of 
high KCl concentrations leads to calcium influx, presumably through activation of voltage 
gated calcium channels (Holy et al., 2000; Hardingham et al., 1999). Indeed, application of 
KCl showed that 655 of the 1574 GFP expressing cells (~ 42%) responded to KCl with 
calcium signals (Figure 3-15 B).  
 
In order to test whether the neurons can be activated by chemosensory stimuli, the cells were 
challenged with several substances (described in the following paragraph) that are known to 
activate cells of the VNO in consecutive applications. If cells responded to pre-application of 
buffer, a control for applicational artifacts, they were removed from evaluation.  
Figure 3-15 | Identification of acutely 
dissociated mouse vomeronasal sensory 
neurons 
[A] Vomeronasal sensory neurons of 
OMP/GFP mice express GFP under 
control of the OMP promotor. GFP 
expressing cells show green fluorescence.  
Total number of cells is visualized by the 
calcium dye Fura-2. [B] 35% of the cells 
isolated via dissociation of the VNO are 
GFP labeled sensory neurons. Of those, ~ 
30% can be activated by KCl. Data are 
summarized for 27 animals. 
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First, it was analyzed whether the neurons respond to classical VNO agonists like ESP-1 
(Kimoto et al., 2005) and n-pentyl acetate (Del Punta et al., 2002). The exocrine gland 
secreted peptidic pheromone ESP-1 is a known activator of distinct V2R positive neurons and 
has since been used in several studies (Kimoto et al., 2005; Leinders-Zufall et al., 2014). The 
volatile pheromone n-pentyl acetate, which is found in mouse urine (Novotny et al., 1986), is 
an activator of distinct V1R associated neurons (Del Punta et al., 2002). When ESP-1 was 
applied to the neurons, 24 of 655 KCl positive neurons (~ 3.7%) responded to the stimulus 
with calcium transients (Figure 3-16 A, B and C).  n-pentyl acetate induced responses in 21 of 
655 (~ 3.2%) of the neurons. V1R neurons and V2R neurons reside in different anatomical 
zones of the VNO (chapter 1.1). It is therefore unlikely, that one neuron responds to both 
stimuli by GPCR-mediated signaling. Analyses showed that only three of 655 neurons (~ 
0.45%) responded to both stimuli (Figure 3-16 B). This was counted as background signal. 
Next it was tested whether the neurons respond to application of classical immune FPR 
ligands: W-peptide, L-W-peptide, f-MLF, ND1-6I, and ND1-6T. The formylated peptides 
f-MLF, ND1-6I, and ND1-6T have already been shown to activate cells in the vomeronasal 
organ (Rivière et al., 2009; Chamero et al., 2011; Leinders-Zufall et al., 2014) and served as 
additional positive controls. The applications scheme was based on a randomized selection. 
First, buffer was applied to check for application artifacts. Second, the ligands L-W-peptide, 
D-W-peptide, f-MLF, ND1-6I, ND1-6T, ESP-1, iso-pentyl acetate, 2-heptanone, and an 
additional buffer application were applied in a randomized order. Following this, the cells 
were stimulated with KCl to check their viability. If a cell responded to the initial buffer 
application, it was removed from evaluation. Although the background caused through 
application artifacts was below 0.5% (Figure 3-16 B and C), only the first ligand-dependent 
response was analyzed (Figure 3-16 D). Analyzes showed that application of the formylated 
peptides f-MLF, ND1-6I, and ND1-6T-induced responses in 1.7%, 1.8%, and 2.3% of the 
neurons, respectively (Figure 3-16 D). Interestingly, 2.4% and 3.4% of the neurons responded 
to W-peptide and L-W-peptide, respectively (Figure 3-16 D). 
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Figure 3-16 | Calcium imaging of vomeronasal sensory neurons 
Calcium imaging of dissociated vomeronasal sensory neurons. [A] Representative calcium trace of VSN 
responding to ESP-1 from one experiment. [B] Quantification of ESP-1 and n-pentyl acetate responses over 
eight experiments. [C] Chart map summarizing calcium transients of KCl positive vomeronasal sensory neurons 
in response to diverse stimuli. Each column represents one of 655 KCl positive VSNs. Calcium responses to a 
certain stimulus are indicated by yellow boxes. Data are summarized over six experiments. [D] Quantification of 
responses to several stimuli. Only the first ligand-induced calcium signal was taken for the statistics. If a neuron 
responded to a second stimulus, this response was not counted. The used concentrations were: L-W-peptide 
[5 µM], W-peptide [5 µM], f-MLF [9 µM], ND1-6I [1 µM], ND1-6T [1 µM], ESP-1 [0.9 nM], n-pentyl acetate 
[1 µM], and KCl [80 mM]. 
These data show that the neurons can be stimulated by application of classical activators of 
the VNO. They furthermore indicate that neurons respond to application of the mFpr-rs1 
agonist W-peptide. In order to address the specificity of the responses a set of experiments 
was analyzed in which the cells were stimulated with the above used ligands. In these 
experiments however, L-W-peptide was applied before W-peptide (both 5 µM). 5 µM is 
below the EC50 value of L-W-peptide on mFpr-rs1 but about ten times higher than that of 
W-peptide (Figure 3-10). It was thus hypothesized that a neuron responding to W-peptide but 
not L-W-peptide might be activated via mFpr-rs1. Of 863 analyzed cells 27 (~ 3.1%) and 23 
(~ 2.7%) responded to L-W-peptide and W-peptide, respectively, with calcium transients 
(Figure 3-17). Only three cells (~ 0.3%) responded to both stimuli. Interestingly, this is close 
to the number of responders toward W-peptide and ESP-1: only two cells (~ 0.2%) responded 
to both stimuli. This corresponds with the background signal: 0.2% of the neurons responded 
to W-peptide and an additional buffer application (Figure 3-17 B). 
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Figure 3-17 | Vomeronasal sensory neurons respond to W-peptide  
Calcium imaging of dissociated vomeronasal sensory neurons. [A] Representative calcium traces of three VSNs 
responding to W-peptide from one experiment. [B] Quantification of W-peptide-induced responses over eight 
experiments. The used concentrations were: L-W-peptide [5 µM], W-peptide [5 µM], f-MLF [9 µM], ND1-6I 
[1 µM], ND1-6T [1 µM], ESP-1 [0.9 nM], n-pentyl acetate [1 µM], 2-heptanone [1 µM], and KCl [80 mM]. 
These data show that a number of vomeronasal sensory neurons can be activated by the 
mFpr-rs1 agonist W-peptide in a specific manner. Since mFpr-rs1 is a receptor for W-peptide, 
these responses could possibly be mediated by mFpr-rs1, expressed in vomeronasal sensory 
neurons. 
 
3.4. Formyl peptide receptor-dependent recognition of bacterial signal 
peptides by the mammalian innate immune system  
As presented in chapter 3.2 the vomeronasal mFpr-rs1 is activated by peptides whose amino 
acid motifs are found in proteins of pathogens. Furthermore, mFpr-rs1 is activated by 
N-terminally formylated peptides, a hallmark attributed to bacteria. By employing and 
extending these data in a side project, conducted by Bufe and Schuman et al., we could 
demonstrate that bacterially-derived N-terminally formylated signal peptides, and their 
N-terminal breakdown products are capable of activating all heterologously expressed human 
and mouse immune FPRs as well as mFpr-rs1 (Bufe et al., 2015). Many secreted proteins or 
proteins inserted into the bacterial cell wall contain a cleavable signal peptide at their 
N-terminus. They serve as sorting tags for the proteins, recognized by the bacterial transport, 
export and secretion machinery and are usually cleaved from the mature protein after export 
(Dalbey et al., 2012). Sec-dependent translocation is by far the best-investigated and 
apparently most common export mechanism. Signal peptides associated with the Sec 
machinery consist of three domains. Typically these domains contain a positively charged 
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N-terminal tail (n-region, 3 - 25 amino acids), a hydrophobic, helix-forming domain (h-region, 
6 - 18 amino acids) and a C-region (1 – 11 amino acids) that contains the cleavage signal 
(Chatzi et al., 2013). We could show that mouse and human immune FPRs (mFpr1, mFpr2, 
hFPR1, hFPR2 and hFPR3) recognize more than 20 of these signal peptides or their 
n-regional domains (Bufe et al., 2015). Some of these peptides exhibited remarkable affinities 
(with EC50 values in the lower picomolar range) to the immune FPRs, underlining their 
biological significance (Bufe et al., 2015).  
Figure 3-18 | Heterologously expressed FPRs of human and mouse recognize bacterial signal peptides in 
single cell calcium imaging  
The diagram shows the result of a single cell calcium imaging experiment of FPRs heterologously expressed in 
HEK293T cells. Twelve out of twelve experimentally confirmed signal peptides activated at least one member of 
the human and mouse FPR family. On average, for each substance and each receptor 702 ± 246 cells have been 
observed. All receptors recognize signal peptides derived from non-pathogens and pathogens as well. All 
agonists were applied at 10 µM. 
However, thus far the pharmacological characterization of these peptides was restricted to 
analysis of heterologously expressed FPRs (Figure 3-18). The next important step was to 
investigate whether these peptides are recognized by FPRs naturally expressed on immune 
cells and whether they can induce immune responses through these receptors. To address 
these questions I first used primary human monocytes isolated from healthy donors.  They are 
known to express hFPR1 and hFPR2, the most prominent FPRs, in high amount (Migeotte et 
al., 2006). In the past, naïve monocytes have frequently been used in calcium imaging to 
investigate the function of formyl peptide receptors. Therefore, I decided to utilize this cell 
type to understand whether and how bacterial signal peptides induce immune responses in 
cells of the innate immune system. 
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3.4.1. Formyl peptide receptor-mediated recognition of bacterial signal peptides by 
human monocytes  
3.4.1.1. Primary human monocytes can be measured by high-throughput calcium imaging 
In order to get first insights into the pharmacology of signal peptides on cells of the innate 
immune system, human monocytes were challenged with Streptococcus-SP1 (SP1). This 
N-terminal signal peptide fragment is derived from a hyaluronidase of the zoonotic pathogen 
Streptococcus suis. It proved to be highly affine for hFPR1 in calcium imaging experiments 
on heterologously expressed FPRs, exhibiting an EC50 value of ~ 2 nM (Bufe et al., 2015). 
When the isolated monocytes were challenged with SP1 in first experiments, they responded 
with clear calcium transients (Figure 3-19). These signals were concentration-dependent, with 
an EC50 value (4.8 ± 4.7 x 10-9 M) closely relating to that described for heterologously 
expressed hFPR1 (Bufe et al., 2015) (Figure 3-19).  
 
Figure 3-19 | Calcium imaging of primary human monocytes upon stimulation with Streptococcus-SP1  
[A] Concentration-response experiment as measured in the FLIPR: shown are calcium transients of primary 
human monocytes of one donor upon stimulation with decreasing concentrations of the signal peptide fragment 
Streptococcus-SP1. RFU = relative fluorescence units. Traces are representative for ten donors. [B] Calculated 
concentration-response curves for monocytes stimulated with Streptococcus-SP1. Curve is averaged over ten 
donors. 
These experiments show that human monocytes can be activated by the signal peptide 
Streptococcus-SP1 in calcium imaging experiments in a concentration-dependent manner. In 
addition, the affinity of SP1 towards monocytes is comparable to that of heterologously 
expressed hFPR1. So far, this does not mean that the signals are produced by monocytes and 
that these signals are mediated by hFPR1. In order to investigate which cells generate the 
calcium signals, single cell calcium imaging was used in combination with post-hoc 
immunocytochemistry. With this method, single cells are observed in calcium imaging and 
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then stained with antibodies directed against specific molecules like hFPR1. Employing this 
method should facilitate the co-localization of calcium signals with cell surface expression of 
hFPR1 or the monocyte marker CD14. 
Before immunocytochemical analysis was performed, it was tested whether the used FPR 
antibodies were specific for the desired FPR. Specificity of the commercially available FPR 
antibody was investigated on fixated, unpermeabilized HEK293T cells, transfected with 
hFPR1, hFPR2 or hFPR38 (Appendix 3). The images showed a clear, intense fluorescence of 
hFPR1 expressing cells stained with the anti-hFPR1 antibody (Appendix 3, upper panel). 
Quantification of the results (Appendix 3, lower panel) showed that 38.5 ± 4 % of the cells 
expressed hFPR1, while no staining was detected for hFPR2 and hFPR3. The anti-hFPR2 and 
anti-hFPR3 antibodies were used to confirm that these receptors are expressed, underlining 
the specificity of the hFPR1 antibody. The anti-hFPR2 antibody stained 25.3 ± 7.8% of 
hFPR2 transfected cells; no stainings were observed for hFPR1 or hFPR3 transfected cells. 
The anti-hFPR3 antibody stained 32.5 ± 3.6 % of the cells transfected with hFPR3. No 
staining was observed for cells transfected with hFPR1 or hFPR2. These data show that the 
antibodies used for immunocytochemical stainings of monocytes can differentiate between 
the FPRs and that they can be used for detection of FPRs expressed on the cells surface of 
monocytes. 
Monocytes are ~ 10 µm in diameter9 (in suspension) with a kidney bean shaped nucleus and 
express the surface marker hCD14 in high amounts (Ziegler-Heitbrock et al., 1993). 
Therefore, first immunocytochemical stainings were done utilizing an anti-hCD14 antibody. 
Evaluations of these stainings showed that 70.1 ± 9.4% of all nucleated cells were positive for 
hCD14 (Figure 3-20 A). In contrast, 4.4 ± 4% of the cells were positive for the corresponding 
isotype control (MOPC-21). Of cells stained with anti-hFPR1, 68.5 ± 10% were positive, 
while the background, determined with the isotype control (anti-KLH), was 5.2 ± 3.1% 
(Figure 3-20 B). Of those stained positive for hFPR1, ~ 70% had a nucleus with a clear bean-
like shape (Figure 3-20 C, red arrow). Similar results were observed for hFPR2. When 
incubated with an anti-hFPR2 antibody, ~ 70% of the cells were stained (Appendix 2). This 
number is comparable to the expression levels monitored for hFPR1. In order to confirm that 
the observed responses are generated by monocytes and that they are hFPR1-dependent, 
single cell experiments were coupled with immunocytochemistry to perform post-hoc analysis. 
                                                     
8 Those three were unmodified receptors, without Rho-tag 
9 Adherent monocytes span up to 20 µm in diameter, according to the strength of adhesive forces. 
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Stimulation of monocytes by 70 nM Streptococcus-SP1 showed a clear calcium response by 
85% of the cells (Figure 3-20 D). Of those, 92 ± 10% were positively stained for hFPR1, 
while the remaining 8 ± 10% of responders were hFPR1 negative (Figure 3-20 E).  
 
Figure 3-20 | Immunefluorescence of surface receptors on human monocytes 
Shown are immunocytochemical cell surface stainings of primary human monocytes with antibodies directed 
against hCD14 and hFPR1, respectively. [A] Left: Representative immunostainings for the 
monocyte/macrophage surface marker hCD14. Right: Column chart showing that 537 of 765 nucleated cells 
cells are stained positive for hCD14. The MOPC-21 antibody served as an isotype control. [B] Left: 
Representative immunostainings for hFPR1. Right: The columns show that 505 of 737 nucleated cells are 
stained positive for hFPR1 while the isotype control (anti-KLH) remained negative. [C] Cells stained positive 
for hFPR1 have a bean shaped nucleus that is typical for monocytes (red arrow) while non-stained cells 
predominantly have a round nucleus (blue arrow). Images are representative for at least three donors. 
Quantifications were averaged over three donors. [D] post-hoc analysis of human monocytes after single-cell 
calcium imaging. Typical post-hoc analysis experiment. After the calcium imaging, the cells were stained for 
hFPR1. Images of the calcium signals and the immunostaining were then merged and analyzed. Cells stained 
positively for hFPR1 are shown in red, nuclear counterstain in cyan. Rise in intracellular calcium is shown in 
green. The images denoted with “buffer” and “Streptococcus-SP1” show the peak calcium responses after 
application of buffer or 68 nM SP1. [E] Quantification of the results shown in B, averaged over three donors. 
The chart shows the percentage of SP1-responders that are stained positively for hFPR1 or the isotype control 
KLH, respectively. Numbers in parentheses show how many cells responded and how many cells were present in 
the visual field. D and E by courtesy of Carsten Kummerow. 
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Repetitions of these experiments with hCD14 stained cells showed comparable results with  
92% of the SP1 responders being positive for hCD14 (Figure 3-20 E). 
These results demonstrate that responses induced by the signal peptide fragment SP1 are 
generated by hFPR1 expressing monocytes.   
3.4.1.2. Bacterial signal peptides activate human monocytes by utilizing FPRs 
To assess the question whether the SP1-induced responses are mediated by formyl peptide 
receptors, several control experiments were performed by employing Streptococcus-SP1. In 
order to get first insights into the specificity of the signal peptide SP1, the calcium responses 
were investigated in cross-desensitization experiments. Application of 20 nM f-MLF induced 
clear calcium responses in monocytes. Subsequent application of 100 nM SP1 elicited a 
calcium signal that was ~ 5 times reduced in amplitude (Figure 3-21).  
 
Figure 3-21 | Cross-desensitization in human monocytes by the FPR1-preferential signal peptide SP1 
[A] Displayed are original calcium transients (measured in the FLIPR) showing the level of cross-desensitization 
in human monocytes to the hFPR1 preferential ligand Strepococcus-SP1 [100 nM] after pre-stimulation with 
f-MLF ([20 nM], left trace) or the CCR1 agonist RANTES ([100 nM)], right trace). Pre-application of f-MLF 
desensitizes the receptor that mediates the SP1 response whereas pre-application of RANTES does not. RFU = 
relative fluorescence units. [B] Quantification of responses shown in A together with control applications, 
averaged over two donors. Pre-stimulation with f-MLF desensitizes the SP1-induced response and vice versa. 
Pre-treatment with RANTES does not affect the subsequent application of SP1 or f-MLF. Subsequent 
application of RANTES, however, demonstrates desensitization of the RANTES receptor CCR1.  
Similar results have been obtained when the sequence of the ligand application was inverted. 
However, pre-stimulation of monocytes with the CCR1 agonist RANTES followed by 
application of either SP1 or f-MLF resulted in an equivalent calcium signal for RANTES and 
the hFPR1 agonist. When the cells were pre-stimulated with RANTES, no signals were 
detected for a second RANTES application. RANTES is a well-known agonist of CCR1, a 
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chemokine GPCR that induces intracellular calcium mobilization upon stimulation with 
RANTES (Neote et al., 1993). This experiment suggests that the well-known f-MLF and 
Streptococcus-SP1 likely bind the same receptor. To verify this theory, monocytes were 
challenged with 100 nM SP1 in concordant use with hFPR inhibitors (Figure 3-22). 
Cyclosporin H (CsH) is a cyclic undecapeptide, commonly used as a specific blocker for 
hFPR1 (Wenzel-Seifert and Seifert, 1993). tBoc2, is a competitive antagonist for hFPR1. Pre-
application of 1 µM CsH completely abolished the Streptococcus-SP1-dependent calcium 
signal. When tBoc2 (10 µM) was mixed with SP1 before application, no calcium signal was 
detected (Figure 3-22 A). RANTES (100 nM) was used to show that the inhibitors did not 
affect general excitability or downstream signaling molecules (Figure 3-22 B).   
Figure 3-22 | Inhibition of signal peptide-induced calcium responses in monocytes by hFPR blockers 
[A] Streptococcus-SP1 [100 nM] was applied either alone or in combination with the hFPR1 inhibitor CsH 
[1 µM] or the FPR1 antagonist tBoc2 [10 µM]. Data are averaged over at least three donors (exact numbers are 
stated in parenthesis). [B] Original FLIPR traces demonstrating viability of the cells after application of 
inhibitors, representative for at least three donors. The used concentrations are as stated in A, RANTES was 
applied at 100 nM. Cyclosporin H (CsH) is a blocker that has to be pre-applied (left) while Boc2 is a competitive 
inhibitor that is applied together with the agonist (right). In both cases, the cells can be activated by RANTES, 
demonstrating that intracellular GPCR associated calcium mobilization is still working and not affected by the 
blockers. RFU = relative fluorescence units. 
These data strongly suggest that the signal peptide Streptococcus-SP1-induced calcium signal 
is mediated by hFPR1. 
3.4.1.3. Primary human monocytes recognize bacterial signal peptides with high sensitivity 
In order to get insights into pharmacological properties and the biological role of bacterially-
derived signal peptide fragments, a selection of these was tested on primary cells of the innate 
immune system. Monocytes were first stimulated with a selection of nine signal peptide 
fragments derived from the N-terminal domain (SP) and two full-length signal peptides 
(SP FuLe) (Figure 3-23). All nine signal peptide fragments 10  (Streptococcus-SP1, 
                                                     
10 The peptides SP1 – SP21 have already been described (Bufe et al., 2015) while the peptides SP22-24 are yet to 
be published as FPR agonists. 
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Staphylococcus-SP3, Salmonella-SP4, Haemophilus-SP5, Psychromonas-SP6, Shewanella-
SP7, Desulfotomaculum-SP8, Borellia-SP9 and Staphylococcus-SP22) were able to induce 
calcium responses when applied at concentrations of 10 µM. Interestingly, the signals 
observed for SP1 and SP5 were about 50% higher in amplitude as those observed for the 
positive controls f-MLF, W-peptide and retro-inverted W-peptide. The signals induced by 
SP3, SP4, SP6, SP7 and SP8 were comparable to that induced by f-MLF. At 10 µM, smaller 
signals were observed for SP22 and SP9, of which the latter was at the detection limit. 
Interestingly, the full-length signal peptides of SP8 and SP22 did induce signals that were  
~50% (SP8 FuLe) to ~ 100% (SP22 FuLe) higher in amplitude than those induced by their 
N-terminal fragments (Figure 3-23).  
 
Figure 3-23 | Human monocytes are activated by a range of bacterial signal peptides 
Calcium imaging of primary human monocytes performed with the FLIPR. Various signal peptides and single 
peptide fragments (red bars) were tested at 10 µM. All peptides induced calcium responses in human monocytes. 
f-MLF, W-peptide and retro-inverted W-peptide (blue bars, each at 10 µM) served as positive controls. Buffer 
application (black) served as control. Numbers in parentheses indicate the averaged number of independent 
donors. t-test: * = p ≤ 0.05 
The data shown above demonstrate that all tested signal peptides activated human monocytes. 
Bufe and Schumann et al. have shown that bacterial signal peptide fragments are recognized 
by human and mouse FPRs with extraordinary affinity (Bufe et al., 2015). In order to 
investigate whether monocytes can detect these signal peptides with equal affinities, they 
were analyzed in concentration-response experiments.  
When Streptococcus-SP1 was tested on monocytes in concentration-response experiments, 
the resulting curve showed a remarkable correlation in onset, shape and slope with that 
calculated for hFPR1 expressing HEK293T cells (Figure 3-24). The EC50 calculated for the 
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monocytes was 4.8 ± 4.7 nM. The corresponding value as determined in HEK293T cells was 
1.9 ± 1.3 nM (Figure 3-24). This close correlation was also observed for the control peptides 
f-MLF and W-peptide (Figure 3-24). When tested on monocytes, f-MLF exhibited an EC50 
value of 2.2 ± 1.2 nM, which is about four times higher than that observed for the 
heterologously expressed receptor (0.7 ± 0.2 nM). Again, both curves ran in parallel. 
W-peptide was detected with equal affinity by monocytes (1.9 ± 1.2 nM) and heterologously 
expressed hFPR1 (2.8 ± 1.8 nM), exhibiting closely overlaying graphs.  
 
Figure 3-24 | Direct comparison between concentration-response curves of human monocytes and hFPR1-
expressing HEK293T cells 
Shown is the comparison of averaged concentration-response curves and EC50 values determined in calcium 
imaging for monocytes (red) and hFPR1 expressed in HEK293T cells (black). The exact number of averaged 
donors/transfections is shown in parentheses. Concentration-response curves recorded from monocytes and 
HEK293T cells expressing hFPR1 are identical in shape, onset, slope, and EC50 value for the hFPR1 preferential 
Streptococcus-SP1. The well-known f-MLF and W-peptide served as controls. The concentration-response 
analysis for Streptococcus-SP1 and f-MLF on heterologously expressed hFPR1 were performed by Bernd Bufe. 
This pharmacological correlation argues for hFPR1-dependent detection of the tested peptides, 
including the signal peptide Streptococcus-SP1, contributing further evidence for the 
selectivity of the receptor towards the signal peptide. Hence, it was assumed that a close 
correlation of the concentration-response relationship between monocytes and hFPR1 
expressing HEK293T cells could be used for selective analysis of given signal peptides on 
monocytes. In order to get further insights into signal peptide recognition by human 
monocytes, eleven additional signal peptide fragments were tested in concentration-response 
experiments (Table 3-4). The signal peptide fragments Salmonella-SP23 (EC50 = 
5.0 ± 2.6 nM), Salmonella-SP24 (EC50 = 1.7 ± 1.1 nM) were similar in affinity as f-MLF 
(EC50 = 2.2 ± 1.2 nM) and W-peptide (EC50 = 1.9 ± 1.2 nM). Intriguingly, two signal peptides 
starting with the f-MLF motif exhibited high affinities on monocytes, surpassing even the 
prototypical f-MLF and the pan-immune FPR agonist W-peptide in affinity. With EC50 values 
of 0.2 ± 0.1 nM (SP6) and 0.2 ± 0.2 nM (SP8), respectively, Psychromonas-SP6 (f-MLFYFS) 
and Desulofotomaculum-SP8 (f-MLFYLA) were ten times more sensitive toward monocytes 
than f-MLF. Although all tested signal peptides were recognized by monocytes, it did not 
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always occur with high affinity. Some of the peptide fragments (SP4 and SP9) exhibited EC50 
values close to those of low affinity agonists like Substance P (EC50 > 1 µM). Salmonella-SP4 
was the fragment with the highest calculated EC50 value, reaching micromolar concentrations 
(1013.5 ± 500.6 nM). The EC50 values determined for Staphylococcus-SP3, Haemophilus-
SP5, Shewanella-SP7 and Staphylococcus-SP22 were in the lower nanomolar range 
(<500 nM); that measured for Borrelia-SP9 was in the upper nanomolar range (> 500 nM).   
Up to this point, only signal peptide fragments comprising six to seven amino acids have been 
tested in concentration response experiments. It has been shown that heterologously expressed 
hFPR1 recognizes full-length peptides, containing up to more than 40 amino acids. However, 
this occurs with a 10- to 1000-fold loss in sensitivity (Bufe et al., 2015). This is also true for 
monocytes (Table 3-4). The full-length peptide of Streptococcus-SP1 exhibited a ~ 5 times 
higher EC50 value (24.1 ± 17.2 nM) than the hexapeptide fragment (4.8 nM). The EC50 value 
of Desulofotomaculum-SP8 FuLe was shifted towards ~ 350-fold higher concentrations 
compared to the hexapeptide: 735.4 ± 17.2 nM (full-length) vs. 0.2 nM (hexapeptide). 
Surprisingly, the full-length version of Staphylococcus-SP22 was not shifted towards higher 
concentrations. On the contrary: the EC50 value gained for the full-length peptide 
Staphylococcus-SP22 FuLe (4.6 ± 1.8 nM) was ten times lower than that for its hexapeptide 
(43.9 ± 26.7 nM). These data show that monocytes are able to detect full signal peptides as 
well as their N-terminal breakdown products albeit with different sensitivity. 
Table 3-4 | Human monocytes exhibit high affinity to bacterial signal peptides* 
Signal peptide EC50 value in 
[nM] 
Amino acid sequence Online 
accession 
 
Streptococcus-SP1 4.8 ± 4.7 (10) f-MGFFIS Q8VLQ8 
Streptococcus-SP1 FuLe 24.1 ± 17.2 (4) f-MGFFISQSKQHYGIRKYKVGVCSALIALSILGTRVAA Q8VLQ8
Staphylococcus-SP3 164.1 ± 133.6 (3) f-MFIYYCK Q6GHI8 
Salmonella-SP4 1013.5 ± 500.6 (5) f-MAMKKL Q8Z9A3 
Haemophilus-SP5 221.2 ± 103.1 (7) f-MVMKFK P45306 
Psychromonas-SP6 0.2 ± 0.1 (3) f-MLFYFS A1ST24 
Shewanella-SP7 64.6 ± 22.6 (3) f-MLFKYS A6WUI7 
Desulofotomaculum-SP8 0.2 ± 0.2 (6) f-MLFYLA A4J7E6 
Desulofotomaculum-SP8 FuLe 735.4 ± 202.7 (4) f-MLFYLALPCTLVIFFASKALYAI A4J7E6
Borrelia-SP9 682.6 ± 556.2 (3) f-MLKKVY Q44743 
Staphylococcus-SP22 43.9 ± 26.7 (4) f-MKKFNILIALLFFTSLVISPLNVKA Q44743
Staphylococcus-SP22 FuLe 4.6 ± 1.8 (2) f-MKKFNI P20723 
Salmonella-SP23 5 ± 2.6 (2) f-MKKFYS P37423 
Salmonella-SP24 1.7 ± 1.1 (2) f-MKKFRW Q8XG71 
Control peptide    
f-MLF 2.2 ± 1.2 (3) f-MLF / 
W-peptide 1.9 ± 1.2 (3) WKYMVm-NH2 / 
retro-inverted W-peptide 9.4 ± 4.8 (3) f-MVMYKW / 
M-peptide 11.8 ± 8.6 (3) MMHWAm-NH2 / 
Substance P 1456 ± 97 (2) RPKPQQFFGLM-NH2 / 
*The table shows EC50 values (in nM) from concentration-response experiments of primary human monocytes 
after stimulation with signal or control peptides in calcium imaging experiments. The tested amino acids are 
shown in one letter code. f = N-terminal formylation. Data are averaged over at least two donors (exact numbers 
are indicated in parenthesis). Accession numbers refer to the UniProt database.  
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3.4.2. Human granulocytes detect bacterial signal peptides through formyl peptide 
receptors 
As shown in chapter 3.4.1 primary human monocytes are capable of hFPR1-mediated 
recognition of signal peptides with high sensitivity and specificity. Human monocytes were 
excellent candidates for first experiments as they are frequently used for calcium imaging and 
they are easy to culture for primary cells. Monocytes are important elements of the innate 
immune defense. However, granulocytes, mainly neutrophil granulocytes (= neutrophils), are 
at the center of immune responses. Constituting the majority of leukocytes in the blood stream, 
granulocytes are easily obtained in large numbers and therefore well-investigated. Human 
neutrophil granulocytes have been used extensively to study FPRs in the past (Migeotte et al., 
2006). The cells express both, hFPR1 and hFPR2 in abundance (Migeotte et al., 2006) and 
should therefore provide a valid tool for investigation of FPR pharmacology in primary cells. 
To collect more data on the effects of signal peptides on the innate immune system the study 
was extended to primary human granulocytes.  
3.4.2.1. Primary human granulocytes recognize signal peptides in high-throughput calcium 
imaging 
Human granulocytes were isolated from whole blood by density gradient centrifugation and 
then incubated in calcium containing Ringer solution. First, it was tested whether the isolated 
cells can be measured in high-throughput calcium imaging. When the cells were challenged 
with f-MLF or the signal peptide Streptococcus-SP1 they responded with stable calcium 
transients (Figure 3-25 A). As observed for the monocytes, the strength of this response was 
concentration-dependent, exhibiting a minimal effective concentration of 100 pM (Figure 
3-25 A + B). Calculation of concentration-response curves yielded EC50 values of 
0.47 ± 0.51 nM (f-MLF) and 0.62 ± 0.43 nM (Streptococcus-SP1), which are approximately 
four to eight times lower than those calculated for human monocytes. In a next step it was 
investigated whether the cells can be stimulated with several signal peptide fragments in 
concentrations to 10 µM. All tested fragments (SP1, SP4, SP5, SP8 and SP22) were 
recognized by the granulocytes. These experiments demonstrate that human granulocytes 
respond to bacterial signal peptides with high sensitivity. 
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Figure 3-25 | Primary human granulocytes are activated by various bacterial signal peptides 
Calcium imaging of primary human granulocytes performed with the FLIPR. [A] Original calcium traces of 
stimulated granulocytes as observed in the FLIPR. The calcium traces show calcium transients of granulocytes 
after application of 10 µM Streptococcus-SP1 or f-MLF. RFU = relative fluorescence units. Each trace is 
representative for at least five donors. [B] Concentration-response analysis of granulocytes stimulated with f-
MLF or SP1. Number of tested donors is given in parentheses. [C] Various single peptide fragments were tested 
at 10 µM. All peptides induced calcium responses in human granulocytes. f-MLF (10 µM) served as positive 
control. Buffer application (black) served as negative control. 
In a next step it was investigated which cells are responsible for the calcium signals. 
Therefore, immunocytochemistry was used in conjunction with single cell analysis. First, to 
determine the purity and morphology of the prepared cells, nuclear staining was used. 
Granulocytes (or polymorphonuclear leukocytes) can easily be identified in 
immunocytochemical analysis by the shape and morphology of their characteristic multi-
lobular nuclei. The most prominent granulocyte (50-70% of all leukocytes in the human blood) 
is the neutrophil granulocyte. The nuclear anatomy of the mature neutrophil’s chromatin is 
organized into two to five dense chromatin segments (Olins et al., 2008). Purity analysis of 
the isolation showed that most cells were in fact granulocytes, since 95.2 ± 2.4% of the cells 
(not shown) had a multi-lobed nucleus that is characteristic for neutrophils (Olins et al., 2008). 
Immunocytochemistry using antibodies targeted against the neutrophil marker CD66 did also 
reveal staining for >95% of the cells (data not shown), confirming these results. Interestingly, 
the stainings showed that the granulocytes did strongly adhere to the well bottom during 
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incubation. Under physiological conditions, non-activated granulocytes remain in suspension. 
However, the Ringer solution used for incubation of the cells does not reflect physiological 
conditions that are found in human blood. To mimic more physiological conditions, it was 
tested whether the cells show different stainings when incubated in culture medium, 
supplemented with 1% of autologous (= donor-self) blood serum. In fact, there were about  
90% less cells attached to the well bottom when incubated in autologous serum (data not 
shown). According to the nuclear morphology, more than 95% (183/191) of those cells were 
granulocytes. However, no significant differences were observed in functional analysis (data 
not shown). Since incubation in the Ringer solution yielded much more granulocytes, the cells 
were generally incubated in Ringer. 
Next, the expression rates of hFPR1 and hFPR2 were addressed. Analysis of 
immunocytochemical stainings of human granulocytes showed that 86.7% ± 3.5% of the cells 
were positive for hFPR1 (Figure 3-26). Immunocytochemistry for hFPR2 showed that 51.6% 
± 16.3% of the cells were stained positive (Figure 3-26). Importantly, 98% of the cells 
expressing hFPR1 had a multi-lobular nucleus. Of the cells stained positively for hFPR2, 97% 
were identified as granulocytes (Figure 3-26 C). This shows that the majority of cells is made 
up by granulocytes and that they express hFPR1 and hFPR2. To verify that the calcium 
signals are generated by granulocytes, single cell calcium imaging was used. First, the 
granulocytes were challenged with 10 µM of Streptococcus-SP1. Of 192 cells in the visual 
field, 173 (= 92%) did respond with calcium elevations within 15 seconds after application of 
SP1 (Figure 3-26 D). In contrast, only 8 of 204 cells (= 3.9%) responded to buffer application 
(not shown). Quantification of these results over several experiments showed that ~ 70% of 
the cells responded with calcium signals to 10 µM of Streptococcus-SP1; ~ 50 - 60% 
responded to 10 µM Desulfotomaculum-SP8, Hydrogenobacter-SP16 and W-peptide, 
respectively (Figure 3-26 D).  
The results illustrated in this chapter demonstrate that granulocytes are activated by a range of 
bacterially-derived signal peptide fragments and that the majority of the observed calcium 
signals are generated by granulocytes that express hFPR1 or hFPR2. However, so far there is 
no evidence that these responses are really mediated by hFPR1 or hFPR2.  
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Figure 3-26 | Signal peptide-induced calcium signals are generated by primary human granulocytes  
[A] Representative confocal immunostainings of non-permeabilized primary human granulocytes with an 
antibody targeted against hFPR1 (upper panel) and an antibody targeted against hFPR2 (lower panel). 321 of 337 
(95%) nucleated cells had a polymorph shaped, multi-lobular nucleus typical for human neutrophil granulocytes 
(neutrophils). [B] Representative confocal images showing the isotype controls for the hFPR1 antibody (KLH) 
and the hFPR2 antibody (MOPC-21). [C] The left column chart shows that hFPR1 is expressed in 87% of the 
nucleated cells while hFPR2 was detected in 52% of the cells. The right chart shows that of those cells, 98% and 
97%, respectively, are granulocytes. All data in A-C are representative for at least three donors. [D] Single cell 
calcium imaging of granulocytes. The upper panel shows that 173 of 189 cells responded to 10 µM SP1. Each 
trace represents one cell. Red traces = positive responders, gray = non-responders. The lower panel shows the 
quantification for one representative donor experiment over at least three repetitions. Numbers in parentheses 
indicate the number of analyzed cells. All data are representative for two similar experiments and two donors. 
3.4.2.2. Signal peptide recognition of human granulocytes is mediated by FPRs 
To verify that the signal peptide-induced calcium elevations are indeed mobilized through 
FPRs, signal peptide fragments were applied alone or in combination with blockers specific 
for hFPR1 or hFPR2. 
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First, it was tested whether Streptococcus-SP1-induced signals are mediated through hFPR1. 
Signals induced by 1 nM of Streptococcus-SP1 were completely abolished if it was applied 
together with the hFPR1 antagonist tBoc2 or after pre-application of CsH, which is another 
potent inhibitor of hFPR1. Very similar results were observed for 1 nM f-MLF. When SP1 or 
f-MLF was applied after pre-incubation with the hFPR2-specific inhibitor PBP10, these 
signals were not significantly reduced (Figure 3-27 A). This strongly suggests that the 
calcium responses are mediated by hFPR1. To verify that blocking hFPR1 with CsH does not 
impair the general signal transmission of the granulocytes, the above-described blocking 
experiments were performed with the hFPR2 preferential signal peptide fragment 
Salmonella-SP4. When applied after pre-incubation with CsH, there was no significant 
reduction in signal amplitude (Figure 3-27 B). This demonstrates that the general excitability 
is not negatively influenced by CsH. When SP4 was applied after pre-incubation with PBP10, 
the responses were blocked, indicating hFPR2-mediated transmission of these signals. Further 
experiments using the signal peptide fragments Hydrogenobacter-SP16 and Staphylococcus-
SP22 showed that both peptides were sufficiently blocked by PBP10. Together these data 
argue for hFPR1 and hFPR2-dependent recognition of bacterial signal peptide fragments in 
human granulocytes. 
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3.4.2.3. Bacterial signal peptides activate primary human granulocytes with high affinity 
In order to analyze the affinity of the tested ligands on human granulocytes, concentration-
response experiments were conducted. First, concentration response curves were created for 
Streptococcus-SP1 and the control substances f-MLF and W-peptide. SP1 and f-MLF are 
known to prefer hFPR1 while W-peptide is more affine to hFPR2 (Migeotte et al., 2006). The 
calculated EC50 for SP1 on granulocytes was 0.6 ± 0.4 nM; about three times lower than the 
value calculated for hFPR1 transfected HEK293T cells (1.9 ± 1.3 nM) (Figure 3-28). Similar 
results have been observed for f-MLF with 0.2 ± 0.07 nM (granulocytes) and 0.7 ± 0.2 nM 
(hFPR1 in HEK293T). The observed results for W-peptide showed an EC50 value of 
0.15 ± 0.1 nM for granulocytes. This value was almost identical to the one calculated for 
Figure 3-27 | Block of signal 
peptide-induced calcium signals by 
hFPR1 and hFPR2 inhibitors in 
human granulocytes 
Isolated human granulocytes were 
challenged with hFPR1 or hFPR2 
preferential signal peptide fragments, 
either alone or in combination with 
receptor specific blockers. All data 
were averaged over at least two 
donors; the exact number of donors is 
given in parentheses above the 
columns. The used concentrations 
were: f-MLF [1 nM], SP1 [1 nM], 
SP4 [1 µM], SP22 [10 nM], SP16 [10 
nM], CsH [10 µM], tBoc2 [10 µM], 
PBP10 [5 µM]. [A] Calcium signals 
induced by hFPR1 preferential signal 
peptides can be inhibited by the 
hFPR1 specific inhibitor CsH and 
tBoc2. These signals are not impaired 
by the hFPR2 specific blocker 
PBP10. [B] Calcium signals induced 
by hFPR2 preferential signal peptides 
can be inhibited by the hFPR2 
selective blocker PBP10. The signals 
are not blocked by the hFPR1-
specific CsH.  
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HEK293T cells expressing hFPR2, which is 0.16 ± 0.02 nM (Figure 3-28). The concentration-
response curves of W-peptide showed a close correlation between granulocytes and hFPR2 
expressed in HEK cells: they were identical in shape, onset slope and EC50 (Figure 3-28). 
 
Figure 3-28 | Direct comparison between concentration-response curves of human granulocytes and 
hFPR1 or hFPR2 expressed in HEK293T cells 
Shown is the comparison of averaged concentration-response curves and EC50 values determined in calcium 
imaging for granulocytes (green) and hFPR1 (black circles) or hFPR2 (gray squares) expressed in HEK293T 
cells. The exact number of averaged donors/transfections is shown in parentheses. Concentration-response 
curves recorded from granulocytes and HEK293T cells expressing hFPR1 are identical in shape, onset slope and 
EC50 value for the hFPR1 preferential Streptococcus-SP1. The well-known f-MLF and W-peptide served as 
controls. The concentration-response analysis for Streptococcus-SP1 and f-MLF on heterologously expressed 
hFPR1 were performed by Bernd Bufe. 
This close correlation indicates that the concentration-response curves measured in this study 
can be transferred from HEK293T cells to granulocytes, underlining the selectivity of the 
ligands. Therefore, several signal peptides were tested on granulocytes in concentration-
response experiments. The most affine of the tested peptides, Desulfotomaculum-SP8, 
exhibited an EC50 of 5 x 10-11 M. Comparison of dose-response curves between granulocytes 
and monocytes indicated that the granulocytes exhibit higher sensitivity towards nine of 
eleven compared agonists. The greatest difference in sensitivity has been observed for SP4: 
granulocytes exhibited ~ 18 times higher sensitivity towards this peptide than monocytes 
(Table 3-5). 
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Table 3-5 | Human granulocytes exhibit high affinity to bacterial signal peptides* 
Agonist Granulocytes EC50 [nM] Monocytes EC50 [nM] Factor M/G 
Streptococcus-SP1 0.62 ± 0.43 (9) 4.8 ± 4.7 (10) 6 
Staphylococcus-SP3 116.81 ± 95.99 (2) 164.1 ± 133.6 (3) 1 
Salmonella-SP4 56.78 ± 1.3 (3) 1013.5 ± 500.6 (5) 18 
Haemophilus-SP5 50.06 ± 23.03 (7) 221.2 ± 103.1 (7) 4 
Shewanella-SP7 52.32 ± 17.24 (2) 64.6 ± 22.6 (3) 1 
Psychromonas-SP6 0.1 ± 0.09 (5) 0.2 ± 0.1 (3) 2 
Desulofotomaculum-SP8 0.05 ± 0.04 (4) 0.2 ± 0.2 (6) 4 
Hydrogenobacter-SP16 5.59 ± 9.34 (8) not determined not tested 
Staphylococcus-SP22 14.08 ± 5.35 (8) 43.9 ± 26.7 (4) 3 
f-MLF 0.16 ± 0.07 (5) 2.2 ± 1.2 (3) 5 
W-peptide 0.15 ± 0.1 (2) 1.9 ± 1.2 (3) 13 
M-peptide 6.21 ± 4.13 (2) 11.8 ± 8.6 (3) 2 
*The table shows EC50 values (in nM) from concentration-response experiments of primary human granulocytes 
and monocytes after stimulation with signal or control peptides in calcium imaging experiments. The right 
column contains the ratio of EC50 values from monocytes/granulocytes, showing how many times the ligands 
were more affine on granulocytes than on monocytes. Data are averaged over at least two donors (exact numbers 
are indicated in parentheses).  
The data presented in chapter 3.4 demonstrate that bacterially-derived signal peptides and 
their N-terminal fragments are recognized by cells of the innate immune system. Activation of 
human monocytes and granulocytes is mediated by hFPR1 and hFPR2 and leads to 
mobilization of intracellular calcium. It would be intriguing to investigate whether activation 
of monocytes and granulocytes does also induce innate immune defense mechanisms.  
 
3.5. Bacterial signal peptides trigger pathogen defense mechanisms in 
human phagocytes  
To investigate the biological actions of N-terminally formylated signal peptides it is of great 
use to see what actions they trigger in phagocytic cells. Cells of the innate immune system, 
especially monocytes and neutrophils are specialized toward pathogen recognition and their 
elimination; they define the first line of defense against invading pathogens. Recruitment of 
neutrophils from blood flow to intra-tissue sites of infection requires adhesion to the 
endothelium, extravasation (transmigration) through the endothelial wall and elimination of 
targets (Kolaczkowska and Kubes, 2013). The following chapter addresses innate defense 
mechanisms of monocytes and granulocytes, starting from migration to elimination of 
pathogens. 
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3.5.1. Bacterial signal peptides induce chemotaxis in neutrophils  
Chemotaxis of phagocytes is one of the first events initiated during immune defense triggered 
by activation of GPCRs (Gambardella and Vermeren, 2013). The cells crawl towards a 
concentration gradient with the aim to come in close proximity to their target. hFPR1 was 
discovered in 1975 as the prototypic chemoattractant receptor (Schiffmann et al., 1975). In 
order to investigate chemotaxis-inducing properties, the hFPR1 selective Streptococcus-SP1 
and the hFPR2 selective Salmonella-SP4 and Hydrogenobacter-SP16 were tested in 
chemotaxis experiments. Figure 3-29 shows that all three peptides induced migration of the 
cells towards the higher agonist concentrations within the gradient. The bar chart displayed 
for Streptococcus-SP1 shows a typical concentration-dependent migration as has been 
described for f-MLF (Campbell et al., 1996). For SP1, the maximal number of migrated cells 
was counted when stimulated with 100 nM. For SP16 and SP4 it was towards 1 µM. 
Activation threshold for SP1 and SP16 was 1 nM11, the threshold for SP4 was 1 µM (Figure 
3-29 A). A typical property of activated, migrating neutrophils is the formation of 
lamellipodia. Granulocytes activated with 10 to 100 nM SP1 or SP16 showed a remarkable 
difference in morphology compared to non-stimulated cells. The cells showed elongated 
protrusions and strong adherence to the bottom measurement chambers (Figure 3-29). Cells 
incubated in medium without stimulus were of round shape and less adherent. 
These experiments illustrate the chemotactic properties of signal peptides on human 
granulocytes. The next question was, whether the peptides can also induce anti-microbial 
actions as an anti-pathogenic effector function. 
                                                     
11 In some occasions, signals have been observed for SP1/SP20 concentrations of < 1 nM (in one case up to 10 
fM), but these were not reliably reproducible and therefore not included. 
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3.5.2. Monocytes and neutrophils produce reactive oxygen species when stimulated with 
bacterial signal peptides 
GPCR-dependent activation of phagocytes by hostile molecules results in the release of 
reactive oxygen species (ROS)12 , which are major contributors to host immune defense 
(Bedard and Krause, 2007). These highly reactive oxygen-based radicals transfer electrons to 
the closest target (e.g. pathogens), thereby breaking covalent bonds of proteins, sugars, fatty 
acids, etc. Controlled formation of these radicals requires NADPH-dependent oxidases (NOX) 
that reside in intracellular vesicles (Bedard and Krause, 2007). In phagocytes, GPCR-
dependent activation leads to assembly and activation of the well-investigated NOX2 enzyme 
complex, whose vesicle is fused with the plasma membrane (Bedard and Krause, 2007). 
NOX-dependent reduction of oxygen results in the formation of superoxide radicals (●O2-). 
This radical reacts with water molecules forming additional ROS species like hydrogen 
peroxide (H2O2) that supports the antimicrobial mode of action (Bedard and Krause, 2007). 
One possibility to monitor the formation of H2O2 requires the use of the fluorescent dye 
                                                     
12 The rapid release of reactive oxygen species is known as respiratory burst or oxidative burst 
Figure 3-29 | Human granulocytes show chemotactic activity 
towards signal peptides 
[A] Incubation of granulocytes in a signal peptide concentration 
gradient, leads to migration toward higher concentrations. The 
number of cells observed in the visual field of the microscope is 
shown above each column. Medium (black column) served as a 
control. Columns show averaged duplicate measurements from one 
donor. All data are representative for three donors. [B] Bright field 
image of migrated granulocytes. The medium control shows that 
migrated cells are not only less in number compared to the 
stimulus, but also different in adhesion and morphology. Scale bar 
= 100 µm. Images are representative for three donors. 
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Amplex®UltraRed (Amplex). Amplex is a fluorogenic substrate for horseradish peroxidase 
(HRP). Upon H2O2 formation, the HRP catalyzes the H2O2-dependent reduction of Amplex to 
a fluorescent dye, which can be monitored in ELISA readouts. 
In order to investigate whether signal peptides can induce the formation of reactive oxygen 
species, a high-throughput, Amplex®UltraRed-based fluorescence assay was used to test a 
number of stimuli. Notably, Amplex®UltraRed is not membrane permeable and does only 
indicate extracellularly produced H2O2 (Bogeski et al., 2011). All tested signal peptides (SP1, 
SP3, SP4 and SP5) were able to induce the formation of H2O2 (Figure 3-30 A). The 
fluorescence measured for f-MLF was two times higher than for SP1. SP5 seemed to be three 
times more potent in inducing formation of H2O2 than SP1, indicating that these peptides 
show different potencies in ROS production. In order to investigate the sensitivity of 
hydrogen peroxide formation, a kinetic measurement was performed (Figure 3-30 B). Steady 
concentration-response effects of SP1-induced signals stabilized 3 minutes after beginning of 
the measurement. Similar results were obtained for f-MLF (not shown). As expected, signal 
peptides, namely SP1 and SP16, also induce peroxide formation in human granulocytes 
(Figure 3-30 C). To determine whether this effect is FPR-dependent, the hFPR1 preferential 
SP1 (100 nM) was also applied in conjunction with hFPR1 inhibiting concentrations of tBoc2 
(10 µM). As expected, the SP1-induced signal was completely abrogated (Figure 3-30 B). The 
same experiment was performed with the hFPR2 preferential SP16 (1 µM). Signals generated 
via SP16 were not diminished when applied together with tBoc2. This suggests that the 
hydrogen peroxide generation induced by Streptococcus-SP1 is dependent on hFPR1. The 
next step was to acquire the sensitivity of these peptides with respect to radical production in 
monocytes and granulocytes. In monocytes both, f-MLF and SP1 produced superoxide with 
EC50 values in the lower nanomolar range. The calculated EC50 values were 34 ± 13 nM for f-
MLF and 74 ± 32 nM for SP1. This corresponds to a ~14-fold (SP1) to 20-fold (f-MLF) shift 
to higher concentrations in the dose-response curves compared to the calcium signals (Figure 
3-30 C). This is in agreement with previously observed data on superoxide production in 
human monocytes (Kemmerich and Pennington, 1988). Similar results have been observed for 
human neutrophils (Figure 3-30 D). Regarding ROS release, Streptococcus-SP1 exhibited an 
EC50 value of 39.3 ± 23.5%, which is about 60 times higher than that calculated for calcium 
mobilization (Figure 3-30 D). Hydrogenobacter-SP16 stimulated the ROS production in 
neutrophils with an EC50 of 104 ± 9.8 nM, approximately twenty times higher than that for 
calcium mobilization (Figure 3-30 D). Similar results have been described before (Gao et al., 
1994).  
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Figure 3-30 | Signal peptide-dependent formation of reactive oxygen species by human monocytes and 
granulocytes 
Amplex-based detection of H2O2 formation by monocytes and granulocytes after stimulation with distinct signal 
peptides. [A] Average H2O2 production (number of donors in parentheses) stimulated with four signal peptides. 
f-MLF, W-peptide (W-pep), and retro-inverted W-peptide (retro-W) were used as positive controls. Buffer was 
used as baseline control. The columns show the x-fold increase in fluorescence over baseline fluorescence 10 
minutes after stimulation with a given substance. All peptides were used at 10 µM, except SP4 (100 µM). [B] 
Concentration-dependent kinetics measurement of H2O2 formation after stimulation with SP1 (representative for 
four donors). [C] Signal peptide-induced H2O2 formation observed in granulocytes. The effect induced by the 
hFPR1 selective SP1 (100 nM) can be inhibited by tBoc2 (10 µM) while the hFPR2 selective SP16 (1 µM) is 
unaffected. [D] Dose-response analysis of H2O2 formation (blue) by monocytes. The curve’s EC50 values are 
shifted towards higher concentrations, compared to those of the calcium measurements (red). [E] Comparison of 
concentration-dependent calcium mobilization (green) and H2O2 formation (blue) in human granulocytes after 
stimulation with signal peptides. EC50 values of C and D are stated above the graphs. Number of donors used for 
calculation of the graphs is given in parentheses. 
In summary, these data demonstrate that bacterial signal peptides activate classical cascades 
of innate defense mechanisms formed during immune responses. First, the signal peptides 
utilize FPRs to induce calcium responses. Second, the cells migrate toward higher 
concentrations of these peptides and third, if a certain concentration threshold is exceeded, 
they start producing reactive oxygen species in the extracellular milieu. 
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3.6. Formyl peptide receptor-dependent activation of murine leukocytes by 
bacterial signal peptides  
The chapters 3.4.1.2 and 3.4.2.2 delivered pharmacological arguments that signal peptide 
recognition of human innate immune cells is mediated by FPRs. However, pharmacological 
manipulation alone does not provide substantial evidence. Hence, a genetic model was used to 
address the specificity of signal peptide recognition in Fpr1 knockout mice.  
First, to investigate whether signal peptides activate mouse FPRs in primary leukocytes, cells 
- including monocytes and granulocytes - were isolated from mouse bone marrow and 
challenged with distinct signal peptides. 
 
3.6.1. Signal peptides activate neutrophils isolated from mouse bone marrow 
3.6.1.1. Immunocytochemical analysis of isolated bone marrow cells 
Bone marrow from long bones like tibia and femur of C57BL/6J mice contain many different 
cell types. With about 40% of the total cell number, neutrophils are the dominant cell type in 
femur bone marrow (Yang et al., 2013). I investigated the purity and quality of my 
preparation using immunocytochemistry. First, crude bone marrow cell extracts were 
compared to granulocytes isolated from whole blood with beads targeted against the mouse 
neutrophil marker Ly6G. No obvious difference was observed for cell morphology, viability, 
calcium signals and dose-response behavior of the cells towards f-MLF, SP1, and SP16 (not 
shown). The bead-isolated cells showed a high degree of purity for mature granulocytes. 
However, this procedure yielded ~10 times less numbers of neutrophils than the bone marrow 
extracts. Therefore, bone marrow isolates were used for further investigation. 
Knockout of the Fpr1 gene could lead to differences in composition of cell populations and 
the differentiation states of the isolated granulocytes. To exclude such experimental bias the 
number and maturity of the cells in knockout mice was compared to that of wild type mice 
(Figure 3-31). Immunocytochemistry showed that 42% ± 1.1% and 44% ± 1.7% (wild type 
and knockout, respectively) of the cells had a clearly polymorph, ring-like shaped nucleus, 
identifying them as polymorphonuclear leukocytes (PMNs) (Figure 3-31 A and B). 94 ± 1.2% 
and 90 ± 4% (wild type and knockout, respectively) of those cells were positively stained for 
the mouse neutrophil marker Ly6G (Figure 3-31 C). The overall number of cells purified and 
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observed in the visual field was also comparable (143 cells for wild type, 129 cells for 
knockout). Morphological differences were not observed. This implies that the health status of 
neutrophils, isolated from Fpr1 -/- mice is not compromised by the knockout.  
Figure 3-31 | Immunocytochemical analysis of mouse bone marrow leukocytes  
The figure compares anatomical aspects of neutrophil granulocytes of bone marrow isolates from wildtype and 
Fpr1 -/- mice. All data and images are representative for three independent experiments. [A] Confocal images of 
non-permeabilized bone marrow isolates from wildtype mice (upper panel) and Fpr-/- mice (lower panel) stained 
with the Ly6G antibody. Ly6G is a surface marker for mature neutrophil granulocytes in mice. Nuclear 
counterstaining enables additional identification of polymorphonuclear leukocytes by their typical multi-lobular, 
circular nucleus (white arrows). [B] 42% (wildtype mice) and 44% (Fpr1-/- mice) of all nucleated cells are 
polymorphonuclear leukocytes (PMNs). The number of analyzed cells (polymorphonuclear / total number) is 
shown inside the columns. Data were analyzed in triplicates. [C] Overlay of Ly6G stained cells with polymorph 
shaped nuclei shows that 94% (wildtype) and 91% (Fpr1-/-) of the PMNs are stained positively for Ly6G. The 
number of analyzed cells (polymorphonuclear / total number) is shown inside the columns. Data were analyzed 
in triplicates. 
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3.6.1.2. Bone marrow leukocytes isolated from mice heterozygous for Fpr1 can be activated by 
bacterial signal peptides 
In order to see if murine leukocytes respond to signal peptides, a selection of six signal 
peptides with dissimilar peptide sequences was tested in calcium imaging on leukocytes 
isolated from mice heterozygous for mFpr1 (Figure 3-32). Application of 1 µM 
Streptococcus-SP1, Staphylococcus-SP3, Hydrogenobacter-SP16 or Bacillus-SP2-induced 
clear calcium signals that were even higher than those observed for the positive control f-
MLF or the CCR1 agonist MIP1-α.  
 
3.6.2. Signals induced by mFpr1-selective concentrations of Streptococcus-SP1 are 
abolished in Fpr1 -/- mice 
Leukocytes of Fpr1 knockout mice were challenged with 1 µM of the mFpr1 preferential 
Streptococcus-SP1 or f-MLF, respectively, and compared to leukocytes from heterozygous 
and wildtype mice in calcium imaging. Both, the SP1 and the f-MLF-induced responses were 
abolished in cells of the knockout mice (Figure 3-33 A). The cells of wild type and knockout 
mice did respond to MIP1-α, a CCR agonist, with comparable intensity. Cells isolated from 
heterozygous animals showed a stronger response to all stimuli than those of wild type mice. 
However, they seem to expose a higher baseline activity because the signals monitored after 
buffer application were also higher than those of wild type mice. These data indicate mFpr1-
dependent transduction of Streptococcus-SP1-induced signals. When SP1 was applied in a 
concentration of 10 µM, which activated mouse Fpr2 in the heterologous expression system, 
the ligand induces a signal in the knockout mice. This signal was 30% smaller compared to 
Figure 3-32 | Bone marrow leukocytes isolated from Fpr1+/- mice 
respond to signal peptides with intracellular calcium mobilization 
Stimulation of bone marrow leukocytes (BMLs) with signal peptides (all 
1 µM) leads to induction of calcium transients. f-MLF (1 µM) and MIP1-
α (10 µM) (white), a CCR agonist, serve as positive controls; buffer 
(black) as a negative control. Data are averaged over two independent 
experiments; all data points were measured in triplicates. 
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the signal of wild type mice, implying activation of mFpr2 by SP1 (Figure 3-33 B). Similar 
results have been observed for f-MLF (not shown). These data are consistent with the 
literature (Southgate et al., 2008) and demonstrate that intracellular calcium mobilization, 
induced by the signal peptide is mediated via mouse formyl peptide receptors.  
 
Figure 3-33 | Calcium signals in murine bone marrow leukocytes induced by 1 µM Streptococcus-SP1 are 
abolished in Fpr1-/- mice 
Calcium imaging of mouse bone marrow leukocytes (BMLs). The cells were isolated from wildtype (Fpr1+/+, 
shown in black) mice and mice heterozygous (Fpr1+/-, shown in gray) or deficient (Fpr1-/-, shown in red) for 
Fpr1. All data were averaged over two independent experiments; each condition was tested in triplicates. [A] 
Stimulation of BMLs by 1 µM SP1 (mFpr1 selective) leads to calcium responses of cells expressing at least one 
genetic copy of Fpr1. These responses are absent in Fpr1-/- mice. This is also observed for 1 µM f-MLF. MIP1-
α (10 µM) that served as excitability control, proves the functionality of the signaling pathway in FPR1-/- mice. 
[B] When the BMLs are stimulated by SP1 in a concentration that activated heterologous expressed mFpr2 
(10 µM), they respond with a strongly diminished calcium signal. 
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Chapter 4 
 
Discussion 
 
 
 
Several major findings emerge from the current thesis. I show for the first time that the 
vomeronasal formyl peptide receptor mFpr-rs1 can be activated by peptides that are derived 
from microorganisms. W-peptide, one of the best mFpr-rs1 activators so far, is capable of 
inducing calcium responses in vomeronasal sensory neurons. This supports the theory that 
vomeronasal FPRs can mediate olfactory detection of pathogens. Furthermore, the data 
provide substantial evidence for a novel FPR-mediated pattern-recognition mechanism. Cells 
from the innate immune system utilize FPRs for highly sensitive detection of bacterial signal 
peptides. Therefore, my data provide first evidence for a mechanism by which mammalian 
immune cells could sense the presence of bacteria.  
 
4.1. DMSO is a newly identified FPR agonist with therapeutic potential 
In order to compare the pharmacology of vomeronasal and immune FPRs a variety of 
substances was tested on heterologously expressed FPRs. Surprisingly, DMSO, used as a co-
solvent for organic compounds and hydrophobic peptides, induced strong calcium signals in 
hFPR2, mFpr1 and mFpr2 transfected HEK293T cells. This is very interesting because 
DMSO has been used in anti-inflammatory treatment of acute ectopic lesions like rheumatic 
disorders for years (Matsumoto, 1965; Trice, 1985). The drug exhibits extrordinary skin-
penetrating capabilities, which is why it has been used as a transdermal penetration enhancer 
in targeting neoplastic cancers (Hagemann and Evans, 1968; Williams and Barry, 2012). 
Because of its cell-permeating properties, DMSO-induced signals must be investigated with 
special care; DMSO evoked FPR-independent signals in HEK293T cells transfected with the 
empty vector control at concentrations ≥ 2% [v/v]. However, the shape of the calcium 
transients of the mFpr1, mFpr2, and hFPR2-dependent signals showed a faster onset and had 
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a steeper slope than that observed for the empty vector control, providing first evidence for 
receptor-mediated signaling. Importantly, responses observed for concentrations below 2% 
[v/v] were certainly mediated by the above mentioned receptors (hFPR2, mFpr1 and mFpr2) 
because no signals have been observed for the empty vector control or other functional FPRs 
like hFPR1, hFPR3, and mFpr-rs1. To verify that DMSO activates the receptor, 
desensitization experiments were conducted. Signals induced by mFpr1 and mFpr2 
expressing cells were absent after desensitization of the receptors by pre-stimulation with the 
mFpr1 and mFpr2 agonist f-MLF, further arguing for receptor-mediated signaling. More 
importantly, the DMSO evoked signals were completely dependent on co-expression of the G 
protein alpha subunit Gα16. Only the combination of receptor and G protein led to the calcium 
transients induced by DMSO at concentrations > 0.1% [v/v]. These evidences strongly 
support the argumentation that DMSO mediates calcium signals via mFpr1, mFpr2, and 
hFPR2. As mentioned above, DMSO has been described to mediate anti-inflammatory actions 
in rheumatic disorders. In this regard, the illustrated data provide first evidence for a possible 
FPR-mediated anti-inflammatory mechanism. There are many studies providing evidence for 
an inflammation-resolving role of hFPR2 in human monocytes and granulocytes 
(Krishnamoorthy et al., 2010; Corminboeuf and Leroy, 2015). In addition, hFPR2 has been 
proposed to be involved in the homeostasis of rheumatic inflammation: application of the 
organic hFPR2 ligand Lipoxin A4 led to a marked reduction of inflammatory cytokines in 
human synovial fibroblasts (Fiore et al., 2005). It is possible that the anti-inflammatory 
potential of DMSO during rheumatic lesions is triggered by DMSO-dependent activation of 
hFPR2. Dose-response analysis of mFpr1 and mFpr2 showed dose-dependent activation of 
both receptors with EC50 values of ~ 100 mM (~ 1% [v/v] DMSO). At first, this might seem 
like a very high concentration. However, application of 50 – 100% DMSO is the standard 
concentration in medication of rheumatic lesions (Matsumoto, 1965; Trice, 1985). Due to its 
remarkable skin-penetrating potential (spilling DMSO on the finger makes one taste it after a 
few seconds; Williams and Barry, 2012) it is realistic that at least 1% DMSO will reach 
hFPR2 expressing inflammatory leukocytes. 
The results provide first insights into a possible new mechanism in which FPR2 is utilized to 
treat immune diseases. If this theory proved right, DMSO could be used to treat many of the 
perilous auto-immune diseases that scourge humanity. Therefore, it would be highly 
interesting to see whether DMSO is able to trigger FPR2-dependent anti-inflammatory 
responses in cells of the innate immune system.  
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4.2. Recognition of pathogen-derived peptides by vomeronasal mFpr-rs1 
In the early course of this study a variety of substances was tested in order to determine 
whether they can activate vomeronasal FPRs when expressed in HEK293T cells. The results 
of this compound screening revealed a number of agonists for the vomeronasal receptor 
mFpr-rs1. The best agonists identified during this screening, W-peptide and M-peptide, 
proved to be very useful pharmacological tools to investigate the receptor’s binding 
properties. Therefore, these peptides were used in structure-function analyses of mFpr-rs1.  
 
4.2.1. Activation of the vomeronasal receptor mFpr-rs1 by W-peptide and M-peptide 
The experiments illustrated in chapter 3.2 clearly show that mFpr-rs1 can be activated by 
M-peptide and W-peptide. Both peptides have been intensively studied in several calcium 
imaging assays. At the time when these substances were identified as mFpr-rs1 activators, not 
even a handful of agonists were known for the entire vomeronasal FPR subfamily (Bufe et al., 
2012). Furthermore, W-peptide was the most sensitive peptide agonist described for 
vomeronasal FPRs so far (EC50 values in the upper nanomolar range). This has been verified 
by the laboratory of Richard Ye; they reported degranulation of mFpr-rs1-transfected rat basic 
leukemia cells (RBL-2H3) upon stimulation with 100 nM W-peptide (He et al., 2013). As 
W-peptide has been demonstrated to be a potent agonist, it was used as a tool to investigate 
pharmacological properties of mFpr-rs1 in structure-function analyses. Results from these are 
discussed below. 
 
4.2.2. Key structures for activation of mFpr-rs1 by small peptides 
During a compound screening to identify agonists for vomeronasal FPRs, W-peptide and 
M-peptide were identified as activators of mFpr-rs1 (chapter 3.2). Both are synthetic peptides 
described as two of the most potent hFPR1 and hFPR2 activators known so far (Bae et al., 
2001; Bae et al., 2012). Dose-response analyses performed in the current work proved that 
both peptides activate hFPR1, hFPR2, and hFPR3 as well as mFpr1, Fpr2, and mFpr-rs1. 
Interestingly, W-peptide displayed a conserved concentration-response profile between FPR1 
and FPR2 of human and mouse. Thus, the results imply that W-peptide inherits a peptide 
motif that is conserved with respect to FPR activation. To test whether such a motif exists, a 
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structure-function analysis including several carefully selected derivatives of W-peptide was 
performed. The results of this analysis led to the prediction of a binding motif for short 
peptides by mFpr-rs1. 
4.2.2.1. A core motif of four amino acids is necessary to activate mFpr-rs1 
Testing N-terminal truncated isomers of W-peptide revealed a core motif of four residues that 
are crucial for mFpr-rs1 activation. When mFpr-rs1 was challenged with shorter W-peptide 
isomers, no responses have been observed. However, small calcium signals were observed 
when f-MLF was tested in high concentrations (100 µM). This indicates that mFpr-rs1 can be 
activated by tripeptides although the motif may be incomplete as four amino acids are 
required for full activation. 
4.2.2.2. mFpr-rs1 prefers peptides with C-terminal D-amino acids rather than L-amino acids 
W-peptide and M-peptide are potent activators of mFpr-rs1 with similar EC50 values. It was 
hypothesized that this functional conservation may be due to a common structural feature that 
was unique in the tested array of ligands: both peptides carry a C-terminally-amidated 
D-methionine at the C-terminus (Table 3-2 and Figure 3-8). To investigate the importance of 
these features in terms of mFpr-rs1 activation they were analyzed in structure-function 
analyses. 
The current work provides fundamental evidence that mFpr-rs1 prefers hexapeptides with 
C-terminal D-amino acids rather than L-amino acids. When the D-methionine of W-peptide or 
M-peptide is substituted by its L-isomer, the affinity towards the receptor was reduced by at 
least 14-times. This strongly argues for a stereo-selective preference of mFpr-rs1 for D-amino 
acids. Furthermore, the signal amplitudes induced by the L-isoforms were approximately 50% 
smaller than those observed for the corresponding D-isomers, indicating lesser efficacy of the 
L-isoforms. Similar results have been observed when the methionine of W-peptide was 
replaced by cysteine, another biogenic sulfuric amino acid (Bufe et al., 2012). These data 
demonstrate that although the L-epimers are recognized by the receptor, C-terminal D-amino 
acids are clearly preferred. 
4.2.2.3. The double-bonded oxygen of terminal carbonyl groups is important for affinity of peptides 
to mFpr-rs1 
Experiments to determine whether the C-terminal amidation is necessary for activation of 
mFpr-rs1 revealed that the amidation is important to preserve the affinity to the receptor. 
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Further investigations revealed that the double-bonded oxygen present in the amidation is the 
determining factor for activation of mFpr-rs1. This is discussed in following the section. 
The importance of the double-bonded oxygen in the carbonyl group has been addressed 
mainly by substitution of the C-terminal amidation (CONH2) in W-peptide. To elucidate 
whether the nitrogen is necessary for receptor activation, a W-peptide derivative carrying a 
formaldehyde (CHO) at its C-terminus was tested on mFpr-rs1 in concentration-response 
experiments. There were almost no differences in EC50 values and efficacy between W-
peptide carrying an amidation (CONH2) or W-peptide carrying a formaldehyde (CHO) when 
tested on mFpr-rs1. Since the aldehyde does not contain a nitrogen atom, nitrogen can be 
excluded as the determinant factor. However, the amide and the formaldehyde contain a 
carbonyl group (C=O). When W-peptide was synthesized without a C-terminal modification, 
exposing the free carboxyl group (COO-), the affinity and efficacy to the receptor were 
significantly reduced. The major physicochemical difference between the carboxy group and 
the distinct carbonyl moieties is that the carboxy group contains no double-covalent-bonded 
oxygen (C=O). Instead, a carboxyl group harbors a delocalized electron, adding a negative net 
charge to the oxygen. These revelations provided enough evidence to hypothesize that, in 
terms of activation, the C-terminal amidation and aldehyde group are equivalent to the N-
terminal formylation. To test this hypothesis, the retro-inverted W-peptide was synthesized 
and tested. As assumed, the retro-inverted peptide showed very similar properties to W-
peptide with respect to affinity and efficacy. More recently, this has also been demonstrated 
for the human and mouse FPR1 and FPR2 (Bufe et al., 2015). The strong pharmacological 
correlation between the retro-inversed W-peptide and the “native” W-peptide proved the 
validity of this hypothesis. Computer-based structural modelling of both substances shows 
that W-peptide and the retro-inverted isomer can adopt conformations with aligning folding 
states (Bufe et al., 2015; Figure 4-1). The rendered three-dimensional structures envision the 
close spatial orientation between the amidation of the C-terminal D-methionine and the N-
terminal formyl-methionine.  
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Figure 4-1 | Retro-inversion of W-peptide reveals a common structural motif of N-terminally formylated 
and C-terminally amidated peptides 
Three-dimensional computer model predicting the secondary alpha-helical structure of W-peptide (green) and 
the retro-inverted W-peptide (dark blue). The spatial overlay shows that both structures align in proximity and 
orientation. The carbonyl double-bonded oxygen (red arrows) of the C-terminal amidation (W-peptide) and the 
N-terminal formylation (retro-inverted W-peptide) share a distance of 2.7Å (red line). The black letters indicate 
the amino acid position of W-peptide and retro-inverted W-peptide, respectively. The colored letters name the 
amino acids of the indicated peptides. By courtesy of Reinhard Kappl.  
The importance of the N-terminal formylation in order to reach high performance in FPR 
activation is known since the discovery of FPR1 (Schiffmann et al., 1975; Showell et al., 
1976). Considering this, it is not very surprising that DMSO also activates FPRs in high 
concentrations. DMSO contains a central sulfoxide consisting of a sulfur atom with a 
covalently double-bonded uncharged oxygen (S=O). With this, the chemical structure 
distantly resembles the carbonyl moiety. This sulfoxide probably retains a residual activation 
potential towards the FPRs. It is also known, that N-terminally acetylated peptides can be as 
effective as formylated ones, underlining the role of the carbonyl group (Gao et al., 1994).  
In my opinion, the current investigation provides the most thorough study of mFpr-rs1. It does 
not only demonstrate activation of mFpr-rs1 by several ligands but also provides a solid 
pharmacological analysis of the structural properties required for activation of the receptor. 
The issues discussed above show that mFpr-rs1 is activated by peptides with certain 
modifications like C-terminal amidation or N-terminal formylation. It is, however, important 
to mention that binding to mFpr-rs1 by peptides takes additional requirements. C-terminal 
amidation alone is not sufficient to activate the receptor, as shown in single cell and cell 
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population calcium imaging. First, only peptides with an amidated methionine were capable 
of activating the receptor in nanomolar concentrations. Second, a minimal motif of four amino 
acids is necessary for complete activation. Third, as shown in our latest publication (Bufe et 
al., 2015), the motif requires a hydrophobic or positively charged amino acid at amino acid 
position C4 (the fourth amino acid if counted from the C-terminus). This does also apply for 
formylated or acetylated peptides. I could show that mFpr-rs1 is activated by formylated 
peptides. However, single cell experiments have shown that formylated peptides like ND1 
and CO1 cannot activate the receptor. In addition, only very few of more than 20 tested 
N-terminally formylated signal peptides derived from bacteria could activate the receptor 
(Bufe et al., 2015). This implies that the discovered peptide motif necessary for mFpr-rs1 
activation is not fully understood and requires further investigation.  
 
4.2.3. mFpr-rs1 detects pathogen-derived peptides: possible novel mechanisms to sense 
microbes 
Former publications have shown that the vomeronasal organ (VNO) recognizes disease-
related molecules (Shirasu and Touhara, 2011), including bacterial products like f-MLF 
(Rivière et al., 2009). More recently, it has been shown that the vomeronasal organ (VNO) 
mediates the avoidance of sick or parasitized conspecifics (Boillat et al., 2015). FPRs 
expressed in the innate immune system are well-known for their capability to detect many 
disease-related and microbial procucts, including the bacterial f-MLF (Migeotte et al., 2006). 
Since a subfamily of FPRs is found in neurons of the VNO, they provide excellent candidates 
as detectors of these avoidance-mediating molecules. As described in the chapters 3.2 and 3.4 
the vomeronasal FPR mFpr-rs1 is activated by several peptides that are derived from bacteria 
or exhibit posttranslational modifications that are typical for bacterial proteins/peptides. This 
is consistent with the idea that vomeronasal FPRs mediate the detection of microbes. 
Arguments supporting this hypothesis are discussed below. 
4.2.3.1. Detection of D-amino acid-containing peptides by mFpr-rs1 
The results illustrated in chapter 3.2 show that W-peptide and L-W-peptide are agonists for 
mFpr-rs1. The peptide sequence of L-W-peptide (WKYMVM) was found to be present in a 
protein of the bacterium Kribella flavida. Interestingly, both peptides were able to activate a 
subset of vomeronasal sensory neurons, a cell type that naturally expresses mFpr-rs1 (Liberles 
et al., 2009). As discussed in chapter 4.2.2, the motif for mFpr-rs1 activation requires at least 
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four amino acids. Database analyses have shown that both, the five-amino acid and the four-
amino acid core motif of W-peptide (KYMVM and YMVM, respectively) can predominantly 
be found in various micro-organisms. Most of these motifs have been identified in bacteria 
but were also identified in viruses and fungi. Some of them are well known human and mouse 
pathogens like L. monocytogenes or S. aureus. This means that mFpr-rs1 is able to detect 
bacterially-derived peptides. More interestingly, the affinity of W-peptide and M-peptide to 
mFpr-rs1 is significantly increased when the C-terminal L-methionine is substituted by its 
corresponding D-enantiomer. In nature, D-amino acids are often found in microbial products 
(Martínez-Rodríguez et al., 2010). It is well known that D-alanine and D-glutamate are 
necessary for the composition of the peptidoglycan layer of bacteria. D-amino acids can also 
be introduced into peptides by non-ribosomal proteins (NRPs). These are non-ribosomal 
peptide/protein complexes in fungi and bacteria that are able to biosynthesize peptides and 
proteins. Their hallmark is the use of very unusual amino acids (e.g. in D-configuration) and 
the addition of various formerly unknown amino acid modifications (Schwarzer et al., 2003; 
Caboche et al., 2007). The results presented in chapter 3.2.3 show that C-terminal 
modifications like amidation or formaldehyde boost the affinity of W-peptide toward mFpr-
rs1. It would be interesting to see if these modifications are regularly formed by NRPs or if 
other NRP-based modifications are capable of activating mFpr-rs1. Expansion of this 
knowledge could lead to a novel mechanism for detecting products of microbial metabolism.  
These results further support the theory that mFpr-rs1functions as a pathogen detector.  
4.2.3.2. Detection of N-terminally formylated peptides by mFpr-rs1 
The experiments depicted in chapter 3.2.4 show that mFpr-rs1 is activated by the formylated 
retro-inverted W-peptide. Although the retro-inverted sequence of W-peptide has not been 
identified in microorganisms so far, this experiment demonstrates that mFpr-rs1 is capable of 
recognizing formyl peptides. When f-MLF was applied at concentrations of 100 µM, small 
calcium signals were observed, further supporting the thesis that mFpr-rs1 acts as a receptor 
for formyl peptides. This finding has more recently been verified by our group (Bufe et al., 
2015): N-terminally formylated bacterial signal peptides, including such from mouse 
pathogens, emerged to be activators of mFpr-rs1. One of these peptides, Desulfotomaculum-
SP8 exhibits the f-MLF motif at the N-terminus and was capable of activating mFpr-rs1 at 
high nanomolar concentrations. This verifies two things: (1) f-MLF activates mFpr-rs1 and (2) 
if the peptide contains more than three amino acids, thereby fulfilling the minimal 
requirements for the binding motif discussed in 4.2.2.1, its sensitivity is markedly increased. 
Discussion 
Page | 99 
 
Although the receptor was activated by several signal peptides with nearly identical EC50 
values, thus far no tested agonist revealed significantly higher affinity than W-peptide. This 
could mean that the identified molecules are not the primary targets of mFpr-rs1. Further 
studies should address this issue. 
4.2.3.3. Activation of vomeronasal sensory neurons by the mFpr-rs1 agonist W-peptide 
An important question following receptor characterization is whether W-peptide is able to 
activate cells of the vomeronasal organ, where mFpr-rs1 is naturally expressed. The data 
illustrated in chapter 3.3 clearly show that 5 µM W-peptide and L-W-peptide each induced 
calcium transients in about 2% of the investigated neurons. Activation of vomeronasal 
sensory neurons (VSNs) by W-peptide has been independently determined by other members 
of our laboratory. P. Chamero and B. Stein showed W-peptide activation in VSNs infected 
with viruses encoding mFpr-rs1 (unpublished results). A. Schmid observed calcium responses 
of dendritic knobs in whole mount preparations of the VNO sensory epithelium induced by 
100 nM W-peptide (unpublished results). Similarly, field potential measures in vomeronasal 
sensory epithelia, revealed that W-peptide induces electrical currents (unpublished results, P. 
Hendrix).  
Further evidence is needed to prove that these responses are mediated by mFpr-rs1. One 
possibility to do so is to co-localize receptor expression with calcium signals induced by 
mFpr-rs1 agonists. Co-localization of both, the receptor and the calcium signal will hint to 
mFpr-rs1-mediated signaling. H. Stempel, a PhD student in our laboratory, has already 
purified anti-mFpr-rs1 antibodies that can be used for surface staining of VSNs. However, to 
prove mFpr-rs1-mediated activation of VSNs by W-peptide and signal peptides, investigation 
of mFpr-rs1 knock-out mice is mandatory. Those could be used for calcium imaging of 
vomeronasal sensory neurons after stimulation with mFpr-rs1 agonists. Furthermore, these 
mice would provide an excellent tool for in-vivo characterization of the receptor, e.g. in 
behavioral avoidance experiments. I expect that if bacterial signal peptides were presented to 
mice expressing intact copies of mFpr-rs1, they would to avoid the presented samples. In 
theory, this behavior is likely to be absent in mFpr-rs1-deficient mice. 
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4.3. Neo-functionalization of mouse Fpr-rs receptors expressed in the VNO  
The results of the structure-function analysis of peptide ligands reveal a clear difference 
between immune FPRs (hFPR1-3, mFpr1-2) and the vomeronasal FPRs (mFpr-rs1, mFpr-rs3, 
mFpr-rs4, mFpr-rs6, and mFpr-rs7). While the immune FPRs responded to the majority of the 
tested substances, particularly the peptides, the vomeronasal FPRs remained silent, with the 
only exception of mFpr-rs1. The tested ligands encompassed more than 30 substances from 
distinct chemical classes like arachidonic acid derivatives, sulfoxides and peptides. The tested 
peptides were varying in primary structure, peptide length and either unmodified or carrying 
distinct naturally-occurring N- or C-terminal modifications (e.g. formylation). Some of the 
peptides are naturally-occurring microbial products (like the bacterial f-MLF) or fragments of 
viral glycoproteins (e.g. T20). I also tested several eukaryotic peptides, like the Temporin A 
amide that is usually found on amphibian skin, or human immune modulators like Ac2-26. 
Among the tested peptides were damage-associated molecular pattern (DAMP) molecules: 
peptides derived from the mitochondrial proteins ND1 and CO1. None of these agonists, 
whose functionality was proven by testing them on immune FPRs (Table 3-2), was able to 
activate the vomeronasal FPRs. The receptors also did not respond to the pan-immune FPR 
agonists W-peptide, M-peptide or their epimers. Bacterially-derived signal peptides that were 
identified as highly affine FPR agonists based on a hidden consensus motif for immune FPR 
activation, could not induce responses in cells transfected with plasmids coding for mFpr-rs3, 
mFpr-rs4, mFpr-rs6, and mFpr-rs7 (data not shown). All peptides were used up to 
concentration of 10 - 30 µM, which are very high for receptors expressed in sensory neurons 
(Leinders-Zufall et al., 2009). Immunocytochemical analysis of the Rho-tagged FPRs showed 
that they are inserted into the plasma membrane in the correct orientation. Their expression 
levels were comparable to those observed for the immune FPRs and mFpr-rs1, all of which 
could readily be activated by several substances. However, the receptors mFpr-rs3, mFpr-rs4, 
mFpr-rs6, and mFpr-rs7 did not respond to any stimulus. The number of viable cells present 
in the visual field was highly similar, arguing against lethal effects due to receptor expression.  
In addition, the cells were readily excitable by the positive control stimulus ATP in single cell 
experiments, excluding lethal damage taken by the transfected constructs. The cloned 
constructs were carefully sequenced several times: besides mFpr-rs7, which had a F147L 
amino acid substitution, no amino acid exchanges were observed for the vomeronasal 
receptors, excluding bias caused by structural deviations from the reference sequences. Since 
all vomeronasal FPRs (besides mFpr-rs1) are expressed in the Gαi2 enriched zone of the 
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vomeronasal organ I tested whether they can interact with G protein chimeras derived from 
distinct G proteins, including Gαi2. Although those were functional (they readily interacted 
with mFpr1 and mFpr2), no calcium signals were observed for mFpr-rs3, mFpr-rs4, mFpr-rs6 
and mFpr-rs7. To couple the FPRs to PLC dependent calcium mobilization pathways in 
HEK293T cells the human Gα16 was co-transfected in most experiments. Although this alpha 
subunit is described to be highly promiscuous in receptor-coupling (Offermanns and Simon, 
1995) it was checked whether the murine FPRs prefer the murine ortholog Gα15. Although 
equally promiscuous in receptor-coupling (Offermanns, 1995), co-transfection of Gα15 did not 
lead to improvement in calcium signaling of the murine FPRs. There are two obvious 
explanations standing to reason. First, the vomeronasal receptors utilize special downstream 
signaling components not present or incomplete in the used cell line. Second, they specialized 
on ligands that remain to be identified. A combination of both might as well be possible. It is 
possible that the vomeronasal FPRs other than mFpr-rs1 are tuned towards recognition of 
substances that are not recognized by immune FPRs, thereby expanding the repertoire of 
detectable molecules. Since those receptors are expressed in the Gαi2 enriched zone of the 
VNO, it is reasonable to assume that they rather recognize lipophilic, volatile substances, 
which are classical activators of neurons in this zone (Chamero et al., 2012). On the other 
hand, mFpr-rs3, mFpr-rs4, mFpr-rs6 and mFpr-rs7 exhibit a striking pattern in structural 
alignment, distinguishing them from FPRs expressed in the immune system. All of them lack 
a certain five amino-acid motif located in the third extracellular loop (Migeotte et al., 2006). 
This gap is also found in the corresponding vomeronasal orthologs found in rat (Liberles et al., 
2009). It is possible that this deletion causes conformational changes of the receptor which 
influence ligand binding or signal transduction behavior. Recent phylogenetic analyses of the 
FPR family in mammals provide genetic evidence for a rodent-specific neo-functionalization 
of the vomeronasal FPRs (Liberles et al., 2009). It is unlikely that a family of conserved 
immune receptors (i.e. immune FPRs) develops into a bigger subfamily (vomeronasal FPRs) 
that will eventually turn out to be non-functional. In 2009, Rivière et al. reported activation of 
heterologously expressed vomeronasal FPRs for the first time. Thus far, this is the only 
publication describing activation of vomeronasal FPRs. Many other studies, including my 
own (Bufe et al., 2012; Liberles et al., 2009; Southgate et al., 2008; Gao et al., 2007; Wang et 
al., 2002) failed to report activation of those vomeronasal FPRs. One possible explanation for 
this discrepancy could be due to structure-related utilization of distinct signaling cascades. 
The signaling apparatus of the VNO is not completely discovered and this organ is known for 
its molecular complexity (Tirindelli et al., 2009). Furthermore, several reports indicate that 
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FPR signaling is dependent on additional interaction partners at the surface of the plasma 
membrane, like CD38 (Partida-Sánchez et al., 2001), RAGE (Slowik et al., 2012) or MARCO 
(Brandenburg et al., 2010). Since Rivière et al. (2009) employed a specialized HEK293 cell 
line, which was formerly used for heterologous expression of taste and olfactory receptors, it 
is possible that this cell line provided factors not present in commercially available cell lines. 
It might therefore be profitable to test the receptors in cell lines that are derived from murine 
sensory neurons or similar cells, increasing the chance to hit the right button. 
 
4.4. Recognition of bacterial signal peptides of innate immune cells is 
mediated by FPRs – evidence for a novel pattern recognition mechanism 
Heterologously expressed FPRs are, without doubt, activated by signal peptides that are 
derived from naturally occurring pathogens (Bufe et al., 2015). However, an important 
question is whether, and how, these peptide cues are detected by cells in a natural 
environment. To demonstrate that these cues are indeed detected in native cells, I used 
primary leukocytes of the innate immune system of human and mouse.  
 
4.4.1. Detection of signal peptides by innate immune cells occurs with extraordinary 
high affinity and receptor specificity  
Over one-third of the bacterial proteome is inserted into, or secreted across the bacterial 
membrane (Papanikou et al., 2007). These processes are mediated by export systems that 
translocate proteins depending on their sorting tags or signal peptides (Blobel, 1980). So far, 
more than 16 such systems are known (Papanikou et al., 2007).  
These transport systems can roughly be classified into two groups: Sec-dependent and Sec-
independent. The Sec-dependent pathway, which is the best-understood pathway thus far, is 
ubiquitous and essential for viability in all three domains of life (Papanikou et al., 2007). All 
proteins that are secreted via Sec-dependent mechanisms are synthesized as pre-(pro-)proteins 
carrying an N-terminal signal sequence (Chatzi et al., 2013). This sequence typically has a 
three-domain structure which is found in eukaryotes and prokaryotes (von Heinje, 1990). 
Although not mandatory, the typical signal peptide contains a positively charged N-terminus 
(1-8 amino acids), a hydrophobic helix-forming core (4-16 amino acids) and a polar 
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C-terminal domain that carries a cleavage site (Chatzi et al., 2013). Most secretory pre-
proteins are exported post-translationally by binding to the SecB/SecA chaperones with the 
signal sequence or the nascent peptide chain as soon as they emerge from the ribosome exit 
tunnel (Chatzi et al., 2013). In gram-negative bacteria13 the pre-pro-protein is then targeted to 
the inner membrane by docking to SecYEG translocase (Chatzi et al., 2013). The signal 
peptide is then cleaved at the C-terminal domain by signal peptidase I, releasing the pro-
protein into the periplasmic space (Dalbey et al., 2012). For full secretion of the protein 
across the outer membrane, distinct pathways can be used (Papanikou et al., 2007). The 
cleaved signal peptide is usually further degraded into smaller fragments by signal peptide 
peptidases (Dalbey et al., 2012). It is important to mention that the utilization of N-terminal 
signal peptides is not restricted to Sec-dependent pathways. There are other pathways that 
mediate export of proteins across the membrane that employ a pathway-specific signal 
peptide sequence at the N-terminus, similar to the Sec-dependent signal peptide. These 
include the twin-arginine-transporter (TAT) signal sequence, the lipoprotein signal peptide, 
the prepilin and the preflagilin signal peptides.  
In this work, several N-terminal signal peptide fragments as well as four full-length signal 
peptides were tested on primary human and murine leukocytes of the innate immune system. 
All of them were able to induce calcium signals through at least one human and mouse FPR. 
However, more important: some signal peptides are recognized with extraordinary sensitivity 
and specificity. Concentration-response experiments showed that several of the signal 
peptides showed extraordinarily high affinity for hFPR1 or hFPR2 when expressed in 
HEK293T cells (Bufe et al., 2015). With EC50 values in the lower picomolar range they are 
among the most affine naturally-derived agonists for FPRs described so far (Ye et al., 2009). 
In addition, these highly affine ligands were also very selective for a particular FPR. SP1, for 
example, showed > 1,000 times higher affinity towards hFPR1 than hFPR2. This high affinity 
paired with the strong selectivity provides an excellent pharmacological tool for the 
characterization of FPRs.  Importantly, the current study on primary leukocytes demonstrates 
that these responses are indeed highly specific in primary cells. This has predominantly been 
proven with the hFPR1 selective ligand Streptococcus-SP1. The high affinity SP1 exhibited 
on hFPR1-transfected HEK293T cells (EC50 = 1.9 nM) was almost identical to that observed 
for human monocytes and granulocytes. Even the shape and onset of the curves were highly 
comparable. This pharmacological resemblance was further strengthened by the fact, that 
                                                     
13 Gram-positive bacteria use a very similar mechanism, which is, however, owed to its higher complexity, not 
that well described in current publications.  
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elongation of SP1 (extending it to its full-length) caused an almost identical reduction of 
sensitivity in HEK293T cells and monocytes (Bufe et al., 2015). Similar behavior was also 
observed in human monocytes. The resulting concentration-response curves were again highly 
comparable in shape and onset. Very similar results have been observed with the control 
substances f-MLF and W-peptide in both, human monocytes and granulocytes. This is valid 
pharmacological evidence arguing for hFPR1-mediated signals in human monocytes and 
granulocytes. Monocyte single cell experiments performed by Carsten Kummerow (Saarland 
University, Medical School Homburg, Department of Biophysics) in which the calcium signal 
was co-localized with hFPR1 expression showed that > 90% of the responding cells were 
positive for hFPR1 and the monocyte marker CD14, further strengthening my argumentation. 
The specificity has further been addressed by the desensitization experiments in human 
monocytes. Only the hFPR1 preferential agonists f-MLF and SP1 were able to induce 
desensitization towards additional application of hFPR1 selective agonists. This 
desensitization was not observed when RANTES, an agonist for the chemokine G protein-
coupled receptor CCR1, was applied prior to SP1 stimulation. On the contrary, the signal 
induced by SP1 after stimulation with RANTES had the same amplitude as the signal caused 
by the RANTES stimulation. This implies that RANTES and SP1 utilize different receptors, 
in contrast to f-MLF and SP1, which both signal through hFPR1. Further pharmacological 
evidence is provided by the hFPR1-selective blockers CsH and tBoc2. Both were able to 
block the SP1-mediated signaling in monocytes whereas calcium transients induced by 
RANTES were unaffected despite presence of the blockers. This has also been shown in 
human neutrophils: CsH was able to abolish the SP1-induced signals but signals evoked by 
SP2 preferential agonists like Staphylococcus-SP22 were not impaired. Finally, the specificity 
of the signals has been validated in Fpr1-deficient animals. Unlike the wild type and the 
heterozygous controls, leukocytes of Fpr1 -/- mice were unable to respond to SP1 or f-MLF 
when applied in concentrations below 10 µM. In order to test whether the function of mFpr2 
is impaired I challenged the cells with higher concentrations of f-MLF and SP1. mFpr2 is 
activated by both substances, however with EC50 values in the micromolar range (Southgate 
et al., 2008; Bufe et al., 2015). In line with the literature the cells were able to respond to 
10 µM SP1, although these responses were strongly reduced in cells of the Fpr1-deficient 
mice, strongly arguing for mFpr2-mediated signaling. These data prove that the detection of 
SP1 by monocytes and granulocytes is indeed committed by FPR1. This careful 
pharmacological characterization of SP1-dependent signals proves that the concentration-
response correlation of this highly affine agonist is a valid tool to investigate receptor-specific 
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signaling in primary cells. Therefore, I concluded that all signal peptides that induced 
responses in human monocytes and granulocytes were mediated by FPRs, if a great overlap 
between the published EC50 values of transfected HEK293T cells (Bufe et al., 2015) and the 
values of primary cells was observed. This was generally the case for hFPR1 preferential 
ligands. However, this was not applicable for hFPR2 preferential signal peptides. There was 
no such strong correlation between the dose-response curves for heterologous hFPR2 and 
monocytes/granulocytes as observed for hFPR1. In one case (SP22) the dose-response curve 
was shifted to higher concentrations by a factor of 77 from heterologously expressed hFPR2 
to monocytes. Similar results have been published by Kretschmer (Kretschmer et al., 2010). 
They showed that EC50 values of the hFPR2 preferential agonists PSMα3 and PSMβ2 
measured in HL60 cells were shifted to higher concentrations in human neutrophils in calcium 
imaging experiments. Utilizing the well-described hFPR2 blocker PBP10, I could show that 
the signals induced by the hFPR2 preferential signal peptides SP4, SP16 and SP22 were 
mediated by hFPR2. PBP10 is a RhodaminB-coupled cell membrane permeable decapeptide 
that has been shown to act via allosteric binding at the C-terminus of hFPR2 but not hFPR1 
(Forsman et al., 2012). My experiments confirm these results: following pre-incubation with 
PBP10, calcium signals have only been observed in human neutrophils when SP1 or f-MLF 
was applied in hFPR1 specific concentrations. Signals mediated by SP4, SP16 and SP22 in 
hFPR2 specific concentrations, however, were completely abolished when applied after pre-
incubation with PBP10. This discrepancy in dose-response behavior cannot be explained by 
differences in receptor structure or expression. The hFPR2 containing plasmid was sequenced 
several times and the nucleotide sequence corresponds to the reference sequence. Expression 
levels and patterns of hFPR2 were comparable to that of hFPR1 in HEK293T cells (Figures 3-
1-1 and 3-3-2). This was also true for monocytes. Although the stainings for granulocytes 
showed lower expression rates for hFPR2 than for hFPR1, the number of hFPR2-positive 
granulocytes was still higher than the number of stained HEK293T cells, excluding a failure 
in receptor expression. However, this pharmacological effect could be due to distinct 
glycosylation patterns caused by the distinct cell types. Another explanation could be the use 
of distinct downstream signaling molecules. For heterologous analysis the human Gα16, which 
is known to be expressed exclusively in hematopoietic cells of the myeloid lineage (Rhee, 
2001) was co-transfected. However, this does not mean that this G protein subunit is 
predominantly used by hFPR2 in monocytes and granulocytes. Besides, the possible influence 
of beta and gamma subunits of the heterotrimeric G proteins was not addressed in this work. It 
is also possible that hFPR2 employs co-receptors like CD38 (Partida-Sánchez et al., 2001), 
Discussion 
Page | 106 
 
MARCO (Brandenburg et al., 2010) or RAGE (Slowik et al., 2012), which has been observed 
for hFPR1. Interesting in this course is that the grade of the observed affinity shift between 
HEK293T cells and monocytes/granulocytes was dependent on the ligand (also seen by 
Kretschmer et al., 2010). It has been proposed, that hFPR2 comprises multiple ligand binding 
sites (Cattaneo et al., 2013). It could even be possible to have several co-receptors or 
accessory molecules modulating the distinct binding pockets. Furthermore, Cooray et al. 
(2013) have shown that hFPR2 is able to undergo homo-/ and heterodimerization, which leads 
to activation of distinct intracellular signaling pathways, adding more items to the complex 
conformational landscape of this receptor. Ligand-dependent activation of distinct signaling 
pathways of a single receptor, a phenomenon called functional selectivity, has been described 
for several GPCRs (Zhou, 2014).  
 
4.4.2. Biological significance of signal peptide detection by innate immune cells – 
evidence for a novel pattern recognition receptor 
Detection of signal peptides occurred with very high affinity and specificity for formyl 
peptide receptors in HEK293T cells as well as in primary human granulocytes and monocytes. 
Several peptides tested in concentration-response experiments were able to activate hFPR1 or 
hFPR2 in the sub-nanomolar range. These peptides belong to the most affine naturally-
derived FPR peptide agonists described so far (Cattaneo et al., 2013; Ye et al., 2009; Migeotte 
et al., 2006). Even in complex cellular systems like the primary leukocytes which express 
myriads of chemosensory receptors, these ligand-induced responses were FPR specific. 
Moreover, the peptides were able to induce cellular responses in human granulocytes that are 
characteristic for neutrophil-dependent inflammation: (I) receptor activation leading to 
downstream cellular signaling (in this case calcium), (II) induction of adhesion/cell migration 
towards higher stimulus concentrations, (III) release of matrix-metalloproteases to enable 
tissue invasion and migration towards the threat (Bufe et al., 2015), and (IV) formation of 
reactive oxygen species during respiratory bursts in order to eliminate pathogenic 
microorganisms (Kolaczkowska and Kubes, 2013; Witko-Sarsat et al., 2000). The latter 
needed higher concentrations of the stimuli for activation. Similar results have already been 
described for f-MLF and some synthetic peptides (Kemmerich and Pennington, 1988; Gao et 
al., 1994). This is not very surprising as the cells usually need very low stimulus 
concentrations to migrate into the direction of the assumed target. The onset of eliminatory 
processes is shifted towards higher concentrations since the concentration of the stimulus is 
Discussion 
Page | 107 
 
increased in close proximity to the pathogen. If such processes would start early on, they 
would primarily harm surrounding host tissue instead of the acquired target.  
Many of the above-mentioned arguments are transferable to the murine immune FPRs. The 
displayed affinities and FPR-discriminating selectivity observed for human FPRs also apply 
to the mouse FPRs, emphasizing their evolutionary conservation. For receptors of both 
species the N-terminal formylation is not mandatory for receptor activation but is required for 
preserving the high affinity (Bufe et al., 2015). This is a valid molecular model for distinction 
between eukaryotic signal peptides, which are not N-terminally formylated, and prokaryotic 
signal peptides. Because of this, FPRs have been proposed as pattern recognition receptors 
(PRRs) for several times already (Thomas and Schroder, 2013), as the structural requirements 
for activation, the N-terminal formylation, fulfills requirements to be defined as PRRs. 
However, to define FPRs as pattern recognition receptors certain experimental evidence is 
missing.  
PRRs, per definition, possess several common characteristics (Akira et al., 2006). First, they 
recognize microbial components, so-called pathogen-associated molecular patterns (PAMPs). 
These components are essential for bacterial survival and hence, are highly conserved. Second, 
PRRs are constitutively expressed in the host and are therefore capable of recognizing the 
pathogenic pattern at each stage of the host’s life cycle. Third, PRRs are germ line encoded, 
independent of immunologic memory and expressed on all cells of a certain cell type. In 
addition, PRRs are highly conserved among species. Activation of a given PRR results in 
activation of distinct signaling pathways and leads to distinct anti-pathogen responses. Formyl 
peptide receptors are expressed in many developmental stages of myeloid cells like native 
monocytes as well as mature macrophages and dendritic cells (Migeotte et al., 2005). 
Orthologs of FPR1 and/or FPR2 have been found in different species like human, rat and 
mouse (Liberles et al., 2009). Mammalian FPRs (human, mouse, rat, rabbit, dog, horse, ape, 
etc.) are highly conserved in structure and, at least those that have been tested, in function. 
My data strongly support these arguments as signal peptide detection was conserved between 
human and mouse. According to the literature, FPRs are generally expressed by granulocytes 
and lead, upon activation, to anti-pathogenic responses. This has also been confirmed by data 
presented in the current work. With this, FPRs seem to share all characteristics common to 
PRRs with one exception: as far as I know, there is no evidence that formylated peptides, as 
part of a functional group, are essential for bacterial survival. However, with 20 - 30% of all 
proteins in bacterial cells localized outside the cytosol, proving the necessity of protein 
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targeting for cell survival, signal peptides are vital for bacterial existence (Kudva et al., 2013). 
All these characteristics have more or less been addressed and confirmed in the scope of this 
work and should enable to classify FPRs as pattern recognition receptors. 
 
4.4.3. Occurrence of signal peptides and their N-terminal fragments in nature 
Interpolation of the results discussed in chapter 4.4.2 underlines the biological relevance of 
signal peptide detection by cells of the innate immune system. However, it is not exactly 
known how these peptides are found in nature and what structural properties they possess in 
the end. This will be discussed in the following section. 
4.4.3.1. Natural occurrence of bacterial peptides starting with N-terminally formylated methionine 
Since the late 1960s it is widely known that bacterial protein synthesis generally starts with 
N-terminally formylated methionine (Capecchi, 1966). According to the literature (Frottin et 
al., 2006), 35 - 70% of those peptides are either deformylated after exiting the ribosomal 
machinery or targeted by N-terminal methionine excision (NME). In the past however, there 
have been plenty of publications reporting the occurrence of N-formyl methionine-containing 
peptides in bacterial supernatants of many bacterial species (Stead et al., 2013; Liu et al., 
2011; Ravipaty and Reilly, 2010; Wang et al., 2007, Watson et al., 1988; Rot et al., 1987; 
Marasco et al., 1984; Fitton et al., 1980; Smith and Shaw, 1981). Besides, investigations by 
Smith and Shaw have shown that the method used for purification of bacterial proteins does in 
part distinguish between non-formylated and formylated peptides (Smith and Shaw, 1981), 
questioning the real extent of N-terminal deformylation or NME. It has been proposed that 
f-MLF, which is present in several signal peptide sequences, is released during a process 
similar to NME (Broom et al., 1993; Schiffmann et al., 1975). However, there are 
possibilities that the N-terminal formyl-methionine of signal peptides is not hydrolyzed at all. 
The nascent peptide chains of proteins that are co-translationally transported via Sec-
dependent pathways are bound by SecB/SecA after exiting the ribosome. This protein could 
serve as a capping molecule, masking the formyl-methionine. Analyses of Frey (Frey et al., 
1987) show that rubredoxin was found in the cytoplasm of Desulfovibrio gigas, still carrying 
its N-terminal formyl-methionyl signal peptide.  
In line with this, there have been reports suggesting that secreted proteins, starting with 
formyl-methionine, still carry their N-terminal signal sequence (Watson et al., 1988). Stead et 
al. identified several proteins in the supernatant that are supposed to be transported via a Sec-
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dependent pathway, still carrying their N-terminally formylated signal sequence (Stead et al., 
2013).   
4.4.3.2. Release of signal peptides and N-terminal signal peptide fragments in nature 
Two major questions arise from the data discussed above. First, what is the exact mechanism 
by which the signal peptides are released? Second, in which form are they presented so that 
formyl peptide receptors can access them in vivo? The following section proposes six 
scenarios (I - VI) describing potent sources of N-terminally formylated bacterial signal 
peptides or their breakdown products in nature. 
(I) Sec-dependent and TAT-dependent signal sequences are cleaved off the pre-protein by the 
bacterial signal peptidase I, releasing the premature protein (Dalbey et al., 2012). The cleaved 
signal peptide is then typically further degraded by signal peptide peptidases (Dalbey et al., 
2012). It has been shown that signal peptide fragments of secreted proteins were found in the 
growth medium of Staphylococcus aureus (Ravipaty and Reilly, 2010). Interestingly, the 
same study proved the presence of five stable full-length signal peptides in the extracellular 
medium of which four start with the N-terminal MKK motif. It is possible that these 
fragments or small full-length peptides escape the periplasm and cross the outer 
membrane/wall via active or passive transport or diffusion. Such a scenario would easily 
explain the presence of f-MLF in the supernatant of gram-negative E.coli (Marasco et al., 
1984).  
(II) For intercellular chemical communication bacteria employ several quorum sensing 
pathways that make use of peptide pheromones. It has been shown that secreted enterococcal 
sex-pheromones are contained within N-terminal signal sequences of several proteins (Cook 
and Federle, 2014). To excise the residing pheromone from the signal sequence, the signal 
peptide is cleaved upon translocation by EEP1 (Chandler and Dunny, 2008), leading to 
release of the pheromone and the remaining N-terminal residue (Cook and Federle, 2014). It 
has been shown that N-terminal cleavage products of AgrD quorum sensing peptides, 
containing the N-terminally formylated methionine, can be found in cell free culture 
supernatants of Staphylococcus aureus (Gonzalez et al., 2014). 
(III) It is not imperative that N-terminal signal peptides are cleaved off the exported protein at 
all. As stated above, some signal peptides are needed fully intact for unmitigated secretion of 
short proteins (Stead et al., 2013; Watson et al., 1988).  Loss of these signal sequences leads 
to a failure in the secretion process (Stead et al., 2013). Furthermore, Bennet et al. (1980) 
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have shown that the pre-mature penicillinase of Bacillus licheniformis, carrying its signal 
sequence, stimulated β-glucoronidase release in rabbit neutrophils. This effect was absent 
when the signal peptide sequence was removed (Bennet et al., 1980). We have shown that the 
immune FPRs of human and mouse detected all tested signal peptides, including the full-
length sequences comprising up to 37 amino acids (Bufe et al., 2015). Thus, it is possible that 
the signal sequence is still recognized by FPRs as part of the premature protein. 
(IV) Protein export is not restricted to secretion. It is also important for proteins that are 
inserted into membranes. Proteins with non-cleavable signal peptide sequences can be 
inserted into the outer membrane as well, without losing the N-terminal leader peptide. Such 
peptides can be part of pili or the injectosome machinery (Cornelis, 2006). The latter 
introduces virulence factors, so called effectors, into the mammalian host cell. Since bacteria 
contain intracellular formyl-methionylated proteins (Frey et al., 1987), it is possible that these 
peptides are retained in the host cell until it becomes necrotic and lyses. It has been shown 
that formylated mitochondrially-translated peptides, potent FPR activators, exit the 
mitochondria of necrotic cells (Carp, 1982; Zhang et al., 2010).  
(V) It has been shown that the FPR ligand f-MIVIL, originating from pathogenic Listeria 
monocytogenes, is presented by the non-classical murine MHC receptor H2M3 (Gulden et al., 
1996). Interestingly, this peptide is part of an N-terminal leader sequence (Princiotta et al., 
1998) and can be found in the signal peptide database (http://www.signalpeptide.de/). 
Presentation of bacterial peptides by MHC class II molecules by antigen presenting cells like 
monocytes is a key mechanism in activation of adaptive immune response. It is imaginable 
that such peptides escape the antigen presentation and are further available for FPRs. 
(VI) Bacteria, no matter if growing intra- or extracellularly, will, for the sake of their 
community, constitutively undergo a process of programmed cell death (Lewis et al., 2000; 
Allocati et al., 2015). Several of these autolytic processes are mainly dependent on autolysins 
that are activated/up-regulated during certain growth phases of the bacterial community. Upon 
autolysis complex intracellular components like DNA or proteins are released into the growth 
medium or substrate, including bacterial biofilms (Målen et al., 2007). Especially biofilms 
would provide a potent source of bacterial signal peptides detectable by the immune system 
and the vomeronasal organ. 
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4.5. Conclusion and Outlook 
The current work will certainly be of interest for many research areas. To my knowledge, it 
provides the most extensive study on vomeronasal FPRs so far. It lead to the discovery that 
vomeronasal mFpr-rs1 is able to discriminate peptides with molecular signatures that are 
attributed to bacteria, like peptides containing D-amino acids as well as N-terminally 
formylated peptides. Together with our findings that bacterial signal peptides activate this 
receptor, it supports the validity of the underlying hypothesis that vomeronasal FPRs mediate 
pathogen sensing. Hence, my data provide first pharmacological insights into a possible new 
mechanism by which animals can smell the presence of bacteria. Moreover, by recognition of 
these peptides the vomeronasal mFpr-rs1 shares a common ligand repertoire with FPRs from 
the innate immune system, providing first functional evidence for a molecular link between 
the olfactory and the immune system. Further experiments should address whether mFpr-rs1 
does recognize these substances in vivo, and if so, whether this affects the animal’s behavior.  
The major finding of this work is that bacterial signal peptides act as novel activators of 
immune responses and that these are mediated by FPRs. This introduces a possible novel 
mechanism of pattern recognition in the innate immune system. Employing this knowledge 
will certainly lead to a better understanding of immune surveillance by innate immune cells. 
Understanding the connection between in vivo signal peptide release and recognition by FPRs 
will certainly yield clinical implications. This could lead to new strategies for fighting 
bacterial diseases in general. FPRs display a very broad expression pattern that is not 
restricted to tissues of the immune system and the vomeronasal organ (Migeotte et al., 2006). 
There is growing evidence for the FPR’s influence in general physiological and 
pathophysiological processes. Their role in neurogenic inflammation is slowly emerging 
(Mollica et al., 2012) and signal peptide-induced MMP-9 release and oxidative burst would 
easily explain the perilous damage caused by bacteria infiltrating the central nervous system 
(Obermeier et al., 2013). Furthermore, recent reports show impairment of bacterium-
dependent homeostasis in colonic crypts of Fpr2-deficient mice (Chen et al., 2013). Bacterial 
signal peptides could be major determinants in controlling the microbial homeostasis in the 
human intestine. My findings could also help to understand the complex regulatory 
mechanisms of the human microbiome (Chu and Mazmanian, 2013). Since FPRs are 
expressed in several other epithelia like the lung (Shao et al., 2011) it is possible that they 
contribute to general management of the microbiome in the host body. On this view, there are 
two major points that should be addressed in future works. The most important one should 
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directly address the key question: how do FPRs meet bacterial signal peptides in vivo. The 
first simple step could be to show that signal peptides that activate FPRs, are secreted by 
bacteria, or vice versa, that secreted peptides activate FPRs. Stead et al. (2013) reported Sec-
dependent secretion of five peptides still carrying their N-terminal signal peptide sequence. 
Studies by de Souza et al. reported the presence of numerous secretory proteins that carried 
their uncleaved signal peptide sequence in Mycobacterium tuberculosis cultures (de Souza et 
al., 2011). Moreover, recent reports (Ravipaty and Reilly, 2010) verified the presence of four 
full-length signal peptides starting with the MKK motif in supernatants of Staphylococcus 
aureus. The group of Woolf has shown that N-terminally formylated peptides released by 
heat-inactivated bacteria (S. aureus among others) directly activate mFpr1 in nociceptor 
neurons of the dorsal root ganglia of mice (Chiu et al., 2013). However, it is vital to elucidate 
the release mechanisms of bacterial signal peptides in nature. More experiments are required 
assessing the whereabouts, the post-cleavage fate, the final concentration and the actual 
phenotype of the signal peptides. It is also important to discriminate between signal peptides 
of the distinct export pathways. It is imaginable that hFPR1 and hFPR2 are tuned toward the 
recognition of signal peptides derived from distinct signal peptide pathways. It would also be 
a great asset to apprehend possible differences in signal peptide usage between pathogenic 
bacteria and non-pathogenic strains. Purposeful growth of bacteria could include 
nuclear/fluorescence-labeling strategies to follow the fate of single molecules. Nano-high-
performance liquid chromatography coupled with mass spectrometry would be a very 
powerful tool to analyze the fate of bacterial signal peptides, their subcellular localization and 
their concentration. In my opinion, the presented work paves the way for a better 
understanding of the mammalian immune system, which might eventually lead to the 
discovery of completely new mechanisms for treating perilous bacterial diseases. 
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Appendix 1 | The mFpr2 agonist CRAMP can elicit unspecific responses in HEK293T cells 
Mouse FPRs were heterologously expressed in HEK293T cells and stimulated with various CRAMP isoforms. 
Calcium responses were measured with the FLIPR. [A] mFpr2 significantly responds to 10 µM of CRAMP39. 
Data are averaged over three independent transfections. [B] 10 µM of CRAMP33, CRAMP39 and rCRAMP33 
elicit unspecific responses in HEK cells transfected with empty vector and the control plasmid encoding the taste 
receptor hTAS2R38. Occasionally, cells are activated by 1 µM of a given CRAMP substance. T-test: * = p ≤ 
0.05. All other calcium signals were not significant compared to the control. Figure A modified after Bufe, 2012. 
B is modified after Schumann, 2010. In this case the mFpr-rs1 plasmid was encoding a non-functional receptor.  
 
 
Appendix 2 | hFPR2 expression in human monocytes 
Immunocytochemical staining of primary human monocytes stained with an anti-hFPR2 antibody or the isotype 
control MOPC-21. Antibody-dependent fluorescence is shown in red, nuclear counterstain in cyan. 
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Appendix 3 | Determination of cross-reactivity of anti-hFPR antibodies with heterologously expressed 
FPRs 
Primary antibodies directed against hFPR1, hFPR2 or hFPR3, respectively, were used for staining of HEK293T 
cells, transfected with plasmids encoding either hFPR1, hFPR2 or hFPR3. All hFPR antibodies were treated with 
a secondary antibody conjugated with the Alexa555 fluorophore. Shown are confocal fluorescence images of 
non-permeabilized cells transfected with plasmids for a given receptor (red stainings). Hoechst 33342 
counterstaining of cell nuclei (cyan) is exemplified for the cells stained with the anti-hFPR3 antibody. 
Quantification of the surface stainings is shown in the lowest panel. All three antibodies stain only their original 
target receptor and do not cross react with the other FPRs, although they are expressed in equal amounts. 
Notably, the percentage of specifically stained cells is comparable to that of Rho-tagged FPRs by staining with 
an anti-Rho antibody (Figure 3-1-1). Results are representable for at least three independent transfections. 
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Appendix 4 | Nucleotide sequence of the rhodopsin fusion element (figure 2.1) 
5’atgaacgggaccgagggcccaaacttctacgtgcctttctccaacaagacgggcgtggtgcgcagccccttcgaggccccgcagt
actacctggcggagccatggcagttctccatgg 3’ 
 
Appendix 5 | Full coding sequences of the cloned formyl peptide receptors  
mFpr1 
atggacaccaacatgtctctcctcatgaacaagtctgcagtgaacctcatgaatgtatctgggagtactcaatcagtatctgctggctacat
cgttctggatgtcttctcatatttgatctttgccgtcacatttgtccttggggttctgggcaacgggctcgtgatctgggtggctggtttccgc
atgaaacacactgtcaccaccatctcttacttgaacttggccattgctgacttttgcttcacttccactttgccattttacattgccagcatggt
catgggaggacattggccatttggttggttcatgtgcaaattcatatatactgtaatagacataaacctatttggaagtgtcttcctgattgcc
ctcattgcactggaccgctgtatttgtgttctacatccagtctgggctcagaaccaccgcactgtgagcctagccaagaaggtaatcatcg
taccctggatttgtgcatttcttcttacattgccagttatcattcgtttgaccacagtccctaatagtagacttggaccagggaaaacagcctg
tactttcgacttctccccctggaccaaagatcctgtagagaagaggaaggtggccgtcaccatgctcactgtcagaggaatcatcaggtt
catcattgggttcagcactcccatgtccattgttgccatttgctatgggttaataaccactaaaattcacaggcagggcctgatcaaatcca
gccgtcctttgcgggttctctcctttgttgtggctgcctttttcctctgctggtgcccatttcaagtagtggccctcatatccacaatccaagtc
cgtgaacggttgaagaacatgactccaggcattgtaactgccttgaaaatcacaagccccttggctttcttcaacagctgcctcaatccaa
tgctttatgtctttatgggccaggacttcagagaaagactaatccactctttacctgccagcctagagagggccctgactgaggactcag
ctcagaccagtgatacaggcaccaatttggggaccaactctacttccctttctgaaaacactttaaatgcaatgtga 
mFpr2 
atggaatccaactactccatccatctgaatggatcagaagtggtggtttatgattctaccatctccagagttctgtggatcctctcaatggtg
gttgtctccatcactttcttccttggtgtgctgggcaatggactagtgatttgggtagctggattccggatgccacacactgtcaccactatc
tggtatttgaatctagcattggctgacttttctttcacagcaactctaccattccttcttgttgaaatggctatgaaagaaaaatggccttttgg
ctggttcctgtgtaaattagttcacattgtggtagatgtaaacctgtttggaagtgtcttcttgattgctctcattgccttggaccgctgcatttg
tgttctgcatccagtctgggctcagaaccaccgcactgtgagcctggctaggaaggtggttgttgggccctggatttttgctctgattctca
ctttgcccatttttattttcttgactactgttagaattcctggaggagatgtgtattgtacattcaactttggatcctgggctcaaactgatgaag
aaaagttgaacacagctatcacttttgtaacaactagagggatcatcaggttccttattggtttcagcatgcccatgtcaattgttgctgtttg
ctatggactcattgctgtcaagatcaacagaagaaaccttgttaattccagccgtcctttacgagtccttacagcagttgtggcttccttcttt
atctgctggtttccctttcagcttgtggcccttttgggcacagtctggtttaaagagacattgcttagtggtagttataaaattcttgacatgttt
gttaacccaacaagctcattggcttacttcaatagttgtctcaatccgatgctctatgttttcatgggccaggactttcgtgagagatttattca
ttccctgccttatagtcttgagagagccctgagtgaggattctggtcaaaccagtgattcaagcaccagttctacttcacctcctgcagaca
ttgagttaaaggccccatga 
mFpr-rs1 
atggaaaccaactactctatccctttgaatggatcagatgtggtgatctatgattctaccatctccagggttctgtggatcctctcaatggtg
gttgtctccatcactttcttccttggtgtgctgggaaatggactagtgatctgggtagctggattccggatgccacacactgtcaccactatc
tggtatctgaatctagcattggctgacttctctttcacagcaactctaccattccttcttgttgaaatggctatgaaagaaaaatggccttttgg
ctggttcctgtgtaaattagttcacattgcagtagatgtaaacctatttggaagtgtcttcttgattgctgtcattgccttggaccgctgtatttg
tgtcctgcatccagtctgggctcagaaccaccgcactgtgagcctggctagaaatgtggttgttgggtcctggatttttgctctcattctca
ctttgccccttttcctcttcttgactacagttagagatgctagaggggatgtgcactgtagattgagctttgtatcctggggcaactctgttga
ggaaaggttgaacacagctatcacgtttgtaacaactagagggatcatcaggttcattgttagcttcagcttgcccatgtcctttgttgccat
ctgctatggactcatcactacaaagattcacaaaaaagcctttgttaattccagccgtcctttccgagttcttacaggagttgtggcttccttc
tttatctgttggtttcctttccaattggtggcccttttaggcacagtctggctcaaagagatgcagtttagtggtagttataaaattattggcag
gttggttaatccaaccagttcattggcctttttcaatagctgcctcaatccaattctctatgttttcatgggccaggactttcaagaaagactg
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attcattccctgtcttctcgtctgcagagagccctgagtgaggactctggtcatatcagtgatacaagaaccaatttggcttcacttcctgaa
gacattgaaataaaggcaatatga 
hFPR1 
atggagacaaattcctctctccccacgaacatctctggagggacacctgctgtatctgctggctatctcttcctggatatcatcacttatctg
gtatttgcagtcacctttgtcctcggggtcctgggcaacgggcttgtgatctgggtggctggattccggatgacacacacagttaccacc
atcagttacctgaacctggccgtggctgacttctgtttcacctccactttgccattcttcatggtcaggaaggccatgggaggacattggc
ctttcggctggttcctgtgcaaattcctctttaccatagtggacatcaacttgttcggaagtgtcttcctgatcgccctcattgctctggaccg
ctgtgtttgcgtcctgcatccagtctggacccagaaccaccgcaccgtgagcctggccaagaaggtgatcattgggccctgggtgatg
gctctgctcctcacattgccagttatcattcatgtgactacagtacctggtaaaacggggacagtagcctgcacttttaacttttcgccctgg
accaacgaccctaaagagaggataaaggtggccgttgccatgttgacggtgagaggcatcatccggttcatcattggcttcagcgcac
ccatgtccatcgttgctgtcagttatgggcttattgccaccaagatccacaagcaaggcttgattaagtccagtcgtcccttacgggtcctc
tcctttgtcgcagcagccttttttctctgctggtccccatatcaggtggtggcccttatagccacagtcagaatccgtgagttattgcaaggc
atgtacaaagaaattggtattgcagtggatgtgacaagtgccctggccttcttcaacagctgcctcaaccccatgctctatgtcttcatggg
ccaggacttccgggagaggctgatccacgcccttcccgccagtctggagagggccctgaccgaggactcaacccaaaccagtgaca
cagctaccaattctactttaccttctgcagaggtggagttacaggcaaagtga 
hFPR2 
atggaaaccaacttctccactcctctgaatgaatatgaagaagtgtcctatgagtctgctggctacactgttctgcggatcctcccattggt
ggtgcttggggtcacctttgtcctcggggtcctgggcaatgggcttgtgatctgggtggctggattccggatgacacgcacagtcacca
ccatctgttacctgaacctggccctggctgacttttctttcacggccacattaccattcctcattgtctccatggccatgggagaaaaatgg
ccttttggctggttcctgtgtaagttaattcacatcgtggtggacatcaacctctttggaagtgtcttcttgattggtttcattgcactggaccg
ctgcatttgtgtcctgcatccagtctgggcccagaaccaccgcactgtgagtctggccatgaaggtgatcgtcggaccttggattcttgct
ctagtccttaccttgccagttttcctctttttgactacagtaactattccaaatggggacacatactgtactttcaactttgcatcctggggtgg
cacccctgaggagaggctgaaggtggccattaccatgctgacagccagagggattatccggtttgtcattggctttagcttgccgatgtc
cattgttgccatctgctatgggctcattgcagccaagatccacaaaaagggcatgattaaatccagccgtcccttacgggtcctcactgct
gtggtggcttctttcttcatctgttggtttccctttcaactggttgcccttctgggcaccgtctggctcaaagagatgttgttctatggcaagta
caaaatcattgacatcctggttaacccaacgagctccctggccttcttcaacagctgcctcaaccccatgctttacgtctttgtgggccaag
acttccgagagagactgatccactccctgcccaccagtctggagagggccctgtctgaggactcagccccaactaatgacacggctg
ccaattctgcttcacctcctgcagagactgagttacaggcaatgtga 
hFPR3 
atggaaaccaacttctccattcctctgaatgaaactgaggaggtgctccctgagcctgctggccacaccgttctgtggatcttctcattgct
agtccacggagtcacctttgtcttcggggtcctgggcaatgggcttgtgatctgggtggctggattccggatgacacgcacagtcaaca
ccatctgttacctgaacctggccctagctgacttctctttcagtgccatcctaccattccgaatggtctcagtcgccatgagagaaaaatgg
ccttttggctcattcctatgtaagttagttcatgttatgatagacatcaacctgtttgtcagtgtctacctgatcaccatcattgctctggaccgc
tgtatttgtgtcctgcatccagcctgggcccagaaccatcgcaccatgagtctggccaagagggtgatgacgggactctggattttcacc
atagtccttaccttaccaaatttcatcttctggactacaataagtactacgaatggggacacatactgtattttcaactttgcattctggggtga
cactgctgtagagaggttgaacgtgttcattaccatggccaaggtctttctgatcctccacttcattattggcttcagcgtgcctatgtccatc
atcacagtctgctatgggatcatcgctgccaaaattcacagaaaccacatgattaaatccagccgtcccttacgtgtcttcgctgctgtggt
ggcttctttcttcatctgttggttcccttatgaactaattggcattctaatggcagtctggctcaaagagatgttgttaaatggcaaatacaaaa
tcattcttgtcctgattaacccaacaagctccttggccttttttaacagctgcctcaacccaattctctacgtctttatgggtcgtaacttccaa
gaaagactgattcgctctttgcccactagtttggagagggccctgactgaggtccctgactcagcccagaccagcaacacagacacca
cttctgcttcacctcctgaggagacggagttacaagcaatgtga 
mFpr-rs3 
atggaagccaactcctccatcccactgaatggctcagaagtggtgttttatgattctaccacctccagagttctatggatcctctcagtgat
agttctctccataacctttgtccttggtgtgctaggtaatgggcttgtgatttgggtggctgggttccggatggcacacactgtgaccacca
tctgttatctgaacctggctttgggtgacttctctttcatggttactttaccactacacatcatctcaatggtcatgaaaggaaaatggctttttg
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gttggttcctttgcaaatttgttctcagcattgtgcacataaacctttttgtaagtgttttcttaatcactctcattgccatggatcgttgtacttgt
gtcctgcacccagtatgggttcagaatcaccgaactgtgagtctggccaggaaagtgattgttggagcttggattctttctctgctgcttac
attgccacattttctcttcttgactacagtgagagatgcaagaggcgaagtgcactgtacatgtaactttgaatctgtggttgcaaaccctg
aggagcaattaaaggtgtcaattaccgtgagcacagcaacaggaatcatcagttttattattggcttcagcctacccatgtccttcattgcc
gtctgctatggactcatggctgccaagatttgtagaaaaggctttctgaactccagccgtcctttacgtgttctcactgctgtagcaatttcct
tctttatgtgttggttcccttttcaactgattattcttctaggtaatatctggaataaggagacaccaagcagcattcacattttgttgaacccag
caagcacactggcttccttcaacagctgtctcaacccaatactctatgtctttcttggtcaagaatttagagagaaactgatatattccctgtc
tgccagtctggagagggcgctgcgagaagactcagtcctaagcagtggcaaaagcagcaacttttcttcatgtcctgccgactctgaac
tatga 
mFpr-rs4 
atggaagtcaacatttcaatgcctctgaatggatcagaagttgtgttttatgattctaccacctcaagagttctatggatcctctcattagtggt
tctctttataacctttgtcctcggtgttctaggtaatgggcttgtgatttgggtggctgggttccagatggcacacactgtgaccactgtctctt
atctgaacttggctttgagtgatttatctttcatggctactctaccacttcacatcatctcaatggtcatgagaggaaaatggctttttggttggt
ttctttgcaaattagttcacataattgcaaacataaacctttttgtaagtatcttcctaatcactcttattgccatggatcgctgtatttgtgtcctg
tgcccagtatggtctcagaatcaccgaactgtgagtctggccagaaaagtggttcttggagcttggatatttgctctgctgcttaccttgcc
acattttctcttcttgactacagtgagagatgcaagaggggatgtgtactgtatatctaaatttgaatcctgggttgcaacctctgaagagca
gttaaaggtgtctgttattgctgccacagcttcaggaatcatcaatttcattattggattcagcatgcccatgtctttcattgctatctgctatgg
actcatggctgccaagatctgcagaagaggctttgtgaattccagtcgtcctttacgtgtcctcactgctgtagcagtttccttctttgtctgtt
ggttcccttttcaattaattatgcttttaggcaacatctttaacaatgagacactgagcattattcatatgttggttaacccagcaaataccttg
gcttcctttaacagctgcctcaacccaatactctatgtattcctgggtcaggaattcagagacagactaatctattctctgtatgccagtcta
gagagggccctgagggaagactga 
mFpr-rs6 
atggaagccaacttctccatacctcagaatggatcagaagtggtgttttatgattctaccacctccagagttatatgtatcttcttagttgtggt
cctctctataacctttctccttggtgtgataggtaatgggcttgtgatttatgtggctgggttccggatgacacacactgtgacaacaatctgt
tatctgaacctggcattgtctgacttctcttacatggcaagtctaccatttcagatcacctcaattgtcatgaatggagaatggctttttggttg
gttcctttgcaaatttgttcacatgattataaacgtaaacctttttctaagtatcttcttgattactttcattgccatggatcgttgtatttgtgttctg
catccagtatgggctcagaatcatcgaactgtgaatgtggcaacgaaagtgatctttggagcttggatacttgttctgatgcttatatttcca
cattgtatcttcgtgactacagtgaaagatgaaagtgggaaagtacattgcatatgtaattttgaatcctgggctgcaacccctgaggagc
aagtaaaagtatctatgactgtgagtttaatttcagtaaccatcagtttcattattggcttcagcataccaatgatcttcattgtcatctgttatg
gactcatggctgccaagataggcagaagaggttttgtgaattccagtcgtcctttacgtgtcctcactgctgtagcaatttctttctttgtctgt
tggttcccttttcaattgatttttcttttaggcaatattgggaacaaggagacacagaataatattgacacgtgggtgaacacagcaagcact
ctggcctccttcaatagttgcctcaacccaatactctatgttttcctaggtcagcaattcagagagagactgatctactccctatcagctagt
ctggagagggccctgagggaggactcagccctgaacagtgacaaaaccagaaacttgtcttcacaaagactctga 
mFpr-rs7 
atggaagccaacttctccatacctcagaatggatcagaagtggtgttttatgattctaccacatccagagttatatgtatcttcttagttgtggt
cctctctataacctttctccttggtgtgataggtaatgggcttgtgatttatgtggctgggttccggatgacacatactgtgacaacaatctgt
tatctgaacctggcattgtctgacttctcttacatgacaagtctaccatttcagatcacctcaattgtcatgaatggagaatggctttttggttg
gttcctttgcaaatttgttcacatgattataaatgtaaacctttttctaagtatcttcttgattactttcattgccatggatcgctgtatttgtgttctg
catccagtatgggctcagaatcatcgaactgtgaatctggcaaggaaagtgattttgggatcttggatacttgttctgatgcttatatttcca
cattttttcttcttgactacagtgaaagatgaaagtggtaaagtacactgtatatgcaattttgaatcctgggctgcaacccctgaggagca
ggtaaacatgtctatgactgtgagtttaatttcagtaaccctcagtttcattgttggcttcagcataccaatgatcttcattgtcatctgctatgg
actcatggctgccaagataggcagaagaggcttggtgaattccagtcgtcctttacgtgtcctcactgctgtagcattttctttctttgtctgtt
ggttcccttttcaattgatttttcttttaggcaatattgggaacaaggagacacagaataatattgacgcgtgggtgaacccagcaagcact
ctggcctccttcaatagttgcctcaacccaatactctatgttttcctaggtcagcaattcagagagagactgatctactccctatcagctagt
ctggagagggccctgagggaggattcagccctgaacagtgacaaaatcagaaacttgtcttcacaaacttaa 
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Bufe B*, Schumann T*, Kappl R, Bogeski I, Kummerow C, Podgórska M, Smola S, Hoth M, 
Zufall F 
* Both authors contributed equally to this work 
 
Formyl peptide receptors from immune and vomeronasal system exhibit distinct agonist 
properties. 
J Biol Chem. 2012 Sep 28;287(40):33644-55. Epub 2012 Aug 2. 
Bufe B*, Schumann T*, Zufall F. 
* Both authors contributed equally to this work  
 
 
 
 
 
 
 
 
Publications 
Page | 129 
 
Abstracts 
 
 
12th International Congress of Neuroimmunology, 9-13 November 2014, Mainz, 
Germany 
Formyl peptide receptors from the innate immune system and the vomeronasal organ 
recognize pathogen derived peptides  
Schumann T, Bufe B and Zufall F 
 
17th STS Meeting 2013: Signal Transduction - Receptors, Mediators and Genes, 4-6 
November, 2013, Weimar, Germany 
Evolution of formyl peptide receptor function in mammals 
Bufe B, Schumann T, Stempel H, Zufall F 
 
XXIInd Congress of the European Chemoreception Research Organization, ECRO 2013, 
27-29 August 2013, Leuven, Belgium 
RNA-editing alters the function of vomeronasal formyl peptide receptors 
Stempel H, Schumann T, Bufe B, , Zufall F 
 
Evolution of formyl peptide receptor function in mammals 
Bufe B, Schumann T, Stempel H, Zufall F 
 
92nd Annual Meeting | Deutsche Physiologische Gesellschaft, 2-5 March, 2013, 
Heidelberg, Germany, 
Evolution of formyl peptide receptor function in mammals 
Bufe B, Schumann T, Zufall F, 
 
 
 
Publications 
Page | 130 
 
XVI International Symposium on Olfaction and Taste, ISOT/ECRO 2012, 23-27 June, 
2012, Stockholm, Sweden 
Formyl peptide detection by vomeronasal sensory neurons is mediated by functionally distinct 
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Schumann T, Bufe B and Zufall F 
 
Agonist profiling of the mouse formyl peptide receptors reveals a stereoselective tuning of 
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create and gather as much knowledge as possible. Demand for quality and scientific 
correctness, should hence be the most important and exalted traits of scientific research. A 
task not easily completed, especially in times where episodes of time pressure urge scientists 
to increase data quantity without any loss of quality. In my opinion, requirements of this 
research philosophy are easily fulfilled by allegorizing three simple traits: honesty, candor and 
teamwork. Following this idea, I will try my best to reveal contributions by other people as 
frank, honest and correct as demanded. 
Cell stock handling, cell culture and transfection were from time to time performed by Sabine Plant, Saarland 
University, Medical School Homburg, Department of Physiology. 
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Medical School Homburg, Department of Physiology) and Regina Bender-Omlor (Saarland University Hospital, 
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Plant (Saarland University, Medical School Homburg, Department of Physiology). 
Ficoll separations were generally performed by Marta Podgórska (Saarland University Hospital, Department of 
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University, Medical School Homburg, Department of Physiology), namely Angelika Ströer and Sarah Boll. 
Single cell calcium imaging of human monocytes was performed by Carsten Kummerow (Saarland University, 
Medical School Homburg, Department of Biophysics).  
Calcium imaging of HEK293T cells was in rare cases performed by Dr. Bernd Bufe (Saarland University, 
Medical School Homburg, Department of Physiology).  
I cloned the genes for mFpr1,mFpr2, and mFpr-rs3 during my diploma thesis (Schumann, 2010). 
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